

UNITED STATES INTERNATIONAL TRADE COMMISSION
WASHINGTON, D.C.

Before the Honorable David P. Shaw
Administrative Law Judge

In the Matter of

**CERTAIN BOTULINUM TOXIN
PRODUCTS, PROCESSES FOR
MANUFACTURING OR RELATING TO
SAME AND CERTAIN PRODUCTS
CONTAINING SAME**

Inv. No. 337-TA-1145

FINAL EXHIBIT LIST OF JOINT, COMPLAINANTS, AND STAFF EXHIBITS

Pursuant to Ground Rule 9 and the Procedural Schedule, Complainants Medytox, Inc. (“Medytox”) and Allergan plc and Allergan, Inc. (together, “Allergan,” and with Medytox, “Complainants”) hereby respectfully submit their Final Exhibit List including CX, CDX, CPX, JX, and SX exhibits¹ (attached hereto as Exhibit A).

Dated: February 21, 2020

Respectfully submitted,

GIBSON, DUNN & CRUTCHER LLP

By: /s/ Joshua A. Jessen

Jeffrey T. Thomas
Joshua A. Jessen
Gibson, Dunn & Crutcher LLP
3161 Michelson Drive
Irvine, CA 92612-4412
Telephone: (949) 551-3967

CLEARY GOTTlieb STEEN & HAMILTON LLP

By: /s/ Nowell D. Bamberger

Nowell D. Bamberger
Elsbeth Bennett
Cleary Gottlieb Steen & Hamilton LLP
2112 Pennsylvania Avenue, N.W.
Washington, D.C. 20037
Telephone: (202) 974-1500

¹ The Staff has requested that Complainants include the SX exhibits in Complainants’ submission.

Fax: (949) 451-4220
AllerganITC3359@gibsondunn.com

Brian M. Buroker
Haley S. Morrisson
Gibson, Dunn & Crutcher LLP
1050 Connecticut Avenue, N.W.
Washington, D.C. 20036-5306
Telephone: (202) 955-8541
Fax: (202) 467-0539
AllerganITC3359@gibsondunn.com

Michael Sitzman
DLA PIPER LLP
555 Mission Street, Suite 2400
San Francisco, California 94105-2933
Telephone: (415) 615-6175
michael.sitzman@us.dlapiper.com

Attorneys for Allergan plc and Allergan, Inc.

Facsimile: (202) 974-1999
Team-ITC-Medytox-1145@cgsh.com

David H. Herrington
Joon H. Kim
Arminda B. Bepko
Charity E. Lee
Cleary Gottlieb Steen & Hamilton LLP
One Liberty Plaza
New York, NY 10006
Telephone: (212) 225-2000
Team-ITC-Medytox-1145@cgsh.com

T. Spence Chubb
Law Office of T. Spence Chubb
1025 Connecticut Avenue, N.W.,
Suite 1000
Washington, D.C. 20036
Telephone: (703) 623-7739
Facsimile: (703) 563-6055
Team-ITC-Medytox-1145@cgsh.com

Attorneys for Medytox Inc.

Certain Botulinum Toxin Products, Processes for Manufacturing or Relating to Same and Certain Products Containing Same, Inv. No. 337-TA-1145

CERTIFICATE OF SERVICE

I, Charity E. Lee, certify that on February 21, 2020, copies of the foregoing document were served on the following in the manner so indicated:

<p>The Honorable Lisa Barton Secretary to the Commission U.S. INTERNATIONAL TRADE COMMISSION 500 E Street, S.W., Washington, DC 20436</p>	<p><i>Via EDIS</i></p>
<p>The Honorable David P. Shaw Administrative Law Judge U.S. INTERNATIONAL TRADE COMMISSION 500 E Street, S.W., Room 317 Washington, DC 20436</p>	<p><i>Via Courier (1 copy)</i> <i>Via E-Mail:</i> Shaw337@usitc.gov Joseph.Speyer@usitc.gov</p>
<p>Brian Koo Office of Unfair Import Investigations U.S. INTERNATIONAL TRADE COMMISSION 500 E Street, S.W., Suite 401 Washington, D.C. 20436 Telephone: (202) 205-2580</p>	<p><i>Via E-mail:</i> Brian.Koo@usitc.gov</p>
<p><i>Counsel for Respondent Daewoong Pharmaceuticals Co., Ltd.</i></p> <p>David F. Nickel (<i>Lead Attorney</i>) FOSTER, MURPHY, ALTMAN & NICKEL, PC 1150 18th St., NW Washington, D.C. 20036 Telephone: (202) 822-4104</p>	<p><i>Via E-mail:</i> FM-Daewoong-1145@fostermurphy.com</p>

*Counsel for Respondent Daewoong
Pharmaceuticals Co., Ltd.*

Michael Kim
Benjamin J. A. Sauter
Benjamin Sirota
Jeffrey Newton
800 3rd Avenue
New York, NY 10022
Telephone: (212) 488-1200
Fax: (212) 488-1220

Daniel Zaheer
150 California St.
San Francisco, CA 94111
Telephone: (415) 582-4800
Fax: (415) 582-4811

Won Joon Lee
Daniel Lee
9F, Tower B, The-K Twin Towers
50, Jong-ro 1-gil, Jongno-gu
Seoul, 03142 South Korea
Telephone: +82 2-369-1212
Fax: +82 2-369-1220

Matthew Boucher
1919 M. Street, NW
Washington, D.C. 20036
Telephone: (202) 664-1950
Fax: (202) 664-1920

Matthew I. Menchel
201 South Biscayne Boulevard, Suite 1900
Miami, Florida 33131
Telephone: (305) 967-6100
Fax: (305) 967-6120

Via E-mail:

KK-Daewoong-1145@kobreKim.com

<p><i>Counsel for Respondent Evolus, Inc.</i></p> <p>Nicholas Groombridge Joseph J. Bial Josephine Young Ariane Rockoff-Kirk PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 1285 Avenue of the Americas New York, NY Telephone: (212) 373-3000</p>	<p><i>Via E-mail:</i> grp-evolus-itc@paulweiss.com</p>
<p><i>Counsel for Complainants Allergan plc and Allergan, Inc.</i></p> <p>Brian M. Buroker (<i>Lead Attorney</i>) Haley Morrisson GIBSON, DUNN & CRUTCHER LLP 1050 Connecticut Avenue, N.W. Washington, D.C. 20036-5306 Telephone: (202) 955-8500</p> <p>Jeffrey T. Thomas Joshua A. Jessen GIBSON, DUNN & CRUTCHER LLP 3161 Michelson Drive Irvine, CA 92612-4412 Telephone: (949) 451-3800</p> <p>Soolean Choy GIBSON, DUNN & CRUTCHER LLP 555 Mission Street, Suite 3000 San Francisco, CA 94105-0921 Telephone: (415) 393-8200</p> <p>Nathan R. Curtis GIBSON, DUNN & CRUTCHER LLP 2100 McKinney Avenue Dallas, TX 75201-6912 Telephone: (214) 698-3100</p> <p>Lori C. Arakaki GIBSON, DUNN & CRUTCHER LLP 333 South Grand Avenue Los Angeles, CA 90071-3197 Telephone: (213) 229-7000</p>	<p><i>Via Email:</i> AllerganITC3359@gibsondunn.com michael.sitzman@us.dlapiper.com</p>

Michael Sitzman DLA PIPER LLP 555 Mission Street, Suite 2400 San Francisco, California 94105-2933 Telephone: (415) 615-6175	
---	--

Date: February 21, 2020

/s/ Charity E. Lee

Charity E. Lee
Cleary Gottlieb Steen & Hamilton LLP
One Liberty Plaza
New York, NY 10006
Telephone: (212) 225-2000

EXHIBIT A

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CDX-0001	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Dr. Seong Hun Chang - BK Lee Strain Access	Seong Hun Chang	Admitted
CDX-0002	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Dr. Seong Hun Chang - Cell Bank Security	Seong Hun Chang	Admitted
CDX-0003	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Dr. Hack Woo Kim	Hack Woo Kim	Admitted
CDX-0004	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Dr. Paul Keim	Paul Keim; David Sherman	Admitted
CDX-0006		N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Sesha Neervannan – BOTOX® Indications Approved by the FDA	James Malackowski	Admitted
CDX-0007	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of Sesha Neervannan – Map of the Allergan Irvine Campus identifying locations where BOTOX®-related activities occur	James Malackowski	Admitted
CDX-0008	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of James Malackowski – Map of the United States identifying relevant facilities where BOTOX®-related activities occur	James Malackowski	Admitted
CDX-0009	C	N/A	N/A	Demonstrative Exhibit Referenced in the Witness Statement of James Malackowski – Allergan’s Investments in Domestic Research and Development from 1992 to 2018	James Malackowski	Admitted
CDX-0010	C	N/A	N/A	Demonstrative Exhibit Reference in the Witness Statement of Dr. Andrew Pickett	Andrew Pickett; Brenda Wilson	Admitted
CDX-0011	C	N/A	N/A	Literature Citations in Daewoong Documents		Withdrawn
CDX-0012	C	N/A	N/A	Pickett Demonstrative		Withdrawn
CDX-0013	C	N/A	N/A	Guidepoint Market Share	David Moatazedi	Admitted
CDX-0014		N/A	N/A	Bacterial Toxins: Methods and Protocols (Otto Holst ed., 2000)	Brenda Wilson	Admitted
CPX-0001		N/A	N/A	Vials of BOTOX®		Withdrawn
CPX-0002		N/A	N/A	Vials of Jeuveau®		Withdrawn
CPX-0003		N/A	N/A	BOTOX® Packaging		Withdrawn
CPX-0004		N/A	N/A	Jeuveau® Packaging		Withdrawn
CPX-0005	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 12	Paul Keim	Admitted
CPX-0006		N/A	N/A	Empty Sample 1.8 ml Vial		Withdrawn
CX-0001		N/A	N/A	Complaint Exhibit A - Evolus, Inc. 10K dated March 29, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0002	C	N/A	N/A	Complaint Exhibit C - Letter from Allergan Asia Ltd. to Daewoong, "Re: Termination of Distributorship Agreement," February 1, 2006	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0003		N/A	N/A	Complaint Exhibit U - Evolus, Inc. S-1, July 16, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0004		N/A	N/A	Complaint Exhibit V - Evolus, Inc. 10-Q, Nov. 5, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0005		N/A	N/A	Complaint Exhibit X - Declaration of Theresa Smith	Brenda Wilson	Admitted
CX-0006		N/A	N/A	Complaint Exhibit EE - Evolus, Inc., 8-K dated January 4, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0007	C	N/A	N/A	Response of Evolus, Inc. to the Complaint and Notice of Institution of Investigation		Withdrawn
CX-0008	C	N/A	N/A	Witness Statement of Ben Marzouk	Ben Marzouk; James Malackowski; Carla Mulhern	Admitted
CX-0009	C	N/A	N/A	Witness Statement of Colleen McKenna	Colleen McKenna; James Malackowski; Carla Mulhern	Admitted
CX-0010	C	N/A	N/A	Witness Statement of Dr. Andrew Pickett	Andrew Pickett; David Sherman; Brenda Wilson; Bal Ram Singh; Ryan Sullivan; Carla Mulhern	Admitted
CX-0011	C	N/A	N/A	Witness Statement of Dr. Chang Hoon Rhee	Chang Hoon Rhee; David Sherman; Ryan Sullivan; Carla Mulhern	Admitted
CX-0012	C	N/A	N/A	Witness Statement of Dr. Hack Woo Kim	Hack Woo Kim; David Sherman; Carla Mulhern	Admitted
CX-0013	C	N/A	N/A	Witness Statement of Dr. Hyun Ho Jung	Hyun Ho Jung; David Sherman; Ryan Sullivan; Carla Mulhern	Admitted
CX-0014	C	N/A	N/A	Contingent Rebuttal Witness Statement of Dr. Kyu Hwan Yang	Kyu Hwan Yang	Admitted
CX-0015	C	N/A	N/A	Witness Statement of Dr. Paul Keim	Paul Keim; David Sherman; Ryan Sullivan; Carla Mulhern	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0016	C	N/A	N/A	Witness Statement of Dr. Sessa Neervannan	Sessa Neervannan; James Malackowski; Carla Mulhern	Admitted
CX-0017	C	N/A	N/A	Witness Statement of Dr. Sung Hun Chang [Seong Hun Chang]	Seong Hun Chang; Carla Mulhern	Admitted
CX-0018	C	N/A	N/A	Witness Statement of James Malackowski	James Malackowski; Ryan Sullivan; Carla Mulhern	Admitted
CX-0019		Medytox-ITC-00000350	Medytox-ITC-00000398	Daewoong Answer in Korean Civil Litigation dated January 26, 2018		Withdrawn
CX-0025	C	Medytox-ITC-00004190	Medytox-ITC-00004196	Presentation titled "P2 - sBTA06XX Plant Media Applications" dated November 9, 2006		Withdrawn
CX-0026	C	Medytox-ITC-00004197	Medytox-ITC-00004213	Batch record dated from August 23, 2006 to September 4, 2006.		Withdrawn
CX-0027	C	Medytox-ITC-00004214	Medytox-ITC-00004310	PowerPoint Presentation for PO.5-sBTA0600 dated September 20, 2006	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0028	C	Medytox-ITC-00004311	Medytox-ITC-00004310	Experimental Batch Record dated October 10, 2006 to October 24, 2006		Withdrawn
CX-0030	C	Medytox-ITC-00004380	Medytox-ITC-00004384	Potency tests conducted dated Sept 29, 2006		Withdrawn
CX-0031	C	Medytox-ITC-00004385	Medytox-ITC-00004394	Potency tests conducted dated October 17 and October 30, 2006		Withdrawn
CX-0035	C	Medytox-ITC-00004408	Medytox-ITC-00004424	Fermentation and purification time schedule dated September 5, 2006		Withdrawn
CX-0036	C	Medytox-ITC-00004425	Medytox-ITC-00004426	Gel electrophoresis conducted on December 15, 2006		Withdrawn
CX-0038	C	Medytox-ITC-00004430	Medytox-ITC-00004434	Process Development Team (Weekly) Work Report dated from November 2, 2006 to November 22, 2006.		Withdrawn
CX-0041	C	Medytox-ITC-00004461	Medytox-ITC-00004474	Collection of academic papers relating to the purification of botulinum toxin		Withdrawn
CX-0042	C	Medytox-ITC-00004484	Medytox-ITC-00004486	Process Development Team (Weekly) Work Report dated from September 1, 2006 to October 18, 2006	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0046	C	Medytox-ITC-00004525	Medytox-ITC-00004531	Gel electrophoresis dated February 12, 2007		Withdrawn
CX-0047	C	Medytox-ITC-00004716	Medytox-ITC-00004723	PowerPoint Presentation for Medy-Tox substrate production process she[ch]eme dated June 7		Withdrawn
CX-0049	C	Medytox-ITC-00005289	Medytox-ITC-00005297	PowerPoint Presentation for Progress Report 20070726 dated July 26, 2007		Withdrawn
CX-0050	C	Medytox-ITC-00005312	Medytox-ITC-00005317	PowerPoint Presentation for Progress Report 20070626 dated June 26, 2007		Withdrawn
CX-0056	C	Medytox-ITC-00005401	Medytox-ITC-00005406	Progress Report 20070921	Andrew Pickett	Admitted
CX-0057	C	Medytox-ITC-00005407	Medytox-ITC-00005419	Progress Report 20070831	Andrew Pickett	Admitted
CX-0058	C	Medytox-ITC-00005420	Medytox-ITC-00005421	Experiment report dated October 24, 2005		Withdrawn
CX-0059	C	Medytox-ITC-00005422	Medytox-ITC-00005425	PowerPoint Presentation for Process Improvement Action Plan: Animal-free media Set-updated December 2, 2005.		Withdrawn
CX-0061	C	Medytox-ITC-00005428	Medytox-ITC-00005433	Stability test schedule dated December 2, 2005		Withdrawn
CX-0062	C	Medytox-ITC-00005434	Medytox-ITC-00005437	Animal-free media Set-updated December 1, 2005		Withdrawn
CX-0066	C	Medytox-ITC-00005470	Medytox-ITC-00005486	Research on stability and manufacturing process dated January 24, 2006		Withdrawn
CX-0067	C	Medytox-ITC-00005558	Medytox-ITC-00005563	Test report on the potency of plant-derived culture medium		Withdrawn
CX-0068	C	Medytox-ITC-00005564	Medytox-ITC-00005568	Test report on the product stability		Withdrawn
CX-0070	C	Medytox-ITC-00005572	Medytox-ITC-00005572	Test report dated February 27, 2006		Withdrawn
CX-0087	C	Medytox-ITC-00006019	Medytox-ITC-00006052	Gel electrophoresis conducted dated July 17-September 17, 2007		Withdrawn
CX-0092	C	Medytox-ITC-00006205	Medytox-ITC-00006222	HPLC analysis of KKS sample dated June 20, 2007		Withdrawn
CX-0097	C	Medytox-ITC-00006367	Medytox-ITC-00006371	Product excipient stability test report dated December 30, 2005		Withdrawn
CX-0098	C	Medytox-ITC-00006481	Medytox-ITC-00006487	HPLC peak analysis dated April 24, 2007		Withdrawn
CX-0099	C	Medytox-ITC-00006547	Medytox-ITC-00006554	KHW 7S Toxin Presentation dated April 20, 2007		Withdrawn
CX-0100	C	Medytox-ITC-00006555	Medytox-ITC-00006560	215 nm analysis & 278 nm analysis presentation		Withdrawn
CX-0101	C	Medytox-ITC-00006561	Medytox-ITC-00006569	HPLC peak analysis presentation dated April 5, 2007		Withdrawn
CX-0102	C	Medytox-ITC-00006624	Medytox-ITC-00006635	PowerPoint Presentation for Purification condition design dated September 28, 2007		Withdrawn
CX-0103	C	Medytox-ITC-00006636	Medytox-ITC-00006638	Process Development Team (Weekly) Work Report dated from October 29, 2007 to November 9, 2007		Withdrawn
CX-0104	C	Medytox-ITC-00006639	Medytox-ITC-00006641	Batch ID: P2sBTA0707-F02 dated May 6, 2007		Withdrawn
CX-0105	C	Medytox-ITC-00006642	Medytox-ITC-00006647	Batch test result reports: P2sBTA0704 - F01 and P2sBTA0705 - F02		Withdrawn
CX-0106	C	Medytox-ITC-00006648	Medytox-ITC-00006649	Process Development Team (Weekly) Work Report dated from March 26, 2007 to April 6, 2007		Withdrawn
CX-0107	C	Medytox-ITC-00006650	Medytox-ITC-00006651	Process Development Team (Weekly) Work Report dated from June 11, 2007 to June 22, 2007		Withdrawn
CX-0108	C	Medytox-ITC-00006652	Medytox-ITC-00006656	Work Report dated July 30, 2007		Withdrawn
CX-0109	C	Medytox-ITC-00006657	Medytox-ITC-00006658	Test reports on vegetable culture medium efficacy test dated April 23, 2007		Withdrawn
CX-0110	C	Medytox-ITC-00006659	Medytox-ITC-00006661	Work Report dated July 12, 2007		Withdrawn
CX-0112	C	Medytox-ITC-00006700	Medytox-ITC-00006705	PowerPoint Presentation for Progress Report 20070824 dated August 24, 2007		Withdrawn
CX-0113	C	Medytox-ITC-00006707	Medytox-ITC-00006727	Process Development Team Monthly Plan regarding fermentation, isolation, and purification by the use of a disposable bag dated August 17, 2007		Withdrawn
CX-0114	C	Medytox-ITC-00006728	Medytox-ITC-00006729	Process Development Team (Weekly) Work Report dated from July 23, 2007 to August 3, 2007		Withdrawn
CX-0115	C	Medytox-ITC-00006730	Medytox-ITC-00006732	Process Development Team (Weekly) Work Report dated from July 30, 2007 to August 24, 2007		Withdrawn
CX-0116	C	Medytox-ITC-00006733	Medytox-ITC-00006737	Process Development Team (Weekly) Work Report dated from June 18, 2007 to July 27, 2007		Withdrawn
CX-0117	C	Medytox-ITC-00006738	Medytox-ITC-00006743	PowerPoint Presentation for Medy-Tox substrate production process she[ch]eme		Withdrawn
CX-0118	C	Medytox-ITC-00006754	Medytox-ITC-00006772	PowerPoint Presentation for Progress Report 20070626 dated June 26, 2007		Withdrawn
CX-0119	C	Medytox-ITC-00006773	Medytox-ITC-00006775	Process Development Team (Weekly) Work Report dated from May 1, 2007 to May 18, 2007		Withdrawn
CX-0120	C	Medytox-ITC-00006776	Medytox-ITC-00006776	Process Development Team (Weekly) Work Report dated from March 26, 2007 to April 6, 2007		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0121	C	Medytox-ITC-00006777	Medytox-ITC-00006778	Process Development Team (Weekly) Work Report dated from February 26, 2007 to March 9, 2007		Withdrawn
CX-0122	C	Medytox-ITC-00006779	Medytox-ITC-00006782	Process Development Team (Weekly) Work Report dated from February 5, 2007 to March 2, 2007		Withdrawn
CX-0123	C	Medytox-ITC-00006785	Medytox-ITC-00006788	Process Development Team (Weekly) Work Report dated from February 12, 2007 to March 5, 2007		Withdrawn
CX-0124	C	Medytox-ITC-00006789	Medytox-ITC-00006789	Process Development Team (Weekly) Work Report dated from January 29, 2007 to February 9, 2007		Withdrawn
CX-0125	C	Medytox-ITC-00006790	Medytox-ITC-00006800	Process Development Team (Weekly) Work Report dated from January 22, 2007 to February 2, 2007	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0126	C	Medytox-ITC-00006801	Medytox-ITC-00006802	Process Development Team (Weekly) Work Report dated from September 1, 2006 to October 18, 2006		Withdrawn
CX-0127	C	Medytox-ITC-00006803	Medytox-ITC-00006807	Process Development Team (Weekly) Work Report dated from March 5, 2007 to March 23, 2007		Withdrawn
CX-0129	C	Medytox-ITC-00007217	Medytox-ITC-00007227	Hand-written notes dated July 3, 2000 to July 27, 2000	Hack Woo Kim; Andrew Pickett Hyun Ho Jung; Seong Hun Chang	Admitted
CX-0130	C	Medytox-ITC-00007228	Medytox-ITC-00007274	Hand-written notes dated August 3, 2000 to August 30, 2000	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted
CX-0131	C	Medytox-ITC-00007275	Medytox-ITC-00007311	8L Culture type A #8 SDS Page	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted
CX-0132	C	Medytox-ITC-00007312	Medytox-ITC-00007325	Hand-written notes dated November 2, 2000 to December 1, 2000	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted
CX-0133	C	Medytox-ITC-00007326	Medytox-ITC-00007345	Hand-written notes dated December 1, 2000 to December 27, 2000	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted
CX-0134	C	Medytox-ITC-00007346	Medytox-ITC-00007348	Handwritten Notes dated January 1, 2001	Hyun Ho Jung	Admitted
CX-0136	C	Medytox-ITC-00007383	Medytox-ITC-00007523	Purification of BoNT/A	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted
CX-0141	C	Medytox-ITC-00007654	Medytox-ITC-00007664	PowerPoint Presentation for Process Improvement Action Plan: Animal-free media Set-updated December 2, 2005	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0143	C	Medytox-ITC-00007668	Medytox-ITC-00007729	Product stability test schedule dated December 2, 2005		Withdrawn
CX-0144	C	Medytox-ITC-00007730	Medytox-ITC-00007750	Research on product stability and manufacturing process development dated January 24, 2006		Withdrawn
CX-0145	C	Medytox-ITC-00007751	Medytox-ITC-00007757	Meeting minutes dated May 11, 2006		Withdrawn
CX-0147	C	Medytox-ITC-00007771	Medytox-ITC-00007773	Sample Table Report dated October 13, 2006		Withdrawn
CX-0148	C	Medytox-ITC-00007802	Medytox-ITC-00007813	Test Plan regarding Effectiveness validation test related to plant-derived medium dated July 28, 2005		Withdrawn
CX-0151	C	Medytox-ITC-00008677	Medytox-ITC-00008697	Stability Test of MCB (CBAM0301) Clostridium botulinum Type A, Hall strain for 3 years dated November 3, 2006	Seong Hun Chang	Admitted
CX-0152	C	Medytox-ITC-00008698	Medytox-ITC-00008715	Report titled "Stability Test of WCB for 3 years" dated November 3, 2006	Seong Hun Chang	Admitted
CX-0153	C	Medytox-ITC-00008984	Medytox-ITC-00009012	Validation Protocol for Method Validation of Potency Assay (Retrospective) dated Sept. 2, 2005	Seong Hun Chang	Admitted
CX-0154	C	Medytox-ITC-00009046	Medytox-ITC-00009059	SDS Page assay Method Validation dated May 18, 2005	Seong Hun Chang	Admitted
CX-0155	C	Medytox-ITC-00009060	Medytox-ITC-00009066	Protein assay (Bradford Method) Method Validation dated October 29, 2005	Seong Hun Chang	Admitted
CX-0156	C	Medytox-ITC-00009077	Medytox-ITC-00009082	Prepared media validation by Sun Hee In dated Sept 22, 2005	Seong Hun Chang	Admitted
CX-0157	C	Medytox-ITC-00009083	Medytox-ITC-00009135	SDS Page assay Method Validation dated June 21, 2005		Withdrawn
CX-0160	C	Medytox-ITC-00009450	Medytox-ITC-00009454	Cell Banking with Plant-derived Media Protocol dated September 7, 2006	Seong Hun Chang	Admitted
CX-0161	C	Medytox-ITC-00009455	Medytox-ITC-00009459	Toxin Production Study Using Plant Media dated September 8, 2006	Seong Hun Chang	Admitted
CX-0164	C	Medytox-ITC-00012566	Medytox-ITC-00012601	Document titled "5. Method of Production, Separation and Purification of Target Molecule in Manufacturing Process". Draft of manufacturing process flow chart and batch record version no. 00, initially dated October 1, 2003	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0166	C	Medytox-ITC-00012715	Medytox-ITC-00012773	Document titled "10. General Test Method Material Relating to All Steps of Manufacturing Process"	Chang Hoon Rhee	Admitted
CX-0170	C	Medytox-ITC-00013807	Medytox-ITC-00013807	Working Cell Bank Management Log for CBAW0301 - Clostridium botulinum type A, Hall	Seong Hun Chang	Admitted
CX-0171	C	Medytox-ITC-00014506	Medytox-ITC-00014515	Statement of Tax Adjustments, 1st Term: from May2, 2000 to December 31, 2000		Withdrawn
CX-0172	C	Medytox-ITC-00014516	Medytox-ITC-00014526	Statement of Tax Adjustments, 2ndTerm: from January 1, 2001 to December 31, 2001		Withdrawn
CX-0173	C	Medytox-ITC-00014527	Medytox-ITC-00014538	Statement of Tax Adjustments, 3rd Term: from January 1, 2002 to December 31, 2002		Withdrawn
CX-0174	C	Medytox-ITC-00014539	Medytox-ITC-00014550	Statement of Tax Adjustments, 4th Term: from January 1, 2003 to December 31, 2003		Withdrawn
CX-0175	C	Medytox-ITC-00014551	Medytox-ITC-00014562	Statement of Tax Adjustments, 5th Term: from January 1, 2004 to December 31, 2004		Withdrawn
CX-0176	C	Medytox-ITC-00014563	Medytox-ITC-00014575	Statement of Tax Adjustments, 6thTerm: from January 1, 2005 to December 31, 2005		Withdrawn
CX-0177	C	Medytox-ITC-00014576	Medytox-ITC-00014590	Statement of Tax Adjustments, 7th Term: from January 1, 2006 to December 31, 2006		Withdrawn
CX-0178	C	Medytox-ITC-00014591	Medytox-ITC-00014596	Statement of Tax Adjustments, 8th Term: from January 1, 2007 to December 31, 2007		Withdrawn
CX-0179	C	Medytox-ITC-00014597	Medytox-ITC-00014604	Statement of Tax Adjustments, 9th Term: from January 1, 2008 to December 31, 2008		Withdrawn
CX-0180	C	Medytox-ITC-00015110	Medytox-ITC-00015113	The effect of Yeast Extract for Clostridium Botulinum Type A Growth Protocol dated April 16, 2008	Seong Hun Chang	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0181	C	Medytox-ITC-00015114	Medytox-ITC-00015118	The effect of Yeast Extract, Carbohydrate, and amino acids on Growth, and Clostridium Botulinum Toxin Type A production without animal and plant derived media Protocol dated May 20, 2008		Withdrawn
CX-0182	C	Medytox-ITC-00015119	Medytox-ITC-00015124	The effect of Yeast Extract for Clostridium botulinum Type A Growth dated May 20, 2008.	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0213	C	Medytox-ITC-00017521	Medytox-ITC-00017525	Bacterial Endotoxin Limit Test: Kinetic Turbidimetric Method Standard Operating Procedure dated August 7, 2006		Withdrawn
CX-0215	C	Medytox-ITC-00021280	Medytox-ITC-00021306	Batch record for Clostridium botulinum Type A, Hall strain MCB, version no. 01 dated April 4, 2008		Withdrawn
CX-0217	C	Medytox-ITC-00021319	Medytox-ITC-00021352	Batch record for Clostridium botulinum Type A, Hall strain MCB, version no. 01 dated February 2, 2008	Hack Woo Kim	Admitted
CX-0261	C	Medytox-ITC-00039390	Medytox-ITC-00039393	The effect of Yeast Extract for Clostridium Botulinum Type A Growth Protocol dated April 16, 2008	Seong Hun Chang	Admitted
CX-0262	C	Medytox-ITC-00039394	Medytox-ITC-00039398	The effect of Yeast Extract, Carbohydrate, and amino acids on Growth, and Clostridium Botulinum Toxin Type A production without animal and plant derived media Protocol dated May 20, 2008		Withdrawn
CX-0263	C	Medytox-ITC-00039399	Medytox-ITC-00039404	The effect of Yeast Extract for Clostridium Botulinum Type A Growth Protocol dated May 20, 2008	Seong Hun Chang	Admitted
CX-0269	C	Medytox-ITC-00039545	Medytox-ITC-00039548	WCB manufacturing protocol dated July 8, 2008		Withdrawn
CX-0273	C	Medytox-ITC-00039577	Medytox-ITC-00039582	MCB manufacturing protocol dated April 3, 2008		Withdrawn
CX-0274	C	Medytox-ITC-00039583	Medytox-ITC-00039589	MCB manufacturing protocol dated February 11, 2008		Withdrawn
CX-0276	C	Medytox-ITC-00039630	Medytox-ITC-00039636	Report for history of Clostridium botulinum strain in Medy-tox Inc. dated November 5, 2008	Chang Hoon Rhee; Hyun Ho Jung	Admitted
CX-0287	C	Medytox-ITC-00041783	Medytox-ITC-00041820	Test request, order and results for various drug substance batches	Chang Hoon Rhee; Paul Keim	Admitted
CX-0330	C	Medytox-ITC-00044212	Medytox-ITC-00044245	Master Batch Record: Botulinum toxin type A dated October 27, 2004	Hack Woo Kim	Admitted
CX-0331	C	Medytox-ITC-00044282	Medytox-ITC-00044315	Master Batch Record: Botulinum toxin type A dated August 10, 2004	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0332	C	Medytox-ITC-00044422	Medytox-ITC-00044496	Master Batch Record: Botulinum toxin type A dated December 27, 2004	Hack Woo Kim Seong Hun Chang	Admitted
CX-0334	C	Medytox-ITC-00067150	Medytox-ITC-00067246	BTA0301 Batch Record version no. 00 dated October 1, 2003	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0335	C	Medytox-ITC-00071215	Medytox-ITC-00071271	BTA0302 Batch Record dated December 2003		Withdrawn
CX-0336	C	Medytox-ITC-00071272	Medytox-ITC-00071376	BTA0601 Batch Record dated January 11, 2006		Withdrawn
CX-0337	C	Medytox-ITC-00071377	Medytox-ITC-00071400	Written Test Request dated February 1, 2006	Seong Hun Chang	Admitted
CX-0338	C	Medytox-ITC-00071401	Medytox-ITC-00071430	BTA0302 Batch Record dated October 1, 2003		Withdrawn
CX-0339	C	Medytox-ITC-00072307	Medytox-ITC-00072403	BTX0804 Batch Record dated October 30, 2008		Withdrawn
CX-0349	C	Medytox-ITC-00080197	Medytox-ITC-00080197	Stability test reports on botulinum toxin type A dated November 12, 2003		Withdrawn
CX-0350	C	Medytox-ITC-00080198	Medytox-ITC-00080198	Stability test reports on botulinum toxin type A dated December 3, 2003		Withdrawn
CX-0351	C	Medytox-ITC-00080199	Medytox-ITC-00080199	Stability test reports on botulinum toxin type A dated December 24, 2003		Withdrawn
CX-0370	C	Medytox-ITC-00080638	Medytox-ITC-00080641	Test report on solution (BTA 0301-24"month"-1.2.3) dated February 10, 2006		Withdrawn
CX-0375	C	Medytox-ITC-00080671	Medytox-ITC-00080673	Test report on solution (BTA 0301-1) dated January 10, 2006 (test conducted by Byung Kook Lee)		Withdrawn
CX-0377	C	Medytox-ITC-00080677	Medytox-ITC-00080680	Test report on solution (BTA 0302-24"month"-1.2.3) dated February 10, 2006		Withdrawn
CX-0379	C	Medytox-ITC-00080689	Medytox-ITC-00080691	Test report on solution (BTA 0302-1) dated January 17, 2006		Withdrawn
CX-0384	C	Medytox-ITC-00080716	Medytox-ITC-00080719	Test report on solution (BTA 0303-24"month"-1.2.3) dated February 10, 2006		Withdrawn
CX-0390	C	Medytox-ITC-00080753	Medytox-ITC-00080755	Test report on solution (BTA 0303-1) dated January 24, 2006		Withdrawn
CX-0391	C	Medytox-ITC-00080756	Medytox-ITC-00080769	Long term stability test (phase 1) on C. botulinum toxin type A (BTA0301) dated December 7, 2006		Withdrawn
CX-0392	C	Medytox-ITC-00080770	Medytox-ITC-00080783	Long term stability test (phase 1) on C. botulinum toxin type A (BTA0302) dated December 7, 2006		Withdrawn
CX-0393	C	Medytox-ITC-00080784	Medytox-ITC-00080797	Long term stability test (phase 1) on C. botulinum toxin type A (BTA0303) dated December 7, 2006		Withdrawn
CX-0394	C	Medytox-ITC-00080798	Medytox-ITC-00080811	Long term stability test (phase 2) on C. botulinum toxin type A (BTA0301) dated December 7, 2006		Withdrawn
CX-0395	C	Medytox-ITC-00080812	Medytox-ITC-00080825	Long term stability test (phase 2) on C. botulinum toxin type A (BTA0302) dated December 7, 2006		Withdrawn
CX-0396	C	Medytox-ITC-00080826	Medytox-ITC-00080839	Long term stability test (phase 2) on C. botulinum toxin type A (BTA0303) dated December 7, 2006		Withdrawn
CX-0397	C	Medytox-ITC-00080840	Medytox-ITC-00080853	Long term stability test (phase 3) on C. botulinum toxin type A (BTA0301) dated December 7, 2006		Withdrawn
CX-0398	C	Medytox-ITC-00080854	Medytox-ITC-00080867	Long term stability test (phase 3) on C. botulinum toxin type A (BTA0302) dated December 7, 2006		Withdrawn
CX-0399	C	Medytox-ITC-00080868	Medytox-ITC-00080881	Long term stability test (phase 3) on C. botulinum toxin type A (BTA0303) dated December 7, 2006		Withdrawn
CX-0415	C	Medytox-ITC-00083176	Medytox-ITC-00083255	Botulinum toxin type A Batch Record dated January 11, 2006		Withdrawn
CX-0416	C	Medytox-ITC-00083382	Medytox-ITC-00083415	Master Batch Record Botulinum toxin type A version no. 00, dated October 1, 2003		Withdrawn
CX-0421	C	Medytox-ITC-00086244	Medytox-ITC-00086249	Identification of Type A Botulinum Toxin Producing Bacterium Strain Using 16s DNA sequencing analysis dated September 4, 2006		Withdrawn
CX-0422	C	Medytox-ITC-00086253	Medytox-ITC-00086255	Morphological analysis of Type A Botulinum Toxin Producing Bacterium Strain dated September 4, 2006		Withdrawn
CX-0423	C	Medytox-ITC-00086256	Medytox-ITC-00086259	Identification of Type A Botulinum Toxin Producing Bacterium Strain Using API 20 A kit dated September 4, 2006		Withdrawn
CX-0424	C	Medytox-ITC-00086260	Medytox-ITC-00086262	Identification of Type A Botulinum Toxin Producing Bacterium Strain Using Multiplex PCR dated September 4, 2006		Withdrawn
CX-0425	C	Medytox-ITC-00086341	Medytox-ITC-00086343	HPLC analysis of BTA Substance dated September 5, 2006		Withdrawn
CX-0426	C	Medytox-ITC-00086344	Medytox-ITC-00086346	IEF analysis of BTA Substance dated September 5, 2006		Withdrawn
CX-0427	C	Medytox-ITC-00086347	Medytox-ITC-00086349	2DE analysis of BTA Substance dated September 6, 2006		Withdrawn
CX-0428	C	Medytox-ITC-00086350	Medytox-ITC-00086354	SDS-PAGE analysis of BTA Substance dated September 6, 2006		Withdrawn
CX-0429	C	Medytox-ITC-00086361	Medytox-ITC-00086371	Peptide mapping analysis of BTA Substance dated September 6, 2006		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0430	C	Medytox-ITC-00086829	Medytox-ITC-00086845	Experimental Batch Record, Version No. 03 dated August 4, 2008	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-0431	C	Medytox-ITC-00086846	Medytox-ITC-00086863	Experimental Batch Record Version, Version No. 04 dated January 11, 2006	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-0432	C	Medytox-ITC-00086864	Medytox-ITC-00086865	New Method of Fermentation and Purification of Clostridium botulinum Type A	Seong Hun Chang	Admitted
CX-0433	C	Medytox-ITC-00086895	Medytox-ITC-00086895	Botulinum Toxin Type A Development of Process Flow chart	Seong Hun Chang	Admitted
CX-0434	C	Medytox-ITC-00086896	Medytox-ITC-00086898	Protocol titled "Validation Confirmation Test Relating to Plant-Derived Medium" drafted by Byung Kook Lee	Seong Hun Chang	Admitted
CX-0435	C	Medytox-ITC-00086899	Medytox-ITC-00086899	Spreadsheet of manufacturing process steps	Seong Hun Chang	Admitted
CX-0436	C	Medytox-ITC-00086900	Medytox-ITC-00086900	Attachment to the Project and Quality Plan titled Construction Project Schedule	Chang Hoon Rhee	Admitted
CX-0437	C	Medytox-ITC-00086901	Medytox-ITC-00086901	Attachment to the Project and Quality Plan titled Segregation Concept in Facility Design	Chang Hoon Rhee	Admitted
CX-0438	C	Medytox-ITC-00086902	Medytox-ITC-00086902	Attachment to the Project and Quality Plan titled Equipment list	Chang Hoon Rhee	Admitted
CX-0439	C	Medytox-ITC-00086903	Medytox-ITC-00086903	Attachment to the Project and Quality Plan titled Cost list	Chang Hoon Rhee	Admitted
CX-0440	C	Medytox-ITC-00086904	Medytox-ITC-00086906	Attachment to the Project and Quality Plan titled Water Specification - Source Water	Chang Hoon Rhee	Admitted
CX-0441	C	Medytox-ITC-00086907	Medytox-ITC-00086909	Attachment to the Project and Quality Plan titled Site Plan	Chang Hoon Rhee	Admitted
CX-0442	C	Medytox-ITC-00086910	Medytox-ITC-00086910	Attachment to the Project and Quality Plan titled Specification of Botulinum Toxin Type A Complex	Chang Hoon Rhee	Admitted
CX-0443	C	Medytox-ITC-00086911	Medytox-ITC-00086918	Attachment to the Project and Quality Plan titled Material Safety Data Sheet	Chang Hoon Rhee	Admitted
CX-0444	C	Medytox-ITC-00086919	Medytox-ITC-00086922	Attachment to the Project and Quality Plan titled Process Scheme for Applying Disposable System	Chang Hoon Rhee	Admitted
CX-0445	C	Medytox-ITC-00086923	Medytox-ITC-00086926	Standard Operating Procedure titled "Media Production and Aseptic Standard," No. MR0300 dated September 2005	Seong Hun Chang	Admitted
CX-0446	C	Medytox-ITC-00086927	Medytox-ITC-00086929	Standard Operating Procedure titled "Strain Inoculation and Cultivation Criteria," No. MR0400 dated September 2005	Seong Hun Chang	Admitted
CX-0447	C	Medytox-ITC-00086930	Medytox-ITC-00086933	Standard Operating Procedure titled "Strain Storage Method and Criteria," No. MR0500 dated September 2005	Seong Hun Chang	Admitted
CX-0448	C	Medytox-ITC-00086934	Medytox-ITC-00086936	Standard Operating Procedure titled "Method of Controlling Botulinum Toxin," No. MR0700 dated September 2005	Seong Hun Chang	Admitted
CX-0449	C	Medytox-ITC-00086937	Medytox-ITC-00086941	Standard Operating Procedure titled "Method of Controlling Botulinum Toxin," No. MR0701 dated August 2006	Seong Hun Chang	Admitted
CX-0450	C	Medytox-ITC-00086942	Medytox-ITC-00086945	Standard Operating Procedure titled "Cleaning and Disinfection of the API Production Site," No. PH15/01 dated December 12, 2006	Seong Hun Chang	Admitted
CX-0451	C	Medytox-ITC-00086946	Medytox-ITC-00086949	Standard Operating Procedure titled "Guideline for In-Process Control," No. PI0100 dated September 2005	Seong Hun Chang	Admitted
CX-0452	C	Medytox-ITC-00086950	Medytox-ITC-00086953	Standard Operating Procedure titled "Guideline for In-Process Control," No. PI0101 dated August 2006	Seong Hun Chang	Admitted
CX-0453	C	Medytox-ITC-00086954	Medytox-ITC-00086957	Standard Operating Procedure titled "In-Process Control," No. PI0200 dated September 2005	Seong Hun Chang	Admitted
CX-0454	C	Medytox-ITC-00086958	Medytox-ITC-00086960	Standard Operating Procedure titled "In-Process Control," No. PI0201 dated October 1, 2003	Seong Hun Chang	Admitted
CX-0455	C	Medytox-ITC-00086961	Medytox-ITC-00086963	Standard Operating Procedure titled "Identification Test for Toxin in Stock Solution," No. QB2001 dated August 2006	Seong Hun Chang	Admitted
CX-0456	C	Medytox-ITC-00086970	Medytox-ITC-00086972	Standard Operating Procedure titled "Identification Test for Botulinum Strain," No. QB2501 dated August 2006	Seong Hun Chang	Admitted
CX-0457	C	Medytox-ITC-00086973	Medytox-ITC-00086976	Standard Operating Procedure titled "Absorbance of Stock Solution," No. QC11/00 dated September 10, 2007	Seong Hun Chang	Admitted
CX-0468		Medytox-ITC-00088398	Medytox-ITC-00088402	Medytox patent application titled Method for Purifying Clostridium Botulinum A Type Toxin dated January 7, 2002	Joint Stipulation (Dkt. No. 701591); Chang Hoon Rhee	Admitted
CX-0469	C	Medytox-ITC-00090687	Medytox-ITC-00090687	Work Report dated January 7, 2008		Withdrawn
CX-0480	C	Medytox-ITC-00093349	Medytox-ITC-00093355	Report titled "The effect of temperature on growth profile of Clostridium botulinum type A"	Hack Woo Kim	Admitted
CX-0490	C	Medytox-ITC-00100642	Medytox-ITC-00100657	PowerPoint Presentation for Progress Report dated July 21, 2008		Withdrawn
CX-0491	C	Medytox-ITC-00100658	Medytox-ITC-00100658	Laboratory Analysis Team (Weekly) Work Report dated July 3, 2008	Chang Hoon Rhee	Admitted
CX-0493	C	Medytox-ITC-00100726	Medytox-ITC-00100738	PowerPoint Presentation for Progress Report September 21, 2007		Withdrawn
CX-0494	C	Medytox-ITC-00101906	Medytox-ITC-00101909	Work Report dated August 2, 2007		Withdrawn
CX-0495	C	Medytox-ITC-00102446	Medytox-ITC-00102463	Presentation titled "First Incubation related to Process Improvement from 27 Jan to 17 Feb"		Withdrawn
CX-0497	C	Medytox-ITC-00105379	Medytox-ITC-00105396	First Culture related to process improvement 1/27 - 2/17		Withdrawn
CX-0506	C	Medytox-ITC-00105965	Medytox-ITC-00105967	Experiment Progress report dated from July 11, 2003 to July 25, 2003	Hack Woo Kim	Admitted
CX-0510	C	Medytox-ITC-00106182	Medytox-ITC-00106187	Experiment Progress report drafted dated July 26, 2003 to August 14, 2003	Hack Woo Kim	Admitted
CX-0514	C	Medytox-ITC-00106551	Medytox-ITC-00106578	Research Center Status Report in the first half of 2004 dated April 7, 2004 to June 28, 2004		Withdrawn
CX-0515	C	Medytox-ITC-00106662	Medytox-ITC-00106679	Presentation titled "First Incubation related to Process Improvement from 27 Jan to 17 Feb"	Hack Woo Kim	Admitted
CX-0518	C	Medytox-ITC-00106894	Medytox-ITC-00106909	Research Center Final Accounts Report in the second half of 2004 dated January 28, 2005		Withdrawn
CX-0520	C	Medytox-ITC-00107409	Medytox-ITC-00107411	Meeting Minutes regarding process improvement dated October 5, 2005		Withdrawn
CX-0521	C	Medytox-ITC-00107706	Medytox-ITC-00107711	Meeting Minutes regarding process and QC improvement dated January 18, 2005		Withdrawn
CX-0522	C	Medytox-ITC-00107739	Medytox-ITC-00107743	Meeting Minutes regarding First TFT process improvement dated January 27, 2005	Hack Woo Kim	Admitted
CX-0524	C	Medytox-ITC-00107798	Medytox-ITC-00107801	Minutes of the meeting titled "The 3rd Meeting on TFT Process Improvement (regarding detailed implementation plan)," dated April 19, 2005	Hack Woo Kim	Admitted
CX-0525	C	Medytox-ITC-00107827	Medytox-ITC-00107829	Minutes of the meeting titled "The 4th Meeting on TFT Process Improvement (regarding detailed implementation plan)," dated July 5, 2005	Hack Woo Kim	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0526	C	Medytox-ITC-00107853	Medytox-ITC-00107856	Minutes of the meeting titled "The 5th Meeting on TFT Process Improvement (regarding detailed implementation plan)," dated July 26, 2006	Hack Woo Kim	Admitted
CX-0527	C	Medytox-ITC-00108152	Medytox-ITC-00108155	List of BoNT/B strain growth media by published academic papers	Hack Woo Kim	Admitted
CX-0528	C	Medytox-ITC-00108413	Medytox-ITC-00108416	Meeting Minutes regarding production process and QC improvement dated January 11, 2005	Hack Woo Kim	Admitted
CX-0529	C	Medytox-ITC-00109038	Medytox-ITC-00109041	Meeting Minutes regarding process and QC improvement dated January 19, 2005		Withdrawn
CX-0530	C	Medytox-ITC-00109106	Medytox-ITC-00109111	Process-Related Implementation Plan drafted dated April 16, 2019	Hack Woo Kim	Admitted
CX-0539	C	Medytox-ITC-00111233	Medytox-ITC-00111233	Slide titled "2.2 Medytox (Inc.) KGMP Current Status of Promotion"	Hyun Ho Jung	Admitted
CX-0540	C	Medytox-ITC-00114591	Medytox-ITC-00114595	Slides regarding the purification of recombinant BoNT/A proteins (GST-AHB and GST-AHS3)	Hack Woo Kim	Admitted
CX-0541	C	Medytox-ITC-00114697	Medytox-ITC-00114702	Slides regarding the purification of recombinant BoNT/E proteins (GST-EHN)	Hack Woo Kim	Admitted
CX-0545	C	Medytox-ITC-00119918	Medytox-ITC-00119933	Research Center Final Accounts Report for the second half of 2004 dated January 28, 2005		Withdrawn
CX-0557	C	Medytox-ITC-00121537	Medytox-ITC-00121537	Weekly schedule for February 17-22, 2003	Hack Woo Kim	Admitted
CX-0558	C	Medytox-ITC-00121541	Medytox-ITC-00121541	Weekly schedule for March 10-15, 2003	Hack Woo Kim	Admitted
CX-0560	C	Medytox-ITC-00121624	Medytox-ITC-00121625	Weekly schedule for August 25-30, 2003	Hack Woo Kim	Admitted
CX-0561	C	Medytox-ITC-00121627	Medytox-ITC-00121628	Weekly schedule for September 1-6, 2003	Hack Woo Kim	Admitted
CX-0562	C	Medytox-ITC-00121645	Medytox-ITC-00121645	Weekly schedule for October 20-25, 2003	Hack Woo Kim	Admitted
CX-0564	C	Medytox-ITC-00121784	Medytox-ITC-00121798	Progress Report dated October 5, 2007		Withdrawn
CX-0565	C	Medytox-ITC-00122307	Medytox-ITC-00122318	Slides titled "P2-sBTA06XX Plant Media Applications" dated November 9, 2006	Hack Woo Kim; Seong Hun Chang	Admitted
CX-0566	C	Medytox-ITC-00122320	Medytox-ITC-00122322	Test plan titled "Validity Confirmation Test Relating to Plant-Derived Medium" dated December 21, 2005	Hack Woo Kim	Admitted
CX-0568	C	Medytox-ITC-00131969	Medytox-ITC-00131971	Kyu-Hwan Yang Employment Agreement (2018)		Withdrawn
CX-0569	C	Medytox-ITC-00131972	Medytox-ITC-00131973	Kyu-Hwan Yang Expert Agreement (2019)		Withdrawn
CX-0572	C	Medytox-ITC-00132852	Medytox-ITC-00132853	Email from Byung Kook Lee to Chang Hoon Rhee, dated July 10, 2008.		Withdrawn
CX-0573	C	Medytox-ITC-00132895	Medytox-ITC-00132895	Email from Byung Kook Lee to Chang Hoon Rhee, dated March 24, 2008	Chang Hoon Rhee	Admitted
CX-0574	C	Medytox-ITC-00132945	Medytox-ITC-00132945	Email from Byung Kook Lee to himself (Medytox email), dated December 10, 2007		Withdrawn
CX-0575	C	Medytox-ITC-00132946	Medytox-ITC-00132946	Email from Byung Kook Lee to himself (Medytox email), dated December 10, 2007		Withdrawn
CX-0576	C	Medytox-ITC-00132956	Medytox-ITC-00132956	Email from Byung Kook Lee to Young Suk Yoon		Withdrawn
CX-0577	C	Medytox-ITC-00132958	Medytox-ITC-00132958	Email from Byung Kook Lee to Gi Hyuk Yang		Withdrawn
CX-0578	C	Medytox-ITC-00132978	Medytox-ITC-00132978	Email from Byung Kook Lee to Seok Keun Choi		Withdrawn
CX-0579	C	Medytox-ITC-00132985	Medytox-ITC-00132985	Email from Byung Kook Lee to Hui Dong Woo		Withdrawn
CX-0580	C	Medytox-ITC-00132999	Medytox-ITC-00132999	Email from Byung Kook Lee to Hui Dong Woo		Withdrawn
CX-0581	C	Medytox-ITC-00133189	Medytox-ITC-00133189	Email from Byung Kook Lee to Chang Hoon Rhee, dated July 14, 2008	Chang Hoon Rhee	Admitted
CX-0582	C	Medytox-ITC-00133366	Medytox-ITC-00133366	Email from Byung Kook Lee to Ik Pyo Hong, dated January 25, 2008		Withdrawn
CX-0583	C	Medytox-ITC-00133725	Medytox-ITC-00133725	Email from Byung Kook Lee to Young Suk Yoon, dated January 11, 2008	Seong Hun Chang	Admitted
CX-0584	C	Medytox-ITC-00133746	Medytox-ITC-00133746	Email from Byung Kook Lee to Chang Hoon Rhee, dated June 19, 2008		Withdrawn
CX-0585	C	Medytox-ITC-00133767	Medytox-ITC-00133767	Email from Byung Kook Lee to Yong Chan Mun, dated June 26, 2008	Seong Hun Chang	Admitted
CX-0587	C	Medytox-ITC-00133883	Medytox-ITC-00133883	Working Seed access log for CBAW0301	Seong Hun Chang	Admitted
CX-0588	C	Medytox-ITC-00133912	Medytox-ITC-00133912	Letter from University of Wisconsin to Areta Kupchuk of Foley Hoag regarding return of bacterial strains on May 2, 2018	Hyun Ho Jung	Admitted
CX-0589	C	Medytox-ITC-00134338	Medytox-ITC-00134366	Report titled "Characterization Report of Botulinum Toxin Type A"	Seong Hun Chang	Admitted
CX-0590	C	Medytox-ITC-00135927	Medytox-ITC-00135936	Attachment to email titled Progress Report 20071005		Withdrawn
CX-0591	C	Medytox-ITC-00135939	Medytox-ITC-00135939	Attachment to email titled Process Development Team (Weekly) Work Report dated September 14, 2007		Withdrawn
CX-0592	C	Medytox-ITC-00136020	Medytox-ITC-00136027	Presentation slides titled "Medy-Tox substrate production process scheme" [sic]		Withdrawn
CX-0593	C	Medytox-ITC-00136078	Medytox-ITC-00136078	Attachment to email titled Process Development Team (Weekly) Work Report dated May 4, 2007		Withdrawn
CX-0594	C	Medytox-ITC-00136115	Medytox-ITC-00136115	Attachment to email titled Factory Construction TFT (Weekly) Work Report dated January 25, 2008		Withdrawn
CX-0595	C	Medytox-ITC-00136116	Medytox-ITC-00136116	Attachment to email titled Process Development Team (Weekly) Work Report dated April 20, 2007		Withdrawn
CX-0596	C	Medytox-ITC-00136351	Medytox-ITC-00136351	Attachment to email titled "Research Center Analysis Team (Weekly) Work Report" dated July 11, 2008	Chang Hoon Rhee; Hack Woo Kim; Byung Kook Lee	Admitted
CX-0597	C	Medytox-ITC-00138697	Medytox-ITC-00138697	Weekly work report of June 18, 2008 for Factory Construction TFT		Withdrawn
CX-0598	C	Medytox-ITC-00139258	Medytox-ITC-00139282	Attachment to email titled "Method of producing Clostridium botulinum type A toxin using Single Use Bioreactor with plant derived medium without Anaerobic Condition"	Chang Hoon Rhee	Admitted
CX-0599	C	Medytox-ITC-00143094	Medytox-ITC-00143102	Progress Report 2007.12.10		Withdrawn
CX-0600	C	Medytox-ITC-00144452	Medytox-ITC-00144462	Progress Report 2007.11.30		Withdrawn
CX-0601	C	Medytox-ITC-00144527	Medytox-ITC-00144539	Progress Report 2007.11.30		Withdrawn
CX-0602	C	Medytox-ITC-00145301	Medytox-ITC-00145311	Progress Report, Dec.10, 2007		Withdrawn
CX-0603	C	Medytox-ITC-00152198	Medytox-ITC-00152201	Document titled "Safety Effectiveness Evaluation History" from September 17, 2001 to August 10, 2002	Hyun Ho Jung	Admitted
CX-0604	C	Medytox-ITC-00152212	Medytox-ITC-00152240	Document regarding "Origin and development details (history)" and "2. Materials regarding Physicochemical property and Biological property" [sic]	Hyun Ho Jung	Admitted
CX-0606	C	Medytox-ITC-00153091	Medytox-ITC-00153097	Process Improvement Action Plan: Animal-free media Set-updated December 2, 2005		Withdrawn
CX-0607	C	Medytox-ITC-00153148	Medytox-ITC-00153150	Meeting Minutes regarding process and QC improvement dated April 4, 2005		Withdrawn
CX-0608	C	Medytox-ITC-00154280	Medytox-ITC-00154286	Presentation titled "Purification condition design" dated September 28, 2007		Withdrawn
CX-0609	C	Medytox-ITC-00154298	Medytox-ITC-00154320	Presentation titled "Progress Report 20070626" dated June 26, 2007		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0611	C	Medytox-ITC-00154483	Medytox-ITC-00154554	Batch Record version no. 04, version date January 11, 2006		Withdrawn
CX-0625	C	Medytox-ITC-00160217	Medytox-ITC-00160217	Weekly work report of October 11, 2006 for Process Development Team	Seong Hun Chang	Admitted
CX-0628	C	Medytox-ITC-00161097	Medytox-ITC-00161113	Presentation titled "Progress Report 2005.07.13-08.22 (Kim HW)"	Hack Woo Kim	Admitted
CX-0634	C	Medytox-ITC-00162380	Medytox-ITC-00162385	Presentation titled "Process Improvement"	Hack Woo Kim	Admitted
CX-0636	C	Medytox-ITC-00165230	Medytox-ITC-00165246	Report on stability test of "Meditoxin inj."	Hack Woo Kim	Admitted
CX-0650	C	Medytox-ITC-00182706	Medytox-ITC-00182729	The Common Technical Document for the Registration of Pharmaceutical for Human Use	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0652	C	Medytox-ITC-00212596	Medytox-ITC-00212602	Minutes of a meeting on January 11, 2005 titled "Process and QC Improvement Meeting" dated January 17, 2007	Seong Hun Chang	Admitted
CX-0654	C	Medytox-ITC-00221572	Medytox-ITC-00221572	Email from Seong Hun Chang to Byung Kook Lee, dated October 10, 2007		Withdrawn
CX-0655	C	Medytox-ITC-00221909	Medytox-ITC-00221910	Attachment to email titled Process Development Team weekly report for the weeks between 6/18/2007 to 6/29/2007		Withdrawn
CX-0656	C	Medytox-ITC-00221935	Medytox-ITC-00221935	Email from Yong Chang Moon to Byung Kook Lee, dated March 10, 2008		Withdrawn
CX-0657	C	Medytox-ITC-00223109	Medytox-ITC-00223109	Email from Hyung Pyo Hong to Byung Kook Lee, re 070622 Business Report and Other Material Attachments dated July 10, 2008		Withdrawn
CX-0658	C	Medytox-ITC-00224273	Medytox-ITC-00224273	Attachment to email titled Wave Seed fermentation results		Withdrawn
CX-0659	C	Medytox-ITC-00224574	Medytox-ITC-00224574	Email from Yong Chang Moon to Byung Kook Lee, dated January 29, 2008		Withdrawn
CX-0660	C	Medytox-ITC-00226017	Medytox-ITC-00226017	Email from Young Suk Yoon to Byung Kook Lee, dated December 17, 2007		Withdrawn
CX-0661	C	Medytox-ITC-00232504	Medytox-ITC-00232506	Employment contract of Byung Kook Lee dated April 17, 2004	Seong Hun Chang	Admitted
CX-0665	C	Medytox-ITC-00237318	Medytox-ITC-00237318	Certificate of Good Manufacturing Practice (KGMP Approval Letter) from the Korea Food & Drug Administration dated November 20, 2004	Hyun Ho Jung	Admitted
CX-0667		Medytox-ITC-00237535	Medytox-ITC-00237559	Snapshots of Daewoong's Nabota presentation slides presented at Dubai conference in 2016	Hyun Ho Jung	Admitted
CX-0670	C	Medytox-ITC-00237841	Medytox-ITC-00237841	Email from Chang Woo Suh to Ki Young Yoon, dated July 9, 2009	Chang Woo Suh	Admitted
CX-0671	C	Medytox-ITC-00237842	Medytox-ITC-00237842	Email from Chang Woo Suh to Ki Young Yoon, dated July 13, 2009	Chang Woo Suh	Admitted
CX-0679	C	Medytox-ITC-00237858	Medytox-ITC-00237859	Email from Chang Woo Suh to Ki Young Yoon, dated June 24, 2009	Chang Woo Suh	Admitted
CX-0684	C	Medytox-ITC-00237868	Medytox-ITC-00237868	Email from Chang Woo Suh to Young Pil Lee, dated May 28, 2009	Chang Woo Suh	Admitted
CX-0687	C	Medytox-ITC-00237872	Medytox-ITC-00237872	Email from Chang Woo Suh to Young Pil Lee, dated May 12, 2009		Withdrawn
CX-0688	C	Medytox-ITC-00237873	Medytox-ITC-00237873	Email from Chang Woo Suh to Young Pil Lee, dated May 13, 2009		Withdrawn
CX-0689	C	Medytox-ITC-00237874	Medytox-ITC-00237874	Email from Chang Woo Suh to Young Pil Lee, dated May 19, 2009	Chang Woo Suh	Admitted
CX-0690	C	Medytox-ITC-00237875	Medytox-ITC-00237875	Email from Chang Woo Suh to Young Pil Lee, dated May 20, 2009		Withdrawn
CX-0691	C	Medytox-ITC-00237876	Medytox-ITC-00237877	Email from Chang Woo Suh to Young Pil Lee, dated May 20, 2009		Withdrawn
CX-0693	C	Medytox-ITC-00237879	Medytox-ITC-00237880	Attachment to email containing draft of a confidentiality agreement		Withdrawn
CX-0694	C	Medytox-ITC-00237881	Medytox-ITC-00237883	Attachment to email containing draft of a confidentiality agreement		Withdrawn
CX-0696	C	Medytox-ITC-00237887	Medytox-ITC-00237888	Attachment to email containing Proposal relating to the development of 7s botulinum toxin type A Injection	Hyun Ho Jung	Admitted
CX-0697	C	Medytox-ITC-00237893	Medytox-ITC-00237893	Email from Byung Kook Lee to personal email, dated July 17, 2008		Withdrawn
CX-0698	C	Medytox-ITC-00237916	Medytox-ITC-00237916	Attachment to email containing spreadsheet list of Byung Kook Lee's credit card and loan debts		Withdrawn
CX-0699	C	Medytox-ITC-00237987	Medytox-ITC-00237988	Attachment to email titled Medytox Security Pledge Agreement dated 2007	Seong Hun Chang	Admitted
CX-0700	C	Medytox-ITC-00242627	Medytox-ITC-00242627	Byung Kook Lee Cautus Spreadsheet	Seong Hun Chang	Admitted
CX-0703	C	Medytox-ITC-00263660	Medytox-ITC-00263661	Transfer of Meditoxin Product Items dated August 10, 2004		Withdrawn
CX-0705	C	Medytox-ITC-00263674	Medytox-ITC-00263675	Notification of GMP suitability for pharmaceutical (biological product) manufacturer dated November 20, 2004		Withdrawn
CX-0706	C	Medytox-ITC-00263676	Medytox-ITC-00263676	The clinical trial schedule & plan for Meditoxin for treatment of Essential blepharospasm dated May 16, 2005	Hyun Ho Jung	Admitted
CX-0707	C	Medytox-ITC-00263682	Medytox-ITC-00263687	Log of the process of KFDA consultation regarding clinical trials for Meditoxin between February 24, 2005 and September 5, 2005	Hyun Ho Jung	Admitted
CX-0708	C	Medytox-ITC-00263688	Medytox-ITC-00263855	KFDA product approval for Meditoxin from March 16, 2006 and amendment history	Hyun Ho Jung	Admitted
CX-0709	C	Medytox-ITC-00263860	Medytox-ITC-00263862	Document describing two purification methods for Clostridium botulinum neurotoxin type A dated July 1999	Hyun Ho Jung; Hack Woo Kim	Admitted
CX-0710	C	Medytox-ITC-00263863	Medytox-ITC-00263863	Document identifying culture medium ingredients for production and purification of Botulinum neurotoxin dated July 1999	Hyun Ho Jung; Hack Woo Kim	Admitted
CX-0711	C	Medytox-ITC-00263864	Medytox-ITC-00263871	Report titled "Plan for the Purification of Botulinum Neurotoxin type A following 'B Project'"	Hyun Ho Jung; Hack Woo Kim	Admitted
CX-0712	C	Medytox-ITC-00263872	Medytox-ITC-00263872	Summary of the purification procedures for the neurotoxin from Clostridium Botulinum	Hyun Ho Jung; Hack Woo Kim	Admitted
CX-0713	C	Medytox-ITC-00264294	Medytox-ITC-00264294	Notification from Medytox to KFDA dated July 2002		Withdrawn
CX-0716	C	DAEWOONG00000709	DAEWOONG00000709	May 12, 2017 BLA Cover Letter		Withdrawn
CX-0717	C	DAEWOONG000349575	DAEWOONG000349577	"Nabota Business Headquarters Weekly Work Report (December, 1st Report)," dated December 3, 2018		Withdrawn
CX-0718	C	DAEWOONG000136920	DAEWOONG000136920	July 7, 2017 Letter to FDA regarding draft labeling		Withdrawn
CX-0719	C	DAEWOONG000136947	DAEWOONG000136947	Response to June 19, 2017 FDA		Withdrawn
CX-0720	C	DAEWOONG000136948	DAEWOONG000136948	Response to June 3, 2017 FDA		Withdrawn
CX-0721	C	DAEWOONG000136949	DAEWOONG000136949	Cover Letter enclosing Response to June 3, 2017 and June 19, 2017 FDA		Withdrawn
CX-0722	C	DAEWOONG000136976	DAEWOONG000136976	Response to June 28, 2017 FDA		Withdrawn
CX-0723	C	DAEWOONG000136980	DAEWOONG000136980	Response to June 28, 2017 FDA		Withdrawn
CX-0724	C	DAEWOONG000137064	DAEWOONG000137071	Response to June 26, 2017 FDA		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0725	C	DAEWOONG000138921	DAEWOONG000138927	Document titled "Appendix A" to SN0006		Withdrawn
CX-0726	C	DAEWOONG000138928	DAEWOONG000138930	Response to June 29, 2017 FDA		Withdrawn
CX-0727	C	DAEWOONG000139052	DAEWOONG000139052	July 12, 2017 Letter to FDA		Withdrawn
CX-0728	C	DAEWOONG000139109	DAEWOONG000139109	Response to June 29, 2017 FDA		Withdrawn
CX-0729	C	DAEWOONG000139136	DAEWOONG000139136	Response to July 18, 2017 FDA		Withdrawn
CX-0730	C	DAEWOONG000139193	DAEWOONG000139193	August 2, 2017 Letter to FDA		Withdrawn
CX-0731	C	DAEWOONG000139224	DAEWOONG000139225	Response to August 15, 2017 FDA		Withdrawn
CX-0732	C	DAEWOONG000139483	DAEWOONG000139483	September 15, 2017 120-Day Safety Update		Withdrawn
CX-0733	C	DAEWOONG000139510	DAEWOONG000139538	Response to August 29, 2017 FDA		Withdrawn
CX-0734	C	DAEWOONG000139539	DAEWOONG000139539	Response to August 29, 2017 FDA		Withdrawn
CX-0735	C	DAEWOONG000139588	DAEWOONG000139654	Response to September 12, 2017 FDA		Withdrawn
CX-0736	C	DAEWOONG000139655	DAEWOONG000139655	Response to September 12, 2017 FDA		Withdrawn
CX-0737	C	DAEWOONG000140140	DAEWOONG000140140	Response to September 12, 2017 FDA		Withdrawn
CX-0738	C	DAEWOONG000140161	DAEWOONG000140163	Response to September 22, 2017 FDA		Withdrawn
CX-0739	C	DAEWOONG000140164	DAEWOONG000140167	Response to September 27, 2017 FDA		Withdrawn
CX-0740	C	DAEWOONG000140168	DAEWOONG000140169	Response to September 22, 2017 and September 27, 2017 FDA		Withdrawn
CX-0741	C	DAEWOONG000140298	DAEWOONG000140316	Response to October 19, 2017 FDA		Withdrawn
CX-0742	C	DAEWOONG000140317	DAEWOONG000140317	Response to October 19, 2017 FDA		Withdrawn
CX-0743	C	DAEWOONG000140829	DAEWOONG000140835	Response to November 13, 2017 FDA		Withdrawn
CX-0744	C	DAEWOONG000140836	DAEWOONG000140836	Response to November 13, 2017 and November 20, 2017 FDA		Withdrawn
CX-0745	C	DAEWOONG000140916	DAEWOONG000140924	Response to November 21, 2017 FDA		Withdrawn
CX-0746	C	DAEWOONG000140925	DAEWOONG000140925	Response to November 2, 2017, November 21, 2017, and November 29, 2017 FDA		Withdrawn
CX-0747	C	DAEWOONG000141423	DAEWOONG000141431	Response to November 28, 2017 FDA		Withdrawn
CX-0748	C	DAEWOONG000141432	DAEWOONG000141432	Response to November 28, 2017 FDA		Withdrawn
CX-0749	C	DAEWOONG000141501	DAEWOONG000141572	Response to December 7, 2017 FDA		Withdrawn
CX-0750	C	DAEWOONG000141573	DAEWOONG000141573	Response to December 7, 2017 FDA		Withdrawn
CX-0751	C	DAEWOONG000142495	DAEWOONG000142498	Response to December 20, 2017 FDA		Withdrawn
CX-0752	C	DAEWOONG000142539	DAEWOONG000142541	Response to January 4, 2018 FDA		Withdrawn
CX-0753	C	DAEWOONG000142542	DAEWOONG000142542	Response to January 4, 2018 FDA		Withdrawn
CX-0754	C	DAEWOONG000142665	DAEWOONG000142665	Response to December 20, 2017 FDA		Withdrawn
CX-0755	C	DAEWOONG000143229	DAEWOONG000143229	Cover letter enclosing data in connection with response to November 28, 2017, December 7, 2017, and December 20, 2017		Withdrawn
CX-0756	C	DAEWOONG000143491	DAEWOONG000143491	Response to February 9, 2018 FDA		Withdrawn
CX-0757	C	DAEWOONG000143532	DAEWOONG000143631	Response to February 21, 2018 FDA		Withdrawn
CX-0758	C	DAEWOONG000143632	DAEWOONG000143632	Response to February 21, 2018 FDA		Withdrawn
CX-0759	C	DAEWOONG000143686	DAEWOONG000143686	Response to November 2, 2017 and December 7, 2017 FDA		Withdrawn
CX-0760	C	DAEWOONG000144531	DAEWOONG000144587	Response to March 2, 2018 FDA		Withdrawn
CX-0761	C	DAEWOONG000144588	DAEWOONG000144588	Response to March 2, 2018 FDA		Withdrawn
CX-0762	C	DAEWOONG000144657	DAEWOONG000144676	Response to February 13, 2018 FDA		Withdrawn
CX-0763	C	DAEWOONG000144677	DAEWOONG000144677	Response to February 13, 2018 FDA		Withdrawn
CX-0764	C	DAEWOONG000144809	DAEWOONG000144809	Response to November 2, 2017, December 7, 2017, December 20, 2017, January 4, 2018, February 9, 2018, and February 21, 2018 FDA		Withdrawn
CX-0765	C	DAEWOONG000145083	DAEWOONG000145083	Response to December 7, 2017, December 20, 2017, February 9, 2018, and February 21, 2018 FDA		Withdrawn
CX-0766	C	DAEWOONG000145173	DAEWOONG000145174	Cover Letter in response to May 15, 2018 FDA Complete Response Letter.		Withdrawn
CX-0767	C	DAEWOONG000151464	DAEWOONG000151464	Response to August 29, 2018 FDA		Withdrawn
CX-0768	C	DAEWOONG000151469	DAEWOONG000151474	Response to August 29, 2018 FDA		Withdrawn
CX-0769	C	DAEWOONG000151571	DAEWOONG000151573	Response to August 29, 2018 FDA		Withdrawn
CX-0770	C	DAEWOONG000151574	DAEWOONG000151574	Response to August 29, 2018 FDA		Withdrawn
CX-0771	C	DAEWOONG000151644	DAEWOONG000151644	Response to August 29, 2018 FDA		Withdrawn
CX-0772	C	DAEWOONG000151670	DAEWOONG000151670	October 18, 2018 Letter from Bruce Krattenmaker to Kendall A. Marcus regarding change in official correspondent		Withdrawn
CX-0773	C	DAEWOONG000151695	DAEWOONG000151695	Response to October 16, 2018 FDA		Withdrawn
CX-0774	C	DAEWOONG000151700	DAEWOONG000151704	Response to October 16, 2018 FDA		Withdrawn
CX-0775	C	DAEWOONG000151742	DAEWOONG000151742	DWP-450 CTD Section 1.11.1 Quality Information Amendment in response to Agency dated Oct. 23, 2018		Withdrawn
CX-0776	C	DAEWOONG000151743	DAEWOONG000151743	Response to October 23, 2018 FDA		Withdrawn
CX-0777	C	DAEWOONG000151818	DAEWOONG000151818	Response to November 14, 2018 FDA		Withdrawn
CX-0778	C	DAEWOONG000151849	DAEWOONG000151849	Response to August 29, 2018, October 16, 2018, and October 23, 2018 FDA		Withdrawn
CX-0779	C	DAEWOONG000151937	DAEWOONG000151937	Response to December 17, 2018 FDA		Withdrawn
CX-0780	C	DAEWOONG000151942	DAEWOONG000151955	Response to December 17, 2018 FDA		Withdrawn
CX-0781	C	DAEWOONG000152025	DAEWOONG000152025	Response to December 21, 2018 FDA		Withdrawn
CX-0782	C	DAEWOONG000152100	DAEWOONG000152102	Response to January 9, 2019 FDA		Withdrawn
CX-0783	C	DAEWOONG000152103	DAEWOONG000152103	Response to January 9, 2019 FDA		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0784	C	DAEWOONG000152128	DAEWOONG000152131	Response to August 29, 2018, October 16, 2018, December 17, 2018, December 18, 2018, and January 11, 2019 FDA		Withdrawn
CX-0785	C	DAEWOONG000152132	DAEWOONG000152132	Response to January 11, 2019 FDA		Withdrawn
CX-0786	C	DAEWOONG000152997	DAEWOONG000152998	Response to January 18, 2019 FDA		Withdrawn
CX-0787	C	DAEWOONG000152999	DAEWOONG000152999	Response to January 18, 2019 FDA		Withdrawn
CX-0788	C	DAEWOONG000153130	DAEWOONG000153130	Response to January 22, 2019 FDA		Withdrawn
CX-0789	C	DAEWOONG000153177	DAEWOONG000153177	Response to January 28, 2019 FDA		Withdrawn
CX-0790	C	DAEWOONG000153218	DAEWOONG000153218	Response to January 29, 2019 FDA		Withdrawn
CX-0791	C	DAEWOONG000153260	DAEWOONG000153316	Daewoong-Evolus License & Supply Agreement dated September 30, 2013		Withdrawn
CX-0792	C	DAEWOONG000153320	DAEWOONG000153325	Daewoong Co. and Daewoong Pharmaceutical Organizational Chart	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0793	C	DAEWOONG000153330	DAEWOONG000153345	Daewoong Safety Management Regulation dated March 15, 2017		Withdrawn
CX-0794	C	DAEWOONG000164938	DAEWOONG000164982	Test Results for Daewoong DWP-450 DS Batch 010		Withdrawn
CX-0795	C	DAEWOONG000174813	DAEWOONG000174846	Test Results for Daewoong DWP-450 DP Batch 001	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0796	C	DAEWOONG000180889	DAEWOONG000180928	Product Item Approval Certificate (Nabota Injectable <i>Clostridium botulinum</i> Toxin Type A) dated November 29, 2013 from MFDS		Withdrawn
CX-0797	C	DAEWOONG000204158	DAEWOONG000204171	Nabota Injection Manufacturing and Quality Control Summary		Withdrawn
CX-0798	C	DAEWOONG000213853	DAEWOONG000213921	Daewoong Annual Business Report from April 2010 through December 2010		Withdrawn
CX-0800	C	DAEWOONG000218548	DAEWOONG000218562	DWP-450 culture record for soil sample #4-029-CBB-IS-001 for the period 11/15/2010 to 11/22/2010		Withdrawn
CX-0801		DAEWOONG000218697	DAEWOONG000218701	GenBank <i>Clostridium botulinum</i> strain Hall neurotoxin type A gene, complete cds	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0802		DAEWOONG000218702	DAEWOONG000218703	GenBank <i>Clostridium botulinum</i> strain Hall neurotoxin type A gene, complete cds	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0803	C	DAEWOONG000218749	DAEWOONG000218750	Letter from Daewoong to C. Marmo at Evolus dated November 11, 2016		Withdrawn
CX-0804	C	DAEWOONG000222230	DAEWOONG000222233	Document titled "Checklist table for safety management of biological agent, etc." for Daewoong's Yong-in Research Center dated June 20, 2017		Withdrawn
CX-0805	C	DAEWOONG000222312	DAEWOONG000222348	Nabota Research Project Presentation Meeting Presentation by Kyung Yoon Kim dated June 22, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0806	C	DAEWOONG000222519	DAEWOONG000222535	Draft of DWP-450 CTD Section 2.3.S.2: Quality Overall Summary, Manufacture		Withdrawn
CX-0807	C	DAEWOONG000223294	DAEWOONG000223294	Draft of Daewoong CTD Section 2.2: Overview and Summary of Materials for Daewoong Botulinum Toxin Liquid Injection Drug 50U		Withdrawn
CX-0808	C	DAEWOONG000223349	DAEWOONG000223349	Daewoong Task Tracker Spreadsheet		Withdrawn
CX-0809	C	DAEWOONG000223579	DAEWOONG000223579	Certification of Analysis for Botulinum MCB, written by Kyung Min Min dated March 10, 2011		Withdrawn
CX-0810	C	DAEWOONG000223591	DAEWOONG000223591	Spreadsheet cell bank inventory from June 24, 2010 to September, 2017		Withdrawn
CX-0811	C	DAEWOONG000224292	DAEWOONG000224300	Weekly report from Bio RA department dated June 15, 2017 to June 21, 2017		Withdrawn
CX-0812	C	DAEWOONG000224711	DAEWOONG000224742	Presentation entitled "Daewoong Botulinum Toxin Injectable (Nabota Injectable)," by Kyung Yoon Kim dated February 26, 2018		Withdrawn
CX-0813	C	DAEWOONG000224818	DAEWOONG000224836	Presentation entitled "NABOTA Botulinum Toxin Injection (<i>Clostridium botulinum</i> Toxin Type A) – Manufacturing Process"		Withdrawn
CX-0814	C	DAEWOONG000226533	DAEWOONG000226575	Response to December 20, 2017 FDA		Withdrawn
CX-0815	C	DAEWOONG000226576	DAEWOONG000226690	Response to February 9, 2018 FDA		Withdrawn
CX-0816	C	DAEWOONG000226939	DAEWOONG000226959	Draft of Standard Operating Procedure for "Management of WCB (Working Cell Bank)", Version 6.00		Withdrawn
CX-0817	C	DAEWOONG000229051	DAEWOONG000229072	DWP450-23s-REP-001: Report on "Botulinum Toxin Injectable (DWP450)"		Withdrawn
CX-0818	C	DAEWOONG000236153	DAEWOONG000236172	DWP450-REP-037: Report for manufacture and test results of DWP450 in-house standard (450ST-001)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0819	C	DAEWOONG000238298	DAEWOONG000238315	Award Examination: Korea New Drug Award (KNDA) Application		Withdrawn
CX-0820	C	DAEWOONG000243040	DAEWOONG000243057	Email from Jin Rok Kwon to other Daewoong employees, dated December 4, 2018		Withdrawn
CX-0821	C	DAEWOONG000244652	DAEWOONG000244652	Email from JiSeong Park to Kyung Yoon Kim, dated December 20, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0822	C	DAEWOONG000244653	DAEWOONG000244653	Attachment to email titled "Spore Test Schedule"	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0823	C	DAEWOONG000245383	DAEWOONG000245383	Email from Ji Seong Park to Kyung Yoon Kim dated December 26, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0824	C	DAEWOONG000245415	DAEWOONG000245421	Email from Min-Gyu Hwang to Dong-Hyuk Chang, dated December 28, 2018		Withdrawn
CX-0825	C	DAEWOONG000246598	DAEWOONG000246602	Email from Sanghee Jeon to Jonghee Kim dated September 21, 2018		Withdrawn
CX-0826	C	DAEWOONG000247585	DAEWOONG000247586	Email from Yun Seon Kim to other Daewoong employees, dated October 1, 2018		Withdrawn
CX-0827	C	DAEWOONG000247587	DAEWOONG000247587	Email attachment titled DS IPC test QC history Spreadsheet		Withdrawn
CX-0828	C	DAEWOONG000247590	DAEWOONG000247593	Email from Chang Jin Choi to Sang Hui Jeon et al., dated October 1, 2018		Withdrawn
CX-0829	C	DAEWOONG000254122	DAEWOONG000254122	Email from Kyung Yoon Kim to Ji Sung Park, dated December 26, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0830	C	DAEWOONG000254123	DAEWOONG000254130	Email Attachment containing Ping-Ke Fang, et al., Analysis of genomic differences among <i>Clostridium botulinum</i> type A1 strains, 11 BMC Genomics 725-732 (2010)	Joint Stipulation (Dkt. No. 701591); Paul Keim	Admitted
CX-0831	C	DAEWOONG000254790	DAEWOONG000254792	Daewoong Update of CTD 3.2.S.2.3 for CFDA approval		Withdrawn
CX-0832	C	DAEWOONG000255779	DAEWOONG000255793	DWP450-REP-002: Isolation and identification of <i>Clostridium Botulinum</i> (English)		Withdrawn
CX-0833	C	DAEWOONG000256900	DAEWOONG000256968	Presentation titled "Daewoong Pharmaceutical Nabota Communication Meeting," dated April 24, 2018		Withdrawn
CX-0834	C	DAEWOONG000261751	DAEWOONG000261756	DWP450-32s42-STP-006: Standard Test Procedure (Method of testing to verify spores that can be generated during the DWP450 DS production process), May 31, 2018		Withdrawn
CX-0835	C	DAEWOONG000264179	DAEWOONG000264186	DWP450-32s26-PLN-016: A draft of method and results of testing to verify whether spores form during the DWP450 DS production process		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0836	C	DAEWOONG000275065	DAEWOONG000275117	DWP 450-REP-002 (Addendum); Isolation and Identification of Clostridium botulinum		Withdrawn
CX-0837	C	DAEWOONG000286498	DAEWOONG000286538	DWP450-32s2-REP-008: Addendum - Technology Transfer Report of NABOTA WCB Drug Substance, April 4, 2017		Withdrawn
CX-0838	C	DAEWOONG000325960	DAEWOONG000325961	"Overview of Manufacturing Process for Nabota Drug Substance" & "Recap of Manufacturing Process for Finished Nabota Product"		Withdrawn
CX-0839	C	DAEWOONG000326021	DAEWOONG000326021	Spreadsheet with seven columns, the first four of which are titled: "Development phase," "Research period (start)," "Research period (end)," and "Who performed research/who took over the duty"		Withdrawn
CX-0840	C	DAEWOONG000331713	DAEWOONG000331736	DWP450-REP-076E: Optimization of the Purification Process for DWP450	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
CX-0841	C	DAEWOONG000349573	DAEWOONG000349574	Email string from S. Park to Daewoong recipients dated December 2, 2018		Withdrawn
CX-0842	C	DAEWOONG000349578	DAEWOONG000349579	Daewoong's November 27, 2018 Nabota Evolus video-conference Meeting Minutes dated November 27, 2018		Withdrawn
CX-0843	C	DAEWOONG000353488	DAEWOONG000353490	Email from Seong Soo Park to Seung Ho Jeon, September 9, 2018	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-0844	C	DAEWOONG000353491	DAEWOONG000353492	Email Attachment titled "Meeting Minutes," September 7, 2018	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-0845	C	DAEWOONG000353493	DAEWOONG000353495	Nabota Business Division Weekly Work Report (September 1) dated September 1, 2018		Withdrawn
CX-0846	C	DAEWOONG000355258	DAEWOONG000355258	Letter to Dr. Del Stagg from LCDR Oumou Barry		Withdrawn
CX-0847	C	DAEWOONG000367270	DAEWOONG000367270	Email from Young Jun Song to other Daewoong employees, dated October 16, 2018		Withdrawn
CX-0848	C	DAEWOONG000367286	DAEWOONG000367286	Email attachment titled "Cell Bank History" (list of events from June 24, 2010 to February 24, 2016)		Withdrawn
CX-0849	C	DAEWOONG000368680	DAEWOONG000368681	Email from Hae Yeon Kwon to Byung Chan Park, dated October 22, 2018		Withdrawn
CX-0850	C	DAEWOONG000368706	DAEWOONG000368720	Email attachment containing SOP: Management of WCB (Working Cell Bank)		Withdrawn
CX-0851	C	DAEWOONG000368757	DAEWOONG000368758	Email from Young Jun Song to Sang Ki Kim, Soo Hyun Kim, Byung Chan Park, Jin Tae Kim, Hae In Jung, Hoon Sik An, and Jin Rok Kwon; dated October 22, 2018		Withdrawn
CX-0852	C	DAEWOONG000368759	DAEWOONG000368764	Attachment to email titled "Cell Bank History" (first page contains list of events from June 24, 2010 to June 6, 2018)		Withdrawn
CX-0853	C	DAEWOONG000369493	DAEWOONG000369494	Email from Ah Kyung Seo to other Daewoong employees, dated October 31, 2018		Withdrawn
CX-0854	C	DAEWOONG000369495	DAEWOONG000369548	Email attachment containing "Clostridium Botulinum Toxin Type A: Process Validation Protocol," A-PVP-NBTN003B, October 30, 2018		Withdrawn
CX-0855	C	DAEWOONG000372070	DAEWOONG000372074	Email from Sujeong Kim to Yujin Jo(A) et al., dated November 26, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0856	C	DAEWOONG000372075	DAEWOONG000372076	Attachment to email titled Appendix 1. Details regarding changes	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0857	C	DAEWOONG000372077	DAEWOONG000372102	Attachment to email "Standard Operation Procedure (SOP): WCB handling and control method (Management of WCB (Working Cell Bank))." NPR02-003, Revision No. 6.00	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0858	C	DAEWOONG000408282	DAEWOONG000408283	Email from S.K. Kim to Daewoong recipients dated January 23, 2019		Withdrawn
CX-0859	C	DAEWOONG000446622	DAEWOONG000446653	Presentation titled "Evolus: Evolving the way Aesthetics are Viewed"	Order No. 37	Admitted
CX-0860	C	DAEWOONG000447269	DAEWOONG000447271	"Root Cause Investigation Report (Investigation Report), July 27-30, 2018		Withdrawn
CX-0861	C	DAEWOONG000447272	DAEWOONG000447272	Attachment 1.		Withdrawn
CX-0862	C	DAEWOONG000447273	DAEWOONG000447273	Attachment 2.		Withdrawn
CX-0863	C	DAEWOONG000447274	DAEWOONG000447274	Attachment 3.		Withdrawn
CX-0864	C	DAEWOONG000447275	DAEWOONG000447276	Attachment 4.		Withdrawn
CX-0865	C	DAEWOONG000447277	DAEWOONG000447277	Attachment 5.		Withdrawn
CX-0866	C	DAEWOONG000496116	DAEWOONG000496118	"Root Cause Investigation Report, January 30, 2018		Withdrawn
CX-0867	C	DAEWOONG000514226	DAEWOONG000514226	Spreadsheet of DWP-450-Related Documents		Withdrawn
CX-0868	C	DAEWOONG000514260	DAEWOONG000514278	Draft of I.I.I. Quality Information Amendment dated Nov. 2, 2017		Withdrawn
CX-0869	C	DAEWOONG000523236	DAEWOONG000523242	Yeon Tae Jung Lab Notebook Excerpt (2009-84)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0870	C	DAEWOONG000524297	DAEWOONG000524303	WCB Control Log, Product Code T-BTLN901B, with entries dated February 27, 2016		Withdrawn
CX-0871	C	DAEWOONG000524304	DAEWOONG000524312	WCB Control Log, Product Code T-BTLN901B, with entries dated February 2016 to May 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0872	C	DAEWOONG000524313	DAEWOONG000524316	WCB Verification Log, Product Code T-BTLN90113, with entries dated September 2017 to April 2019		Withdrawn
CX-0873	C	DAEWOONG000524317	DAEWOONG000524323	WCB Disposal Log, Product Code T-BTLN 901B		Withdrawn
CX-0874	C	DAEWOONG000524436	DAEWOONG000524438	Email from Seung Ho Jeon to Seong Soo Park et al., dated October 10, 2018		Withdrawn
CX-0875	C	DAEWOONG000524445	DAEWOONG000524447	Email from Shawn Park to other Daewoong employees, dated October 18, 2018		Withdrawn
CX-0876	C	DAEWOONG000524449	DAEWOONG000524449	Email attachment containing letter from David Moatzeadi, CEO, Evolus, to Sengho Jeon, CEO, Daewoong, September 21, 2018, agreed to September 27, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0877	C	DAEWOONG000524450	DAEWOONG000524453	Email from S.H. Chun to Daewoong recipients dated October 18, 2018		Withdrawn
CX-0878	C	DAEWOONG000524474	DAEWOONG000524474	Reporting on the Results of the US Non-deal Road Show		Withdrawn
CX-0879	C	DAEWOONG000524576	DAEWOONG000524577	Email from Shawn Park to Daewoong recipients dated November 27, 2018		Withdrawn
CX-0880	C	DAEWOONG000524578	DAEWOONG000524579	Minutes from November 27, 2018 Daewoong-Evolus Meeting dated November 27, 2018		Withdrawn
CX-0881	C	DAEWOONG000525070	DAEWOONG000525072	Email from Young Ho Park (Karl, Park YH), to Jae Choon Yun, dated January 11, 2019		Withdrawn
CX-0882	C	DAEWOONG000525204	DAEWOONG000525208	Email from S.H. Chun to Daewoong recipients dated January 28, 2019		Withdrawn
CX-0883	C	DAEWOONG000525243	DAEWOONG000525250	Email from Jae Choon Youn to Jae Choon Youn, dated November 18, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0884	C	DAEWOONG000527250	DAEWOONG000527252	January 9, 2019 FDA		Withdrawn
CX-0885	C	DAEWOONG000527866	DAEWOONG000527871	Email from Hana Kim to other Daewoong employees, dated January 10, 2019		Withdrawn
CX-0886	C	DAEWOONG000527872	DAEWOONG000527872	Email attachment containing excel spreadsheet titled PERT chart		Withdrawn
CX-0887	C	DAEWOONG000531459	DAEWOONG000531459	Email from Hoon Sik An to other Daewoong employees, dated January 28, 2019		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0888	C	DAEWOONG000531460	DAEWOONG000531461	Email attachment containing "Meeting Minutes: Verify the matters required to produce MCB strains and expected kick-off date," January 28, 2019		Withdrawn
CX-0889	C	DAEWOONG000531462	DAEWOONG000531463	Email from Sang Hee Jeon to Byoung Chan Park, dated January 28, 2019		Withdrawn
CX-0890	C	DAEWOONG000531828	DAEWOONG000531828	Email from Hoon Sik An to other Daewoong employees, dated January 30, 2019		Withdrawn
CX-0891	C	DAEWOONG000531829	DAEWOONG000531830	Email attachment containing "Meeting Minutes: To check on what is necessary for MCB strain production and an expected kick-off date," January 30, 2019		Withdrawn
CX-0892	C	DAEWOONG000532537	DAEWOONG000532539	Email from Seong Su Park to Jae Seung Yoon, et al., dated December 17, 2017		Withdrawn
CX-0893	C	DAEWOONG000533097	DAEWOONG000533104	Email from Yoon Kyoung Cha to Jeff Kwon and Daewoong employees, dated January 17, 2018		Withdrawn
CX-0894	C	DAEWOONG000533105	DAEWOONG000533105	Document describing experience of Mr. Yoon, Jae-Seung: Chairman & CEO of Daewoong Corporation	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0895	C	DAEWOONG000533976	DAEWOONG000533981	Email from Jong Wook Lee to Shawn Park, et al., dated March 12, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0896	C	DAEWOONG000534188	DAEWOONG000534190	Email from Sung Soo Park [Shawn Park] to Jae-Seung Yoon, et al., dated March 25, 2018		Withdrawn
CX-0897	C	DAEWOONG000535133	DAEWOONG000535134	Email from Sung Soo Park (Shawn Park) to Jae Seung Yoon, dated May 8, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0898	C	DAEWOONG000535135	DAEWOONG000535139	Attachment to email titled "Evolus Business Trip Report: Pre-launching strategy meeting for sales of Nabota in the USA," April 30-May 3, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0899	C	DAEWOONG000536998	DAEWOONG000537001	Email from Jae Choon Yoon [Jae Chun Yoon] to Seong Soo Park [Shawn Park], dated September 9, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0900	C	DAEWOONG000537102	DAEWOONG000537102	Email from Changjae Lee to Jaehoon Yoon [Jae Chun Yoon], dated September 19, 2018		Withdrawn
CX-0901	C	DAEWOONG000537575	DAEWOONG000537578	Email from Jae Choon Yoon to Sung Soo Park (Shawn Park), dated October 29, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0902	C	DAEWOONG000538318	DAEWOONG000538319	Email from Yoo Chang Kim [Yoochang Kim] to Seung Ho Jeon et al., dated December 17, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0903	C	DAEWOONG000538320	DAEWOONG000538323	Attachment to email titled Alphaeon, "Tx Toxin Update," November 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0904	C	DAEWOONG000538324	DAEWOONG000538326	Attachment to email titled Alphaeon, "AEON Biopharma Process," December 4, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0905	C	DAEWOONG000538327	DAEWOONG000538338	Attachment to email titled H.C. Wainwright & Co., "AEON: Discussion Materials," December 4, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0906	C	DAEWOONG000538339	DAEWOONG000538339	Attachment to email titled containing Letter from Robert E. Grant and Vikram Malik, Alphaeon, to Shawn Park, re RE: Proposed Confidential Term Sheet dated December 4, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0907	C	DAEWOONG000538350	DAEWOONG000538352	Email from I.H. Kim to Daewoong recipients dated December 17, 2018		Withdrawn
CX-0908	C	DAEWOONG000538353	DAEWOONG000538353	AEON Valuation Analysis dated December 17, 2018		Withdrawn
CX-0909	C	DAEWOONG000541933	DAEWOONG000541937	Email chain between Shawn Park, Seng Ho Jeon and other Daewoong employees, dated September 27, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0910	C	DAEWOONG000546117	DAEWOONG000546119	Email from Lee Jong Park to other Daewoong employees, dated October 22, 2015		Withdrawn
CX-0911	C	DAEWOONG000547441	DAEWOONG000547444	Email from Yang Kyu Cho to other Daewoong employees, dated October 22, 2015		Withdrawn
CX-0912	C	DAEWOONG000547445	DAEWOONG000547467	Presentation titled "Basic design of the new factory," dated September 13, 2013		Withdrawn
CX-0913	C	DAEWOONG000547472	DAEWOONG000547473	Email from Yang Kyu Cho to Yoon Seok Jang, dated August 29, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0914	C	DAEWOONG000547542	DAEWOONG000547542	Email Attachment titled Master Plan of New Facility Construction		Withdrawn
CX-0915	C	DAEWOONG000547543	DAEWOONG000547559	Email Attachment titled User Requirements Specification for New Facility Design dated July 7, 2010	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0916	C	DAEWOONG000547560	DAEWOONG000547593	Email Attachment titled SNC Lavalin Pharma, "User Requirements for Basic and Detailed Design," 504495-UR-GXG-00001 Rev.2, March 14, 2011	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0917	C	DAEWOONG000547656	DAEWOONG000547661	Email from Dae Yong Kang to Yang Kyu Cho and other Daewoong employees, dated December 12, 2013		Withdrawn
CX-0918	C	DAEWOONG000547662	DAEWOONG000547760	Email Attachment titled SNC Lavalin Pharma, "Product Block Flow Diagram," 504495-SK-PBC-00000 Rev.1, February 28, 2011		Withdrawn
CX-0919	C	DAEWOONG000548774	DAEWOONG000548790	Daewoong URS for Building a New Plant	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0920	C	DAEWOONG000552918	DAEWOONG000552968	Medytox, "Technical Specification: Pure Stream Generation," Project No. PH.2.213, December 14, 2011		Withdrawn
CX-0921	C	DAEWOONG000617548	DAEWOONG000617551	Email from Del Stagg to Chung Sei Kim and Scott Cannizzaro, dated August 26, 2016		Withdrawn
CX-0922	C	DAEWOONG000618473	DAEWOONG000618476	Consulting Service Agreement between Daewoong Pharmaceutical Co., Ltd. and Chung Sei Kim, December 1, 2017	Chung Sei Kim	Admitted
CX-0923	C	DAEWOONG000618477	DAEWOONG000618479	Consulting Service Agreement between Daewoong Pharmaceutical Co., Ltd. and Chung Sei Kim, December 1, 2018	Chung Sei Kim	Admitted
CX-0924	C	DAEWOONG000622841	DAEWOONG000622844	Evolus FUSE Discussion - updated long term forecast dated March 2019	James Malackowski	Admitted
CX-0925	C	DAEWOONG000623659	DAEWOONG000623677	DWP450-REP-080 Development and Optimization of the Fermentation Process for DWP450		Withdrawn
CX-0926	C	DAEWOONG000623806	DAEWOONG000623814	DWP450-REP-066: Development of the Purification Process for DWP450	Andrew Pickett	Admitted
CX-0927	C	DAEWOONG000630705	DAEWOONG000630717	Wenger, Aaron et al. Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome		Withdrawn
CX-0928	C	DAEWOONG000630718	DAEWOONG000630732	Besser, John et al. Next-Generation Sequencing Technologies and their Application to the Study and Control of Bacterial Infections (April 2018)		Withdrawn
CX-0929	C	DAEWOONG000630744	DAEWOONG000630759	Schirmer, Melanie et al. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform (Dec. 12, 2014)		Withdrawn
CX-0930	C	DAEWOONG000630760	DAEWOONG000630772	Timme, Ruth E. et al. Benchmark datasets for phylogenetic pipeline validation, applications for foodborne pathogen surveillance (Oct. 6, 2017)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0931	C	AGN-ITC-00002805	AGN-ITC-00002840	Allergan-Medytox Pharmacovigilance Agreement		Withdrawn
CX-0932	C	AGN-ITC-00002841	AGN-ITC-00002875	Allergan-Medytox Quality Agreement	Sesha Neervannan	Admitted
CX-0933	C	AGN-ITC-00002914	AGN-ITC-00002914	Medytox Final Invoice	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0934		AGN-ITC-00003642	AGN-ITC-00003886	Evolus' Amended Registration Statement (Form S-1) dated February 1, 2018	James Malackowski	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0935		AGN-ITC-00003887	AGN-ITC-00004036	Evolus, Inc. 10-K for FYE 12/31/2017		Withdrawn
CX-0936		AGN-ITC-00004798	AGN-ITC-00004799	Allergan Pricing Sheet		Withdrawn
CX-0937		AGN-ITC-00004811	AGN-ITC-00004821	Allergan Inc.'s Amended and Restated Certificate of Incorporation (April 14, 1977), filed on May 1, 2013		Withdrawn
CX-0938	C	AGN-ITC-00005176	AGN-ITC-00005178	JSC Meeting Agenda dated June 6, 2016	Sesha Neervannan	Admitted
CX-0939		AGN-ITC-00005352	AGN-ITC-00005371	Allergan 10-K for FYE December 31, 1999		Withdrawn
CX-0940	C	AGN-ITC-00007388	AGN-ITC-00007388	Allergan Internal Agenda re Evolus, dated April 29, 2019		Withdrawn
CX-0941	C	AGN-ITC-00007389	AGN-ITC-00007464	Allergan Internal Deck re Evolus, dated May 6, 2019	Colleen McKenna	Admitted
CX-0942	C	AGN-ITC-00007618	AGN-ITC-00007636	May 2016 Facial US Competitive Update		Withdrawn
CX-0943	C	AGN-ITC-00007658	AGN-ITC-00007680	June 2016 Global Facial Aesthetics Update		Withdrawn
CX-0944	C	AGN-ITC-00007759	AGN-ITC-00007777	April 2016 Global Facial Aesthetics Update		Withdrawn
CX-0945	C	AGN-ITC-00007778	AGN-ITC-00007796	May 2016 Global Facial Aesthetics Update		Withdrawn
CX-0946	C	AGN-ITC-00007797	AGN-ITC-00007829	March 2016 AMWC Global Facial Aesthetics Update		Withdrawn
CX-0947	C	AGN-ITC-00008047	AGN-ITC-00008087	November/December 2017 Bimonthly U.S. Facial Aesthetics Report		Withdrawn
CX-0948	C	AGN-ITC-00008792	AGN-ITC-00008793	Allergan email dated April 7, 2016		Withdrawn
CX-0949	C	AGN-ITC-00009909	AGN-ITC-00009911	Allergan marketing material		Withdrawn
CX-0950	C	AGN-ITC-00009923	AGN-ITC-00009924	Allergan marketing material		Withdrawn
CX-0951	C	AGN-ITC-00009928	AGN-ITC-00009928	Screenshot re Jeuveau		Withdrawn
CX-0952	C	AGN-ITC-00009966	AGN-ITC-00009966	Allergan Internal Data re Evolus		Withdrawn
CX-0953	C	AGN-ITC-00010042	AGN-ITC-00010042	Allergan email dated May 3, 2019		Withdrawn
CX-0954	C	AGN-ITC-00010043	AGN-ITC-00010057	Allergan social media analysis, dated May 2, 2019		Withdrawn
CX-0955	C	AGN-ITC-00010058	AGN-ITC-00010065	Allergan social media analysis, dated April 29, 2019 - May 5, 2019		Withdrawn
CX-0956	C	AGN-ITC-00010066	AGN-ITC-00010066	Allergan email dated April 27, 2019		Withdrawn
CX-0957	C	AGN-ITC-00010067	AGN-ITC-00010067	Screenshot re Evolus dated April 27, 2019		Withdrawn
CX-0958	C	AGN-ITC-00010068	AGN-ITC-00010068	Screenshot re Evolus dated April 27, 2019		Withdrawn
CX-0959	C	AGN-ITC-00010074	AGN-ITC-00010075	Allergan email dated May 2, 2019		Withdrawn
CX-0960	C	AGN-ITC-00010076	AGN-ITC-00010078	Allergan email dated May 14, 2019		Withdrawn
CX-0961	C	AGN-ITC-00010079	AGN-ITC-00010082	Allergan email dated April 29, 2019		Withdrawn
CX-0962	C	AGN-ITC-00010083	AGN-ITC-00010087	Allergan email dated April 30, 2019		Withdrawn
CX-0963	C	AGN-ITC-00010088	AGN-ITC-00010088	Allergan email dated March 19, 2019		Withdrawn
CX-0964	C	AGN-ITC-00010089	AGN-ITC-00010091	Allergan email dated April 24, 2019		Withdrawn
CX-0965	C	AGN-ITC-00010106	AGN-ITC-00010107	Allergan email dated May 6, 2019		Withdrawn
CX-0966	C	AGN-ITC-00010126	AGN-ITC-00010127	Allergan email dated April 27, 2019		Withdrawn
CX-0967	C	AGN-ITC-00010132	AGN-ITC-00010138	Allergan email dated May 3, 2019		Withdrawn
CX-0968	C	AGN-ITC-00010142	AGN-ITC-00010143	Allergan email dated May 3, 2019		Withdrawn
CX-0969	C	N/A	N/A	Complainant Medytox, Inc.'s Third Supplemental Responses and Objections to the Staff's Contention Interrogatories to Medytox, Inc. dated October 2, 2019	Order No. 37	Admitted
CX-0970	C	AGN-ITC-00010264	AGN-ITC-00010265	Allergan email dated May 13, 2019		Withdrawn
CX-0971	C	AGN-ITC-00010267	AGN-ITC-00010268	Allergan trend report re Evolus, for week of May 20, 2019		Withdrawn
CX-0972	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s First Supplemental Responses and Objections to Complainant Medytox Inc.'s First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 1-74) dated May 14, 2019	Joint Stipulation (Dkt. No. 701591); Chang Woo Suh	Admitted
CX-0973	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s First Supplemental Responses and Objections to Staff's First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 1 - 78), May 29, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0974	C	AGN-ITC-00010364	AGN-ITC-00010367	Summary of Allergan ASAPS 2019 Professional Relations dated May 23, 2019		Withdrawn
CX-0975	C	AGN-ITC-00010372	AGN-ITC-00010376	Allergan marketing material		Withdrawn
CX-0976	C	AGN-ITC-00010444	AGN-ITC-00010444	Allergan Financial Projections for 2017		Withdrawn
CX-0977	C	AGN-ITC-00011200	AGN-ITC-00011208	Allergan email dated March 1, 2018		Withdrawn
CX-0981		AGN-ITC-00011682	AGN-ITC-00011850	"Botulinum Neurotoxins: A Comparative Industry Analysis Of Products, Pipelines, Technologies And Stakeholders," La Merie Publishing dated July 12, 2014		Withdrawn
CX-0982	C	AGN-ITC-00011968	AGN-ITC-00011994	Allergan internal material re Nabota/Evosyal, dated November 7, 2016	Colleen McKenna	Admitted
CX-0983	C	AGN-ITC-00013576	AGN-ITC-00013591	Evolus Investor Relations Presentation, "Creating an Aesthetic Evolution," dated June 2018		Withdrawn
CX-0984	C	AGN-ITC-00014136	AGN-ITC-00014137	Allergan email dated November 15, 2018		Withdrawn
CX-0985	C	AGN-ITC-00014138	AGN-ITC-00014139	Allergan email dated November 15, 2018		Withdrawn
CX-0986	C	AGN-ITC-00014140	AGN-ITC-00014140	Allergan email dated November 15, 2018		Withdrawn
CX-0987	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Fourth Supplemental Responses and Objections to Staff's First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 57, 59, 60, 61, 63 and 66), June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0988	C	AGN-ITC-00014172	AGN-ITC-00014174	Allergan email dated November 15, 2018		Withdrawn
CX-0989		AGN-ITC-00014178	AGN-ITC-00014193	Evolus Investor Relations Presentation, "Creating an Aesthetic Evolution," dated November 2018		Withdrawn
CX-0990	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Fifth Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 90-93) dated July 15, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-0991	C	AGN-ITC-00014847	AGN-ITC-00014854	"Evolus Bets Future on Impending Jeuveau Commercial Launch in U.S." Article from Medical Insight dated February 27, 2019		Withdrawn
CX-0992	C	AGN-ITC-00014910	AGN-ITC-00014914	Allergan memo dated July 2017		Withdrawn
CX-0993	C	AGN-ITC-00015111	AGN-ITC-00015112	Allergan email dated February 25, 2019		Withdrawn
CX-0994	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Fourth Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 79-89) dated June 26, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0995	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Third Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 76-78) dated June 10, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-0996	C	AGN-ITC-00015715	AGN-ITC-00015720	Allergan email dated February 7, 2019		Withdrawn
CX-0997	C	AGN-ITC-00015721	AGN-ITC-00015721	Screenshot re Evolus		Withdrawn
CX-0998	C	AGN-ITC-00017113	AGN-ITC-00017137	Toxin Portfolio Discussion: "Cross-Franchise and Region Alignment," dated March 2015		Withdrawn
CX-0999	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainants Allergan PLC's and Allergan, Inc.'s First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 1-3) dated July 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1000	C	AGN-ITC-00019949	AGN-ITC-00019959	Allergan slides dated September 24, 2018		Withdrawn
CX-1001	C	AGN-ITC-00020045	AGN-ITC-00020047	Allergan email dated February 5, 2019		Withdrawn
CX-1002	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Second Supplemental Responses and Objections to Complainant Medytox Inc.'s First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 31) dated June 28, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1003	C	AGN-ITC-00023391	AGN-ITC-00023393	Allergan email dated February 21, 2017		Withdrawn
CX-1004	C	AGN-ITC-00023394	AGN-ITC-00023447	Allergan deck dated January 31, 2017		Withdrawn
CX-1005	C	AGN-ITC-00027570	AGN-ITC-00027570	Allergan email dated November 20, 2018		Withdrawn
CX-1006	C	AGN-ITC-00027571	AGN-ITC-00027608	Facial Aesthetics presentation 2018	Colleen McKenna	Admitted
CX-1007	C	AGN-ITC-00030181	AGN-ITC-00030185	Allergan Financial Modeling, dated May 2019		Withdrawn
CX-1008	C	AGN-ITC-00030187	AGN-ITC-00030188	Allergan U.S. Brand Price Change Form dated January 2016		Withdrawn
CX-1009	C	AGN-ITC-00030189	AGN-ITC-00030377	Evolus, Inc. 10-K for FYE 12/31/2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1010	C	AGN-ITC-00030378	AGN-ITC-00030516	Evolus, Inc. 10-Q for quarterly period end March 31, 2019	Order No. 37	Admitted
CX-1011	C	AGN-ITC-00030517	AGN-ITC-00030573	Evolus Prospectus Supplement dated May 15, 2019		Withdrawn
CX-1012	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Second Supplemental Responses and Objections to Staff's First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 61-62), May 31, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1013	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Supplemental Responses and Objections to Complainants' Interrogatories (Nos. 9-12, 16-17) and Medytox's Third Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 76) dated June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1014	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Supplemental Responses and Objections to Complainants' Interrogatories (Nos. 9 & 17) and Medytox's Third Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 76) dated July 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1015	C	AGN-ITC-00031230	AGN-ITC-00031233	Allergan internal notes re Evolus		Withdrawn
CX-1016	C	AGN-ITC-00031501	AGN-ITC-00031542	Manuscript re Evolus study, dated May 3, 2019		Withdrawn
CX-1017	C	AGN-ITC-00032063	AGN-ITC-00032063	Allergan email dated June 5, 2019	Colleen McKenna	Admitted
CX-1018	C	AGN-ITC-00032102	AGN-ITC-00032104	Call Report - Evolus - Jefferies 2019 Healthcare Conference dated June 5, 2019		Withdrawn
CX-1019	C	AGN-ITC-00032169	AGN-ITC-00032170	Allergan email dated June 17, 2019		Withdrawn
CX-1020	C	AGN-ITC-00032171	AGN-ITC-00032186	Allergan social media analysis, dated June 17, 2019		Withdrawn
CX-1021	C	AGN-ITC-00032305	AGN-ITC-00032309	"Evolus, Inc. at The JMP Securities Life Sciences Conference," JMP Group, June 19, 2019		Withdrawn
CX-1022	C	AGN-ITC-00032785	AGN-ITC-00032790	Allergan email dated April 8, 2019		Withdrawn
CX-1023	C	AGN-ITC-00032791	AGN-ITC-00032832	"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects," dated April 2019		Withdrawn
CX-1024	C	AGN-ITC-00033667	AGN-ITC-00033667	Allergan email dated May 3, 2019		Withdrawn
CX-1025	C	AGN-ITC-00033854	AGN-ITC-00033854	Allergan email		Withdrawn
CX-1026	C	AGN-ITC-00033856	AGN-ITC-00033872	Allergan social media analysis dated May 5, 2019		Withdrawn
CX-1027	C	AGN-ITC-00034626	AGN-ITC-00034626	Allergan email dated May 13, 2019		Withdrawn
CX-1028	C	AGN-ITC-00037074	AGN-ITC-00037093	Allergan slides re March 27, 2019 team meeting		Withdrawn
CX-1029	C	AGN-ITC-00037578	AGN-ITC-00037578	Allergan email dated June 10, 2019		Withdrawn
CX-1030	C	AGN-ITC-00037579	AGN-ITC-00037605	Allergan deck re Evolus dated June 10, 2019		Withdrawn
CX-1031	C	AGN-ITC-00038206	AGN-ITC-00038206	Allergan email dated May 13, 2019		Withdrawn
CX-1032	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Third Supplemental Responses and Objections to Staff's First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 57-60, 63-66), June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1033	C	N/A	N/A	It's Alive! Uncovering the roots of life in forest soil, SoilWeb, https://biology.soilweb.ca/#		Withdrawn
CX-1034	C	AGN-ITC-00038305	AGN-ITC-00038305	Allergan email dated May 16, 2019		Withdrawn
CX-1035	C	AGN-ITC-00038306	AGN-ITC-00038310	Allergan deck re Evolus, dated May 16, 2019		Withdrawn
CX-1036	C	AGN-ITC-00038878	AGN-ITC-00038879	Allergan V.A.T. No. IE 9839941K dated February 27, 2015		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1037	C	AGN-ITC-00038891	AGN-ITC-00038891	Medytox Commercial Invoice re MT10109L dated April 24, 2014		Withdrawn
CX-1038	C	AGN-ITC-00038892	AGN-ITC-00038892	Medytox Commercial Invoice re MT10109L dated April 10, 2015		Withdrawn
CX-1039	C	AGN-ITC-00038893	AGN-ITC-00038893	Medytox End Use Letter dated April 9, 2015		Withdrawn
CX-1040	C	AGN-ITC-00038894	AGN-ITC-00038894	Medytox Commercial Invoice re MT10109L dated May 29, 2014		Withdrawn
CX-1041	C	AGN-ITC-00043207	AGN-ITC-00043234	Presentation to Dermatology Scientific Advisory Board dated May 31, 2017	Sesha Neervannan	Admitted
CX-1042	C	AGN-ITC-00043236	AGN-ITC-00043302	Global Development Strategy Presentation, dated May 30, 2019	James Malackowski; Sesha Neervannan	Admitted
CX-1043		N/A	N/A	Jacob Waugh et al., Nonclinical and Clinical Experiences with CPP-Based Self-Assembling Peptide Systems in topical drug development, Cell-Penetrating Peptides Methods and Protocols 553-572 (Ulo Langel ed., 2011).		Withdrawn
CX-1044	C	AGN-ITC-00050720	AGN-ITC-00050720	Allergan Revenue Modeling re Medytox for 2023-2030		Withdrawn
CX-1045	C	AGN-ITC-00052263	AGN-ITC-00052272	Allergan presentation dated March 22, 2019		Withdrawn
CX-1046	C	AGN-ITC-00060983	AGN-ITC-00061097	Allergan Financial Projections, dated June 7, 2019		Withdrawn
CX-1047	C	AGN-ITC-00061098	AGN-ITC-00061098	Allergan Financial Projections, dated June 12, 2019		Withdrawn
CX-1048	C	AGN-ITC-00061948	AGN-ITC-00061948	Allergan email dated June 16, 2019		Withdrawn
CX-1049	C	AGN-ITC-00061949	AGN-ITC-00061974	Allergan Brand Plan, dated June 16, 2019		Withdrawn
CX-1050	C	AGN-ITC-00061998	AGN-ITC-00062000	Allergan email dated June 18, 2019	Colleen McKenna	Admitted
CX-1051	C	AGN-ITC-00062001	AGN-ITC-00062016	BOTOX® Evolus Launch May 2019 Guidepoint Data dated June 18, 2019	Colleen McKenna	Admitted
CX-1052	C	AGN-ITC-00063185	AGN-ITC-00063186	Allergan email dated June 5, 2019		Withdrawn
CX-1053	C	AGN-ITC-00063187	AGN-ITC-00063187	Allergan Financial Modeling dated June 5, 2019		Withdrawn
CX-1054	C	AGN-ITC-00063188	AGN-ITC-00063189	Allergan Financial Modeling dated June 5, 2019		Withdrawn
CX-1055	C	AGN-ITC-00067434	AGN-ITC-00067530	"2019 Facial Injectable Dosing Records NTX Report" for April 11, 2019 Meeting dated April 11, 2019	Colleen McKenna	Admitted
CX-1056	C	AGN-ITC-00070875	AGN-ITC-00070892	Neurotoxin Monthly Tracker Report for April 2019 data month		Withdrawn
CX-1057	C	AGN-ITC-00071307	AGN-ITC-00071307	Allergan email dated June 19, 2019		Withdrawn
CX-1058	C	AGN-ITC-00071308	AGN-ITC-00071334	Allergan Brand Plan, dated June 19, 2019		Withdrawn
CX-1059	C	AGN-ITC-00072006	AGN-ITC-00072018	Allergan Pricing Analysis, dated August 14, 2018		Withdrawn
CX-1060	C	AGN-ITC-00073381	AGN-ITC-00073405	Allergan Financial Modeling, dated May 2019		Withdrawn
CX-1061	C	AGN-ITC-00073422	AGN-ITC-00073453	ABEC Revised Proposal - Allergan Manufacturing Facility		Withdrawn
CX-1062	C	AGN-ITC-00073454	AGN-ITC-00073466	ACER 3730 (Amendment to ACER 1951)		Withdrawn
CX-1063	C	AGN-ITC-00073524	AGN-ITC-00073524	Allergan Capital Expenditure Request (Form CE1)		Withdrawn
CX-1064	C	AGN-ITC-00073525	AGN-ITC-00073544	Allergan Licensure		Withdrawn
CX-1065	C	AGN-ITC-00073545	AGN-ITC-00073553	Allergan presentation dated May 2018	Ben Marzouk	Admitted
CX-1066	C	AGN-ITC-00073554	AGN-ITC-00073556	Allergan presentation dated April 24, 2018		Withdrawn
CX-1067	C	AGN-ITC-00073833	AGN-ITC-00073833	Allergan floor plan		Withdrawn
CX-1068	C	AGN-ITC-00073834	AGN-ITC-00073834	Allergan floor plan		Withdrawn
CX-1069	C	AGN-ITC-00073835	AGN-ITC-00073835	Allergan floor plan		Withdrawn
CX-1070	C	AGN-ITC-00073836	AGN-ITC-00073926	2018 Facial Injectable Dosing Records NTX Final Report		Withdrawn
CX-1071	C	AGN-ITC-00073927	AGN-ITC-00073947	Facial Injectable Presentation		Withdrawn
CX-1072	C	AGN-ITC-00073948	AGN-ITC-00074196	Allergan Toxin Franchise Strategy deck, dated July 30 2014		Withdrawn
CX-1073	C	AGN-ITC-00074197	AGN-ITC-00074197	Allergan HR Information		Withdrawn
CX-1074	C	AGN-ITC-00074198	AGN-ITC-00074198	PMD Lot Transaction Report - July 1, 2019		Withdrawn
CX-1075	C	AGN-ITC-00074330	AGN-ITC-00074367	2019 Allergan 360 Aesthetics Report		Withdrawn
CX-1076	C	AGN-ITC-00082670	AGN-ITC-00082671	Allergan email dated November 16, 2018		Withdrawn
CX-1077	C	AGN-ITC-00082783	AGN-ITC-00082783	WBS Integration RD Future		Withdrawn
CX-1078		AGN-ITC-00086008	AGN-ITC-00086008	Apr 10 ASP Pricing File 031811		Withdrawn
CX-1079		AGN-ITC-00086009	AGN-ITC-00086009	Apr 13 ASP Pricing file updated 112513		Withdrawn
CX-1080		AGN-ITC-00086010	AGN-ITC-00086010	Apr 14 ASP Pricing File updated 022615		Withdrawn
CX-1081		AGN-ITC-00086011	AGN-ITC-00086011	Apr 15 ASP Pricing File - updated 090115		Withdrawn
CX-1082		AGN-ITC-00086012	AGN-ITC-00086012	Apr 16 ASP Pricing File updated 090116		Withdrawn
CX-1083		AGN-ITC-00086013	AGN-ITC-00086013	Apr 17 ASP Pricing File updated 082817		Withdrawn
CX-1084		AGN-ITC-00086014	AGN-ITC-00086014	Apr 2012 ASP Pricing file - revised 030513		Withdrawn
CX-1085		AGN-ITC-00086015	AGN-ITC-00086015	Apr 2018 ASP Pricing File 031318		Withdrawn
CX-1086		AGN-ITC-00086016	AGN-ITC-00086016	April 2009 ASP Pricing File Revised 031810		Withdrawn
CX-1087		AGN-ITC-00086017	AGN-ITC-00086017	Jan 08 NOC ASP Pricing File 121307		Withdrawn
CX-1088		AGN-ITC-00086018	AGN-ITC-00086018	Jan 08 NOC ASP Pricing File 121307		Withdrawn
CX-1089		AGN-ITC-00086019	AGN-ITC-00086019	Jan 14 ASP Pricing File updated 120514		Withdrawn
CX-1090		AGN-ITC-00086020	AGN-ITC-00086020	Jan 15 ASP Pricing File - updated 120915		Withdrawn
CX-1091		AGN-ITC-00086021	AGN-ITC-00086021	Jan 16 ASP Pricing File updated 052716		Withdrawn
CX-1092		AGN-ITC-00086022	AGN-ITC-00086022	Jan 17 ASP Pricing File updated 121217		Withdrawn
CX-1093		AGN-ITC-00086023	AGN-ITC-00086023	Jan 18 ASP Pricing File updated 030218		Withdrawn
CX-1094		AGN-ITC-00086024	AGN-ITC-00086024	JAN 2009 ASP Pricing File by HCPCS revised 121409		Withdrawn
CX-1095		AGN-ITC-00086025	AGN-ITC-00086025	Jan 2012 ASP Pricing File 120911		Withdrawn
CX-1096		AGN-ITC-00086026	AGN-ITC-00086026	Jan 2013 ASP Pricing File updated 112513		Withdrawn
CX-1097		AGN-ITC-00086027	AGN-ITC-00086027	Jan11 ASP Pricing file revised 092011		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1098		AGN-ITC-00086028	AGN-ITC-00086028	January 2010 ASP Price File 092010		Withdrawn
CX-1099		AGN-ITC-00086029	AGN-ITC-00086029	Jul 13 ASP Pricing File updated 060614		Withdrawn
CX-1100		AGN-ITC-00086030	AGN-ITC-00086030	Jul 15 ASP Pricing File - updated 090115		Withdrawn
CX-1101		AGN-ITC-00086031	AGN-ITC-00086031	Jul 16 ASP Pricing File updated 053017		Withdrawn
CX-1102		AGN-ITC-00086032	AGN-ITC-00086032	Jul 2011 ASP Pricing File updated 121411		Withdrawn
CX-1103		AGN-ITC-00086033	AGN-ITC-00086033	Jul 2012 ASP Pricing File - revised 060513		Withdrawn
CX-1104		AGN-ITC-00086034	AGN-ITC-00086034	Jul 2014 ASP Pricing File updated 022615		Withdrawn
CX-1105		AGN-ITC-00086035	AGN-ITC-00086035	Jul 2017 ASP Pricing File 082817		Withdrawn
CX-1106		AGN-ITC-00086036	AGN-ITC-00086036	Jul 2018 ASP Pricing File updated 052919		Withdrawn
CX-1107		AGN-ITC-00086037	AGN-ITC-00086037	Jul 2019 ASP Pricing File 061719		Withdrawn
CX-1108		AGN-ITC-00086038	AGN-ITC-00086038	July 2008 ASP NOC Pricing File 091708		Withdrawn
CX-1109		AGN-ITC-00086039	AGN-ITC-00086039	July 2008 ASP Pricing File by HCPCS 032509		Withdrawn
CX-1110		AGN-ITC-00086040	AGN-ITC-00086040	July 2009 ASP Pricing File by HCPCS Revised 061810		Withdrawn
CX-1111		AGN-ITC-00086041	AGN-ITC-00086041	July 2010 ASP Pricing File 061611		Withdrawn
CX-1112		AGN-ITC-00086042	AGN-ITC-00086042	Oct.10 ASP Pricing File revised 09152011		Withdrawn
CX-1113		AGN-ITC-00086043	AGN-ITC-00086043	Oct 11 ASP Pricing File updated 121411		Withdrawn
CX-1114		AGN-ITC-00086044	AGN-ITC-00086044	Oct 12 ASP Pricing File revised 060513		Withdrawn
CX-1115		AGN-ITC-00086045	AGN-ITC-00086045	Oct 13 ASP Pricing File updated 060614		Withdrawn
CX-1116		AGN-ITC-00086046	AGN-ITC-00086046	Oct 15 ASP Pricing File - updated 120915		Withdrawn
CX-1117		AGN-ITC-00086047	AGN-ITC-00086047	Oct 16 ASP Pricing File updated 082817		Withdrawn
CX-1118		AGN-ITC-00086048	AGN-ITC-00086048	Oct 17 ASP Pricing File 083017		Withdrawn
CX-1119		AGN-ITC-00086049	AGN-ITC-00086049	Oct 18 ASP Pricing File updated 052919		Withdrawn
CX-1120		AGN-ITC-00086050	AGN-ITC-00086050	Oct14 ASP Pricing File - revised 090115		Withdrawn
CX-1121		AGN-ITC-00086051	AGN-ITC-00086051	October 2007 ASP NOC Pricing File 121407		Withdrawn
CX-1122		AGN-ITC-00086052	AGN-ITC-00086052	October 2008 ASP Pricing File by HCPCS revised 032509		Withdrawn
CX-1123		AGN-ITC-00086053	AGN-ITC-00086053	October 2009 ASP Price File Revised 092010		Withdrawn
CX-1124		AGN-ITC-00086054	AGN-ITC-00086054	October 2009 ASP Price File Revised 092010		Withdrawn
CX-1125		AGN-ITC-00086055	AGN-ITC-00086055	Section 508 Apr 10 ASP Pricing File 031811		Withdrawn
CX-1126		AGN-ITC-00086056	AGN-ITC-00086056	Section 508 April 2009 ASP Pricing File Revised 031810		Withdrawn
CX-1127		AGN-ITC-00086057	AGN-ITC-00086057	Section 508 JAN 2009 ASP Pricing File by HCPCS revised 121409		Withdrawn
CX-1128		AGN-ITC-00086058	AGN-ITC-00086058	Section 508 January 2010 ASP Price File 092010		Withdrawn
CX-1129		AGN-ITC-00086059	AGN-ITC-00086059	Section 508 July 2009 ASP Pricing File by HCPCS Revised 061810		Withdrawn
CX-1130		AGN-ITC-00086060	AGN-ITC-00086060	Section 508 July 2010 ASP Pricing File 061611		Withdrawn
CX-1131		AGN-ITC-00086061	AGN-ITC-00086061	Section 508 version of Apr 13 ASP Pricing file updated 112513		Withdrawn
CX-1132		AGN-ITC-00086062	AGN-ITC-00086062	Section 508 version of Apr 14 ASP Pricing File updated 022615		Withdrawn
CX-1133		AGN-ITC-00086063	AGN-ITC-00086063	Section 508 version of Apr 15 ASP Pricing File - updated 090115		Withdrawn
CX-1134		AGN-ITC-00086064	AGN-ITC-00086064	Section 508 version of Apr 16 ASP Pricing File updated 090116		Withdrawn
CX-1135		AGN-ITC-00086065	AGN-ITC-00086065	Section 508 version of Apr 17 ASP Pricing File updated 082817		Withdrawn
CX-1136		AGN-ITC-00086066	AGN-ITC-00086066	Section 508 version of Apr 2012 ASP Pricing file - revised 030513		Withdrawn
CX-1137		AGN-ITC-00086067	AGN-ITC-00086067	Section 508 version of Apr 2018 ASP Pricing File 031318		Withdrawn
CX-1138		AGN-ITC-00086068	AGN-ITC-00086068	Section 508 version of April 2008 NOC ASP Pricing File 091808		Withdrawn
CX-1139		AGN-ITC-00086069	AGN-ITC-00086069	Section 508 version of Jan 14 ASP Pricing File updated 120514		Withdrawn
CX-1140		AGN-ITC-00086070	AGN-ITC-00086070	Section 508 version of Jan 15 ASP Pricing File - updated 120915		Withdrawn
CX-1141		AGN-ITC-00086071	AGN-ITC-00086071	Section 508 version of Jan 16 ASP Pricing File updated 052716		Withdrawn
CX-1142		AGN-ITC-00086072	AGN-ITC-00086072	Section 508 version of Jan 17 ASP Pricing File updated 121217		Withdrawn
CX-1143		AGN-ITC-00086073	AGN-ITC-00086073	Section 508 version of Jan 18 ASP Pricing File updated 030218		Withdrawn
CX-1144		AGN-ITC-00086074	AGN-ITC-00086074	Section 508 version of Jan 2012 ASP Pricing File 120911		Withdrawn
CX-1145		AGN-ITC-00086075	AGN-ITC-00086075	Section 508 version of Jan 2013 ASP Pricing File updated 112513		Withdrawn
CX-1146		AGN-ITC-00086076	AGN-ITC-00086076	Section 508 version of Jan11 ASP Pricing file revised 092011		Withdrawn
CX-1147		AGN-ITC-00086077	AGN-ITC-00086077	Section 508 version of Jul 13 ASP Pricing File updated 060614		Withdrawn
CX-1148		AGN-ITC-00086078	AGN-ITC-00086078	Section 508 version of Jul 15 ASP Pricing File - updated 090115		Withdrawn
CX-1149		AGN-ITC-00086079	AGN-ITC-00086079	Section 508 version of Jul 16 ASP Pricing File updated 053017		Withdrawn
CX-1150		AGN-ITC-00086080	AGN-ITC-00086080	Section 508 version of Jul 2011 ASP Pricing File updated 121411		Withdrawn
CX-1151		AGN-ITC-00086081	AGN-ITC-00086081	Section 508 version of Jul 2012 ASP Pricing File - revised 060513		Withdrawn
CX-1152		AGN-ITC-00086082	AGN-ITC-00086082	Section 508 version of Jul 2014 ASP Pricing File updated 022615		Withdrawn
CX-1153		AGN-ITC-00086083	AGN-ITC-00086083	Section 508 version of Jul 2017 ASP Pricing File 082817		Withdrawn
CX-1154		AGN-ITC-00086084	AGN-ITC-00086084	Section 508 version of Jul 2018 ASP Pricing File updated 052919		Withdrawn
CX-1155		AGN-ITC-00086085	AGN-ITC-00086085	Section 508 version of Jul 2019 ASP Pricing File 061719		Withdrawn
CX-1156		AGN-ITC-00086086	AGN-ITC-00086086	Section 508 version of July 2008 ASP NOC Pricing File 091708		Withdrawn
CX-1157		AGN-ITC-00086087	AGN-ITC-00086087	Section 508 version of July 2008 ASP Pricing File by HCPCS 032509		Withdrawn
CX-1158		AGN-ITC-00086088	AGN-ITC-00086088	Section 508 version of Oct 10 ASP Pricing File revised 09152011		Withdrawn
CX-1159		AGN-ITC-00086089	AGN-ITC-00086089	Section 508 version of Oct 11 ASP Pricing File updated 121411		Withdrawn
CX-1160		AGN-ITC-00086090	AGN-ITC-00086090	Section 508 version of Oct 12 ASP Pricing File revised 060513		Withdrawn
CX-1161		AGN-ITC-00086091	AGN-ITC-00086091	Section 508 version of Oct 13 ASP Pricing File updated 060614		Withdrawn
CX-1162		AGN-ITC-00086092	AGN-ITC-00086092	Section 508 version of Oct 15 ASP Pricing File - updated 120915		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1163		AGN-ITC-00086093	AGN-ITC-00086093	Section 508 version of Oct 16 ASP Pricing File updated 082817		Withdrawn
CX-1164		AGN-ITC-00086094	AGN-ITC-00086094	Section 508 version of Oct 17 ASP Pricing File 083017		Withdrawn
CX-1165		AGN-ITC-00086095	AGN-ITC-00086095	Section 508 version of Oct 18 ASP Pricing File updated 052919		Withdrawn
CX-1166		AGN-ITC-00086096	AGN-ITC-00086096	Section 508 version of Oct14 ASP Pricing File - revised 090115		Withdrawn
CX-1167		AGN-ITC-00086097	AGN-ITC-00086097	Section 508 version of October 2008 ASP Pricing File by HCPCS revised 032509		Withdrawn
CX-1168		AGN-ITC-00086098	AGN-ITC-00086103	FDA Supplemental Approval - Fulfillment of Postmarketing Requirements, Fulfillment of Postmarketing Commitment relating to Allergan's BLA103000/S-5309		Withdrawn
CX-1169		AGN-ITC-00086104	AGN-ITC-00086151	Highlights of Prescribing Information re BOTOX		Withdrawn
CX-1170	C	AGN-ITC-00093720	AGN-ITC-00093720	Allergan headcount - June 19, 2019		Withdrawn
CX-1171	C	AGN-ITC-00094383	AGN-ITC-00094383	Cost Centers	James Malackowski; Ben Marzouk	Admitted
CX-1172	C	AGN-ITC-00095131	AGN-ITC-00095131	Inventory held		Withdrawn
CX-1173	C	AGN-ITC-00106843	AGN-ITC-00106861	Allergan presentation dated May 29, 2019	James Malackowski	Admitted
CX-1174	C	AGN-ITC-00106863	AGN-ITC-00106908	Allergan Operations Overview		Withdrawn
CX-1175	C	AGN-ITC-00106941	AGN-ITC-00106941	California State Drug Manufacturing License	James Malackowski; Sesha Neervannan	Admitted
CX-1176		AGN-ITC-00132655	AGN-ITC-00132660	Manufacturing Facility XL Construction		Withdrawn
CX-1177		AGN-ITC-00132661	AGN-ITC-00132678	"Botox Academy" - BOTOX (onabotulinumtoxinA) for Medical Professionals		Withdrawn
CX-1178		AGN-ITC-00132684	AGN-ITC-00132692	Tamara Mathias, "Evolus says launch of its Botox rival ahead of its expectations," Reuters dated August 12, 2019		Withdrawn
CX-1179		AGN-ITC-00132693	AGN-ITC-00132695	"Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program", Evolus, Inc. dated September 4, 2019	James Malackowski	Admitted
CX-1180		AGN-ITC-00132696	AGN-ITC-00132702	Mee Young Park, et al., "Botulinum Toxin Type A Treatment for Contouring of the Lower Face," Dermatol Surg, May 5, 2003; Vol (29).		Withdrawn
CX-1181		AGN-ITC-00132712	AGN-ITC-00132713	"Allergan in the United States," from Allergan's website		Withdrawn
CX-1182		AGN-ITC-00132714	AGN-ITC-00132715	"About," from Allergan's website		Withdrawn
CX-1183		AGN-ITC-00132716	AGN-ITC-00132717	"Medy Tox Inc.," Profile, Reuters		Withdrawn
CX-1184		AGN-ITC-00132718	AGN-ITC-00132719	"About Medytox – Overview," from Medytox's website		Withdrawn
CX-1185		AGN-ITC-00132722	AGN-ITC-00132724	"Botulinum Toxin Product - Meditoxin® (Neuronox)," from Medytox's website		Withdrawn
CX-1186		AGN-ITC-00132725	AGN-ITC-00132725	"Company Profile - Introduction," from Daewoong Pharmaceuticals Co. Ltd.'s website		Withdrawn
CX-1187		AGN-ITC-00132726	AGN-ITC-00132728	"Global Business - Introduction," from Daewoong Pharmaceuticals Co. Ltd.'s website		Withdrawn
CX-1188		AGN-ITC-00132729	AGN-ITC-00132732	"Global R&D Centers," from Daewoong Pharmaceuticals Co. Ltd.'s website		Withdrawn
CX-1189		AGN-ITC-00132733	AGN-ITC-00132734	"Overseas": Overview of Daewoong's overseas labs, from Daewoong Pharmaceuticals Co. Ltd.'s website		Withdrawn
CX-1190		AGN-ITC-00132735	AGN-ITC-00132735	"Daewoong Pharmaceutical's botulinum toxin becomes the first Korea-made Botulinum Toxin to obtain US FDA approval," Daewoong Pharmaceuticals Co. Ltd. dated February 2, 2019		Withdrawn
CX-1191		AGN-ITC-00132736	AGN-ITC-00132736	"Company Overview – Evolus, Inc.," Bloomberg		Withdrawn
CX-1192		AGN-ITC-00132737	AGN-ITC-00132742	"Hello, Jeuveau"		Withdrawn
CX-1193		AGN-ITC-00132743	AGN-ITC-00132749	Hannah Nichols, "Everything you need to know about Botox," Medical News Today dated August 15, 2017		Withdrawn
CX-1194		AGN-ITC-00132750	AGN-ITC-00132755	"Science of BOTOX® Cosmetic"		Withdrawn
CX-1195		AGN-ITC-00132756	AGN-ITC-00132759	"The Story Behind BOTOX® Cosmetic"		Withdrawn
CX-1196		AGN-ITC-00132763	AGN-ITC-00132764	"What is Strabismus?," Optometrists Network, https://www.strabismus.org .		Withdrawn
CX-1197		AGN-ITC-00132765	AGN-ITC-00132812	"Highlights of Prescribing Information, BOTOX," FDA, June 2019	Sesha Neervannan	Admitted
CX-1198		AGN-ITC-00132813	AGN-ITC-00132835	"Highlights of Prescribing Information, BOTOX Cosmetic," FDA, October 2017	Sesha Neervannan	Admitted
CX-1199		AGN-ITC-00132836	AGN-ITC-00132850	Bahman Jabbari, "History of Botulinum Toxin Treatment in Movement Disorders," NIH dated November 28, 2016		Withdrawn
CX-1200		AGN-ITC-00132851	AGN-ITC-00132853	"Botulinum Toxin Type A (BOTOX) - Product Approval Information – Licensing Action," Department of Health and Human Services dated December 21, 2000	Sesha Neervannan	Admitted
CX-1201		AGN-ITC-00132854	AGN-ITC-00132856	"Botulinum Toxin Type A (BOTOX) - Product Approval Information – Licensing Action," Department of Health and Human Services dated April 12, 2002	Sesha Neervannan	Admitted
CX-1202		AGN-ITC-00132857	AGN-ITC-00132860	"Center for Drug Evaluation and Research – Approval Package Letter," Department of Health and Human Services relating to Allergan's BLA 103000 dated July 19, 2004	Sesha Neervannan	Admitted
CX-1203		AGN-ITC-00132861	AGN-ITC-00132865	"Center for Drug Evaluation and Research – Approval Package Letter," Department of Health and Human Services relating to Allergan's BLA 103000 dated March 9, 2010	Sesha Neervannan	Admitted
CX-1204		AGN-ITC-00132866	AGN-ITC-00132870	"Center for Drug Evaluation and Research – Approval Package Letter," Department of Health and Human Services relating to Allergan's BLA 103000 dated October 15, 2010	Sesha Neervannan	Admitted
CX-1205		AGN-ITC-00132871	AGN-ITC-00132875	"Supplement BLA Approval," Department of Health and Human Services relating to Allergan's BLA 103000 dated August 24, 2011	Sesha Neervannan	Admitted
CX-1206		AGN-ITC-00132900	AGN-ITC-00132904	"Supplement Approval," Department of Health and Human Services relating to Allergan's BLA 103000 dated January 18, 2013	Sesha Neervannan	Admitted
CX-1207		AGN-ITC-00132905	AGN-ITC-00132907	"Company Overview – Solstice Neurosciences, LLC," Bloomberg		Withdrawn
CX-1208		AGN-ITC-00132908	AGN-ITC-00132910	"Why Myobloc?," Solstice Neurosciences		Withdrawn
CX-1209		AGN-ITC-00132911	AGN-ITC-00132914	"Supplement Approval," Department of Health and Human Services relating to Allergan's BLA 103000 dated September 11, 2013	Sesha Neervannan	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1210		AGN-ITC-00132915	AGN-ITC-00132920	"Supplement Approval – Release From Post Marketing Commitment," Department of Health and Human Services relating to Allergan's BLA 103000 dated January 21, 2016		Withdrawn
CX-1211		AGN-ITC-00132921	AGN-ITC-00132923	"Supplement Approval," Department of Health and Human Services relating to Allergan's BLA 103000 dated October 2, 2017		Withdrawn
CX-1212		AGN-ITC-00132924	AGN-ITC-00132929	"Supplement Approval – Fulfillment of Post Marketing Requirements/Commitment," Department of Health and Human Services relating to Allergan's BLA 103000 dated June 20, 2019		Withdrawn
CX-1213		AGN-ITC-00132930	AGN-ITC-00132931	J.E. Kim, et al., "The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines," Plastic and Reconstructive Surgery, published March 2015		Withdrawn
CX-1214		AGN-ITC-00132932	AGN-ITC-00132943	"Department of Health and Human Services U.S. License No. 1787," Department of Health and Human Services relating to Ipsen Biopharm Limited's Dysport dated April 29, 2009		Withdrawn
CX-1215		AGN-ITC-00132944	AGN-ITC-00132949	Lisette Hilton, "Jeuveau takes aim at aesthetic market share," Dermatology Times dated February 4, 2019	James Malackowski	Admitted
CX-1216		AGN-ITC-00132950	AGN-ITC-00132959	Definition of "Neurotoxin" by Merriam-Webster		Withdrawn
CX-1217		AGN-ITC-00132960	AGN-ITC-00132961	"Toxin," Biology Online dated October 3, 2005		Withdrawn
CX-1218		AGN-ITC-00132962	AGN-ITC-00132986	Ram Kumar Dhaked, et al., "Botulinum toxin: Bioweapon & magic drug," 132(5) Indian J. Med. Res. 489-503, November 2010		Withdrawn
CX-1219		AGN-ITC-00132987	AGN-ITC-00132989	"Clostridium botulinum" Overview, United States Department of Agriculture		Withdrawn
CX-1220		AGN-ITC-00133005	AGN-ITC-00133009	"Select Agents and Toxins List," CDC		Withdrawn
CX-1221		AGN-ITC-00133010	AGN-ITC-00133029	"Highlights of Prescribing Information, MYOBLOC," FDA, August 2019		Withdrawn
CX-1222		AGN-ITC-00133030	AGN-ITC-00133034	"BOTOX (OnabotulinumtoxinA) Injection and BOTOX Cosmetic Treatment Information		Withdrawn
CX-1223		AGN-ITC-00133035	AGN-ITC-00133041	"Ipsen Group" Overview, Ipsen		Withdrawn
CX-1224		AGN-ITC-00133042	AGN-ITC-00133044	"Drugs@FDA: MYOBLOC," FDA		Withdrawn
CX-1225		AGN-ITC-00133049	AGN-ITC-00133054	"Supplement Approval," FDA relating to Solstice Neurosciences' Myobloc dated August 20, 2019		Withdrawn
CX-1226		AGN-ITC-00133055	AGN-ITC-00133086	"Highlights of Prescribing Information, DYSPORT," FDA, November 2018		Withdrawn
CX-1227		AGN-ITC-00133087	AGN-ITC-00133093	Bonaparte, James P, et al., "A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses," Systematic reviews vol. 2 40 dated June 13, 2013		Withdrawn
CX-1228		AGN-ITC-00133094	AGN-ITC-00133097	"Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity," Drugs.com dated July 16, 2015		Withdrawn
CX-1229		AGN-ITC-00133098	AGN-ITC-00133102	"Supplement Approval," Department of Health and Human Services relating to Ipsen Biopharm Limited's Dysport dated July 29, 2016		Withdrawn
CX-1230		AGN-ITC-00133103	AGN-ITC-00133106	"Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults," drugs.com dated June 16, 2017		Withdrawn
CX-1231		AGN-ITC-00133107	AGN-ITC-00133111	"Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW," BusinessWire dated February 5, 2014		Withdrawn
CX-1232		AGN-ITC-00133112	AGN-ITC-00133120	"About Merz," Merz Pharma		Withdrawn
CX-1233		AGN-ITC-00133121	AGN-ITC-00133122	"Biosafety Levels," U.S. Department of Health and Human Service		Withdrawn
CX-1234		AGN-ITC-00133123	AGN-ITC-00133142	"Highlights of Prescribing Information, XEOMIN," FDA, May 2019		Withdrawn
CX-1235		AGN-ITC-00133143	AGN-ITC-00133156	"BLA Approval," Department of Health and Human Services relating to Merz Pharmaceuticals' Xeomin July 30, 2010		Withdrawn
CX-1236		AGN-ITC-00133157	AGN-ITC-00133161	"Merz Aesthetics Announces FDA Approval of XEOMIN (incobotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Glabellar Lines in Adult Patients," CISION PR Newswire dated July 21, 2011		Withdrawn
CX-1237		AGN-ITC-00133162	AGN-ITC-00133167	"Supplement Approval – Fulfillment of Post Marketing Commitment," Department of Health and Human Services relating to Merz Pharmaceuticals' Xeomin dated December 22, 2015		Withdrawn
CX-1238		AGN-ITC-00133168	AGN-ITC-00133172	"Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States" Article, GlobeNewswire dated May 15, 2019		Withdrawn
CX-1239		AGN-ITC-00133173	AGN-ITC-00133177	"Supplement Approval," Department of Health and Human Services relating to Merz Pharmaceuticals' Xeomin dated July 3, 2018		Withdrawn
CX-1240		AGN-ITC-00133178	AGN-ITC-00133185	"Highlights of Prescribing Information, JEUEVAU," FDA, July 2019		Withdrawn
CX-1241		AGN-ITC-00133186	AGN-ITC-00133200	"Evolus, Inc. (EOLS) CEO David Moatzedi on Q2 2019 Results – Earnings Call Transcript," Seeking Alpha dated August 12, 2019	James Malackowski	Admitted
CX-1242		AGN-ITC-00133228	AGN-ITC-00133251	"Allergan PLC (AGN) Q1 2019 Earnings Call Transcript," Motley Fool dated May 7, 2019		Withdrawn
CX-1243		AGN-ITC-00133252	AGN-ITC-00133264	"The Physician Payments Sunshine Act" by Elizabeth Richardson, Health Affairs dated October 2, 2014		Withdrawn
CX-1244		AGN-ITC-00133265	AGN-ITC-00133266	"Company Officers" Overview, Evolus		Withdrawn
CX-1245		AGN-ITC-00133267	AGN-ITC-00133268	"Daewoong Pharmaceutical Built 2nd Plant for Nabota with Annual Capacity of 4.5 Million Vials for International Expansion" Article, Daewoong dated October 10, 2017	James Malackowski	Admitted
CX-1247		AGN-ITC-00133273	AGN-ITC-00133276	Transcript of "Mad Money – Evolus," Cramer, CNBC dated August 12, 2019	James Malackowski	Admitted
CX-1248		AGN-ITC00133300	AGN-ITC00133300	Jon Vmedispa "Botox Manufacturing" YouTube video		Withdrawn
CX-1249		AGN-ITC00133301	AGN-ITC00133302	CDC "Occupational Health Program, Appendix 1: List of Tier 1 BSAT"		Withdrawn
CX-1250		AGN-ITC00133303	AGN-ITC00133304	CDC "Occupational Health Program, Introduction"		Withdrawn
CX-1251		AGN-ITC00133305	AGN-ITC00133305	Evolus "Q2 2019 Evolus Earnings Conference Call" mp4 file, dated August 12, 2019		Withdrawn
CX-1252		AGN-ITC00133306	AGN-ITC00133312	CDC "Security Plan Guidance, Section 11(f) – Tier 1 Security"		Withdrawn
CX-1253		EVOLUS00004091	EVOLUS00004099	"Drug Approval Package: JEUEVAU," FDA, approved on February 1, 2019		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1254	C	EVOLUS00004284	EVOLUS00004369	FDA Product Quality Review of Evolus' Jeuveau		Withdrawn
CX-1255	C	EVOLUS00004529	EVOLUS00004534	BLA Approval Letter relating to Evolus' Jeuveau dated February 1, 2019		Withdrawn
CX-1256		EVOLUS00004747	EVOLUS00004757	Transcript of May 16, 2018 Evolus Special Conference Call re FDA pre-approval for Daewoong's manufacturing facility		Withdrawn
CX-1257		EVOLUS00004758	EVOLUS00004770	Transcript of May 17, 2018 Evolus Presentation at Bank of America Merrill Lynch 2018 Healthcare Conference		Withdrawn
CX-1258		EVOLUS00004784	EVOLUS00004793	Transcript of Evolus Q2 2018 Earnings Call		Withdrawn
CX-1259		EVOLUS00004794	EVOLUS00004803	Transcript of Evolus Q3 2018 Earnings Call	James Malackowski	Admitted
CX-1260		EVOLUS00004804	EVOLUS00004814	Transcript of Evolus Q4 2018 Earnings Call	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1261	C	EVOLUS00006386	EVOLUS00006386	Email from Chris Marmo to Scott Cannizzaro, dated September 24, 2013		Withdrawn
CX-1262	C	EVOLUS00006420	EVOLUS00006420	Email from Chris Marmo to Doyoung Kim, dated September 27, 2013		Withdrawn
CX-1263	C	EVOLUS00006674	EVOLUS00006675	Email from SengHo Jeon to Chris Marmo, dated November 5, 2013		Withdrawn
CX-1264	C	EVOLUS00006688	EVOLUS00006689	Email from Chris Marmo to Larry Thieme, dated November 6, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1265	C	EVOLUS00014036	EVOLUS00014037	Email from C. Marmo to S. Riharb, dated November 19, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1266	C	EVOLUS00014372	EVOLUS00014372	DWP-450 Illustrative Financial Information		Withdrawn
CX-1267	C	EVOLUS00015333	EVOLUS00015334	June 2, 2017 FDA		Withdrawn
CX-1268	C	EVOLUS00017331	EVOLUS00017331	Email from Chris Marmo to Murthy Simhambhatla dated August 10, 2017		Withdrawn
CX-1269	C	EVOLUS00019540	EVOLUS00019541	November 20, 2017 FDA		Withdrawn
CX-1270	C	EVOLUS00019729	EVOLUS00019731	November 29, 2017 FDA		Withdrawn
CX-1271	C	EVOLUS00019976	EVOLUS00019977	Email from Chris Marmo to Sierra Webb, dated December 6, 2017		Withdrawn
CX-1272	C	EVOLUS00020192	EVOLUS00020193	December 20, 2017 FDA		Withdrawn
CX-1273	C	EVOLUS00020284	EVOLUS00020286	January 4, 2018 FDA		Withdrawn
CX-1274	C	EVOLUS00021139	EVOLUS00021140	Email from Chris Marmo to Del Stagg		Withdrawn
CX-1275	C	EVOLUS00051727	EVOLUS00051727	Spreadsheet of Evolus Projected Expenses, titled "Nabota P&L in US"		Withdrawn
CX-1276	C	EVOLUS00051923	EVOLUS00051923	Evolus spreadsheet re Nabota P&L in US dated May 2, 2013		Withdrawn
CX-1277	C	EVOLUS00052785	EVOLUS00052787	Daewoong - Evolus Executed Term Sheet	Joint Stipulation (Dkt. No. 701591); Christopher Marmo	Admitted
CX-1278	C	EVOLUS00053852	EVOLUS00053853	Email from Chris Marmo to Del Stagg, dated August 14, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1279	C	EVOLUS00054613	EVOLUS00054615	Email from Chung Sei Kim to Larry Thieme and Chris Marmo, dated September 29, 2013		Withdrawn
CX-1280	C	EVOLUS00054622	EVOLUS00054623	Email from J. Lee to C. Marmo dated September 30, 2013		Withdrawn
CX-1281	C	EVOLUS00056982	EVOLUS00056982	Email from Chung Sei Kim to Larry Thieme, dated November 21, 2013		Withdrawn
CX-1282	C	EVOLUS00057810	EVOLUS00057815	Email from Brian Kim (Do Young Kim) to Chris Marmo, dated November 27, 2013		Withdrawn
CX-1283	C	EVOLUS00058820	EVOLUS00058820	Email from Chris Marmo to Del Stagg, dated January 7, 2014		Withdrawn
CX-1284	C	EVOLUS00058821	EVOLUS00058833	Letter from Del Stagg to Dr. Susan Walker at the Center for Drug Evaluation and Research re: Request for a Pre-IND Meeting for DWP-450 (Botulinum purified neurotoxin, Type A) dated January 9, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1285	C	EVOLUS00059172	EVOLUS00059172	Email from Chung Sei Kim to Chris Marmo, dated January 15, 2014		Withdrawn
CX-1286	C	EVOLUS00060197	EVOLUS00060199	Email from Chris Marmo to Chung Sei Kim, dated February 23, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1287	C	EVOLUS00060524	EVOLUS00060544	Email from Juyeong Kang to Del Stagg, dated February 27, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1288	C	EVOLUS00060545	EVOLUS00060547	Attachment to email titled Evolus / Daewoong TC minutes: February 25, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1289	C	EVOLUS00061991	EVOLUS00061994	Email from R. Grant to Strathspey Crown and Evolus recipients dated April 6, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1290	C	EVOLUS00062632	EVOLUS00062635	Email from Chris Marmo to Seung Ho Jeon, dated April 24, 2014		Withdrawn
CX-1291	C	EVOLUS00062735	EVOLUS00062742	Email from Chris Marmo to Del Stagg, dated April 28, 2014		Withdrawn
CX-1292	C	EVOLUS00063276	EVOLUS00063276	Email from C. Marmo to L. Zou of Sandoz dated May 14, 2014		Withdrawn
CX-1293	C	EVOLUS00078992	EVOLUS00078993	Email from Chris Marmo to Rui Avelar and Scott Cannizzaro, dated January 19, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1294	C	EVOLUS00080813	EVOLUS00080815	Email from Shawn Park to Chris Marmo, dated April 4, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1295	C	EVOLUS00081376	EVOLUS00081377	Email from September Riharb to John Gross, dated April 14, 2017		Withdrawn
CX-1296	C	EVOLUS00081378	EVOLUS00081380	Email from Chris Marmo to Sierra Webb, John Gross, and Del Stagg, dated April 14, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1297	C	EVOLUS00085162	EVOLUS00085163	June 19, 2017 FDA		Withdrawn
CX-1298	C	EVOLUS00085501	EVOLUS00085503	June 26, 2017 FDA		Withdrawn
CX-1299	C	EVOLUS00087058	EVOLUS00087059	Email string from M. Simhambhatia to Evolus and Alphaeon recipients dated July 30, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1300	C	EVOLUS00087460	EVOLUS00087462	Email from Chris Marmo to Scott Cannizzaro, September Riharb, Rui Avelar, and Sierra Webb, dated August 8, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1301	C	EVOLUS00087990	EVOLUS00087992	August 8, 2017 FDA		Withdrawn
CX-1302	C	EVOLUS00088111	EVOLUS00088113	August 15, 2017 FDA		Withdrawn
CX-1303	C	EVOLUS00089108	EVOLUS00089110	August 29, 2017 FDA		Withdrawn
CX-1304	C	EVOLUS00090359	EVOLUS00090361	September 12, 2017 FDA		Withdrawn
CX-1305	C	EVOLUS00092371	EVOLUS00092373	September 22, 2017 FDA		Withdrawn
CX-1306	C	EVOLUS00093085	EVOLUS00093087	September 27, 2017 FDA		Withdrawn
CX-1307	C	EVOLUS00094736	EVOLUS00094740	October 19, 2017 FDA		Withdrawn
CX-1308	C	EVOLUS00095329	EVOLUS00095337	C. Koons, "The Wonder Drug for Aging (Made From One of the Deadliest Toxins on Earth)," Bloomberg.com (Oct. 26, 2017), https://www.bloomberg.com/news/features/2017-10-26/inside-fort-botox-where-a-deadly-toxin-yields-2-8-billion-drug		Withdrawn
CX-1309	C	EVOLUS00096068	EVOLUS00096070	November 13, 2017 FDA		Withdrawn
CX-1310	C	EVOLUS00096671	EVOLUS00096674	November 21, 2017 FDA		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1311	C	EVOLUS00096873	EVOLUS00096875	November 28, 2017 FDA		Withdrawn
CX-1312	C	EVOLUS00098059	EVOLUS00098062	December 7, 2017 FDA		Withdrawn
CX-1313	C	EVOLUS00102698	EVOLUS00102698	Email from Sierra Webb to Chris Marmo, Scott Cannizzaro, Del Stag, and Larry Thieme, dated January 12, 2018		Withdrawn
CX-1314	C	EVOLUS00102699	EVOLUS00102741	1.11.1. Quality Information Amendment, 20 December 2017		Withdrawn
CX-1315	C	EVOLUS00105383	EVOLUS00105383	Email from Del Stag to Jungin Lee, lunar@daewoong.co.kr, Soo Hyun Kim, Yoochang Kim, and yann@daewoong.co.kr; dated February 9, 2018		Withdrawn
CX-1316	C	EVOLUS00105400	EVOLUS00105405	February 9, 2018 FDA		Withdrawn
CX-1317	C	EVOLUS00105529	EVOLUS00105531	February 13, 2018 FDA		Withdrawn
CX-1318	C	EVOLUS00106664	EVOLUS00106666	February 21, 2018 FDA		Withdrawn
CX-1319	C	EVOLUS00107766	EVOLUS00107768	March 2, 2018 FDA		Withdrawn
CX-1320	C	EVOLUS00109240	EVOLUS00109241	March 14, 2018 FDA		Withdrawn
CX-1321	C	EVOLUS00110108	EVOLUS00110108	Email from Christina Shin to Gregg Peterson, Chris Marmo, and Scott Cannizzaro, dated March 19, 2018		Withdrawn
CX-1322	C	EVOLUS00110109	EVOLUS00110223	1.11.1. Quality Information Amendment, February 9, 2018		Withdrawn
CX-1323	C	EVOLUS00111592	EVOLUS00111594	March 30, 2018 FDA		Withdrawn
CX-1324	C	EVOLUS00118507	EVOLUS00118509	December 17, 2018 FDA		Withdrawn
CX-1325	C	EVOLUS00132555	EVOLUS00132558	Email from Chris Marmo to Scott Cannizzaro, dated April 25, 2014		Withdrawn
CX-1326	C	EVOLUS00138491	EVOLUS00138496	Email from Chris Marmo to Larry Thieme, dated December 23, 2015		Withdrawn
CX-1327	C	EVOLUS00138501	EVOLUS00138511	Email from Chris Marmo to Scott Cannizzaro and Larry Thieme, dated December 28, 2015		Withdrawn
CX-1328	C	EVOLUS00138999	EVOLUS00139001	Email from Chris Marmo to Scott Cannizzaro, dated March 10, 2016		Withdrawn
CX-1329	C	EVOLUS00149815	EVOLUS00149854	1.11.1. Quality Information Amendment		Withdrawn
CX-1330	C	EVOLUS00187566	EVOLUS00187573	Response to June 26, 2017 FDA		Withdrawn
CX-1331	C	EVOLUS00197055	EVOLUS00197072	2.3.9 Drug Product - Stability Study Record for DWP-450 with Certificates of Analysis of the Daewoong Botulinum Toxin		Withdrawn
CX-1332	C	EVOLUS00206983	EVOLUS00207029	Strathspey Crown Confidential Information Memorandum		Withdrawn
CX-1333	C	EVOLUS00207409	EVOLUS00207419	Summary of November 17, 2018 Evolus Leadership Summit - Practice Experience & Connectivity Workshop in Dallas, TX		Withdrawn
CX-1334	C	EVOLUS00207420	EVOLUS00207426	Summary of Evolus Leadership Summit - DWP-450 Clinical Messaging Workshop		Withdrawn
CX-1335	C	EVOLUS00207454	EVOLUS00207460	Evolus Press Release, "Evolus Reports First Quarter 2019 Financial Results," (Apr. 30, 2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1336	C	EVOLUS00207568	EVOLUS00207571	Evolus Press Release, "Evolus Announces First Shipment of Jeuveau," (May 15, 2019)		Withdrawn
CX-1337	C	EVOLUS00207607	EVOLUS00207617	Transcript of March 18, 2019 Evolus FQ4 2018 Earnings Call		Withdrawn
CX-1338	C	EVOLUS00207618	EVOLUS00207630	Transcript of Evolus FQ1 2019 Earnings Call	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1339	C	EVOLUS00207643	EVOLUS00207659	Notes from January 10-11, 2019 Evolus Advisory Board Meeting in Seoul, South Korea		Withdrawn
CX-1340	C	EVOLUS00207670	EVOLUS00207675	Summary of February 22, 2019 Evolus Advisory Board (NPPA Advisors)		Withdrawn
CX-1341	C	EVOLUS00207679	EVOLUS00207685	Summary of March 9, 2019 Evolus Advisory Board (WID Advisors)		Withdrawn
CX-1342	C	N/A	N/A	2019.10.02 - Medytox's Third Supplemental Responses to Daewoong's Contention Interrogatories	Ryan Sullivan	Admitted
CX-1343	C	EVOLUS00207731	EVOLUS00207731	Draft Jeuveau Consumer Positioning Statement		Withdrawn
CX-1344	C	EVOLUS00207851	EVOLUS00207851	Jeuveau Pricing Comparison Spreadsheet		Withdrawn
CX-1345	C	EVOLUS00207852	EVOLUS00207852	Pricing Spreadsheet		Withdrawn
CX-1346	C	EVOLUS00207881	EVOLUS00207896	Berglas Research Management slides re Alphaeon Neurotoxin Qualitative Research, March 2017		Withdrawn
CX-1347	C	EVOLUS00207899	EVOLUS00207990	Berglas Research Management slides re Evolus Neurotoxin Qualitative Research dated July 10, 2018		Withdrawn
CX-1348		N/A	N/A	Jane Lee et al., Experiences with CPP-Based Self Assembling Peptide Systems for Topical Delivery of Botulinum Toxin, Cell-Penetrating Peptides (Ulo Langel ed., 2015)		Withdrawn
CX-1349	C	EVOLUS00208775	EVOLUS00208775	Evolus Facial Aesthetics Influencer Analysis Spreadsheet		Withdrawn
CX-1350	C	EVOLUS00208776	EVOLUS00208834	Evolus slides re Facial Aesthetics Influencer Analysis dated November 9, 2018		Withdrawn
CX-1351		N/A	N/A	List Biological Laboratories, Inc., listlabs.com (last visited Nov. 6, 2019)		Withdrawn
CX-1352		N/A	N/A	Metabiologics, Metabiologics, https://www.metabiologics.com/	Ryan Sullivan	Admitted
CX-1353	C	EVOLUS00210008	EVOLUS00210131	Medical Insight December 2018 Global Facial Injectables Market Study		Withdrawn
CX-1354	C	EVOLUS00210883	EVOLUS00210883	Spreadsheet re Evolus Client Relationship Management dated November 28, 2018		Withdrawn
CX-1355	C	EVOLUS00210892	EVOLUS00210892	Spreadsheet of Evolus National Accounts		Withdrawn
CX-1356	C	EVOLUS00211002	EVOLUS00211002	Spreadsheet re Evolus Client Relationship Management dated October 31, 2018		Withdrawn
CX-1357	C	EVOLUS00211019		Operational Inventory Detail		Withdrawn
CX-1358	C	EVOLUS00214466	EVOLUS00214476	Evolus Natural Presentation		Withdrawn
CX-1359	C	EVOLUS00258398	EVOLUS00258400	October 23, 2018 FDA		Withdrawn
CX-1360	C	EVOLUS00288677	EVOLUS00288696	Email from Melina Dass to Jihyun Yu, dated January 24, 2019		Withdrawn
CX-1361	C	EVOLUS00288926	EVOLUS00288926	Email from Scott Peterson to Rui Avelar, dated January 17, 2019		Withdrawn
CX-1362	C	EVOLUS00289727	EVOLUS00289727	Email from Bruce Kattenmaker to Rui Avelar, dated May 15, 2019		Withdrawn
CX-1363	C	EVOLUS00289728	EVOLUS00289737	Sales FAQ (Post-Approval) from Evolus about Jeuveau	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1364	C	EVOLUS00291566	EVOLUS00291566	Email from Bruce Krattenmaker to Alex Sabad		Withdrawn
CX-1365	C	EVOLUS00291567	EVOLUS00291567	Email from Scott Peterson to Rui Avelar and Lyndell Wright, dated March 26, 2019		Withdrawn
CX-1366	C	EVOLUS00291574	EVOLUS00291577	Medical Affairs FAQs (Myth Busters) from Evolus about Jeuveau		Withdrawn
CX-1367	C	EVOLUS00295747	EVOLUS00295760	Email from Bruce Krattenmaker to Michael Taylor		Withdrawn
CX-1368	C	EVOLUS00302779	EVOLUS00302780	Email from Chris Marmo to Sun Yoo, et al., dated July 9, 2018		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1369	C	EVOLUS00302781	EVOLUS00302781	A spreadsheet titled, 'DW-Evolus_CRL and EU D120 Tracker_20180709', that includes questions and comments relating to US CRL review and EU D120 review.		Withdrawn
CX-1370	C	EVOLUS00307359	EVOLUS00307361	August 29, 2018 FDA		Withdrawn
CX-1371	C	EVOLUS00309075	EVOLUS00309075	Email from Chung Sei Kim to Scott Cannizzaro, dated October 18, 2016		Withdrawn
CX-1372	C	EVOLUS00309532	EVOLUS00309533	Email from Chris Marmo to Chung Sei Kim, dated February 23, 2014		Withdrawn
CX-1373	C	EVOLUS00310138	EVOLUS00310140	Email from Bongyong Lee to Scott Cannizzaro, dated December 21, 2015		Withdrawn
CX-1374	C	EVOLUS00310151	EVOLUS00310151	Email from Larry Thieme to Chris Marmo, dated September 8, 2015		Withdrawn
CX-1375	C	EVOLUS00310465	EVOLUS00310467	Email from Del Stagg to Julia Kang and Larry Thieme, dated June 21, 2016		Withdrawn
CX-1376	C	EVOLUS00310640	EVOLUS00310640	Email from Larry Thieme to Scott Cannizzaro, dated March 13, 2017		Withdrawn
CX-1377	C	EVOLUS00311956	EVOLUS00311957	Email from Larry Thieme to Del Stagg and Scott Cannizzaro, dated May 8, 2015		Withdrawn
CX-1378	C	EVOLUS00312175	EVOLUS00312178	Email from Sierra Webb to Scott Cannizzaro, dated January 25, 2016		Withdrawn
CX-1379	C	EVOLUS00312186	EVOLUS00312188	Email from Rui Avelar to Scott Cannizzaro and others, dated January 24, 2016		Withdrawn
CX-1380	C	EVOLUS00312515	EVOLUS00312516	Email from Eric Johnson to Scott Cannizzaro, dated February 4, 2015	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1381	C	EVOLUS00312583	EVOLUS00312586	Email from Eric Johnson to Scott Cannizzaro		Withdrawn
CX-1382	C	EVOLUS00313626	EVOLUS00313626	Email from Scott Cannizzaro to Larry Thieme, et al., dated April 29, 2014		Withdrawn
CX-1383	C	EVOLUS00313628	EVOLUS00313628	Comparison of Manufacturing Process (Allergan vs Daewoong)		Withdrawn
CX-1384	C	EVOLUS00316980	EVOLUS00316980	Email from Scott Cannizzaro to Eric Johnson, dated August 23, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1385	C	EVOLUS00316982	EVOLUS00316989	Genbank DNA Sequence Report, authored by C.S. Kim [Chung Sei Kim] and K. Min [Kyoung Min Min] at Daewoong Pharmaceuticals on June 16, 2014		Withdrawn
CX-1386	C	EVOLUS00316990	EVOLUS00316990	Spreadsheet of Genbank Accession Numbers for Certain Strains		Withdrawn
CX-1387	C	EVOLUS00316991	EVOLUS00316992	Specific toxicity - 3.2.S.4.1. Specific activity definitions		Withdrawn
CX-1388	C	EVOLUS00316993	EVOLUS00316995	Document titled "Amino acid sequences of toxin complex"		Withdrawn
CX-1389	C	EVOLUS00316996	EVOLUS00317044	DWP450-REP-110: Spore-forming test of MCB		Withdrawn
CX-1390	C	EVOLUS00317061	EVOLUS00317061	Email from Scott Cannizzaro to Larry Thieme, dated February 18, 2014		Withdrawn
CX-1391	C	EVOLUS00317710	EVOLUS00317712	Email from Scott Cannizzaro to Chung Sei Kim and others, dated August 19, 2015		Withdrawn
CX-1392	C	EVOLUS00317820	EVOLUS00317822	Email from Scott Cannizzaro to Sierra Webb, dated August 18, 2015		Withdrawn
CX-1393	C	EVOLUS00317852	EVOLUS00317853	Email from Scott Cannizzaro to Chung Sei Kim, dated November 7, 2014		Withdrawn
CX-1394	C	EVOLUS00317987	EVOLUS00317987	Email from Scott Cannizzaro to Chris Marmo, dated January 11, 2015		Withdrawn
CX-1395	C	EVOLUS00318709	EVOLUS00318720	Letter from Jeff Yuen & Associates Inc. to Youngchoon Kim dated October 21, 2015		Withdrawn
CX-1396	C	EVOLUS00318730	EVOLUS00318735	Email from Scott Cannizzaro to Larry Thieme, dated December 28, 2015		Withdrawn
CX-1397	C	EVOLUS00318737	EVOLUS00318742	Email from Scott Cannizzaro to Bongyong Lee, dated December 28, 2015		Withdrawn
CX-1398	C	EVOLUS00318797	EVOLUS00318797	Email from Scott Cannizzaro to Chris Marmo, dated September 29, 2015		Withdrawn
CX-1399	C	EVOLUS00318893	EVOLUS00318896	Email from Scott Cannizzaro to Larry Thieme, dated January 6, 2016		Withdrawn
CX-1400	C	EVOLUS00319110	EVOLUS00319111	Email from Scott Cannizzaro to Chris Marmo, dated July 22, 2016		Withdrawn
CX-1401	C	EVOLUS00320325	EVOLUS00320325	Email from Scott Cannizzaro to Chung Sei Kim, dated October 19, 2016		Withdrawn
CX-1402	C	EVOLUS00320349	EVOLUS00320350	Email from Scott Cannizzaro to Sierra Webb, Gregg Peterson, dated February 8, 2017		Withdrawn
CX-1403	C	EVOLUS00321213	EVOLUS00321214	Email from Del Stagg to Chris Marmo and Scott Cannizzaro, dated August 25, 2017		Withdrawn
CX-1404	C	EVOLUS00321219	EVOLUS00321219	Email from Chris Marmo to Del Stagg, Larry Thieme		Withdrawn
CX-1405	C	EVOLUS00321866	EVOLUS00321866	Email from Larry Thieme to Sierra Webb, Chris Marmo, Scott Cannizzaro, John Gross, Del Stagg, dated January 10, 2018		Withdrawn
CX-1406	C	EVOLUS00321894	EVOLUS00321936	Response to December 20, 2017 FDA		Withdrawn
CX-1407	C	EVOLUS00324134	EVOLUS00324136	Email from Jungin Lee to Larry Thieme and Del Stagg and others, dated January 10, 2018		Withdrawn
CX-1408	C	EVOLUS00324377	EVOLUS00324377	Email from Scott Cannizzaro to Gregg Peterson, dated August 8, 2017		Withdrawn
CX-1409	C	EVOLUS00325345	EVOLUS00325347	Email from Scott Cannizzaro to Chris Marmo, dated January 25, 2018		Withdrawn
CX-1410	C	EVOLUS00325377	EVOLUS00325380	Email from Del Stagg to Scott Cannizzaro, Larry Thieme, dated September 9, 2015	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1411	C	EVOLUS00326127	EVOLUS00326149	Evolus Launch Update by M. Jafar dated February 12, 2019		Withdrawn
CX-1412	C	EVOLUS00326292	EVOLUS00326315	Investor Relations Call presentation by M. Jafar		Withdrawn
CX-1413	C	EVOLUS00331790	EVOLUS00331790	Email string from D. Miller to C. Gores and S. Lee dated May 2, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1414	C	EVOLUS00331792	EVOLUS00331801	Lorrie Klein's Slides re marketing Evolus		Withdrawn
CX-1415	C	EVOLUS00332531	EVOLUS00332532	Email string from C. Gores to M. Jafar dated February 27, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1416	C	EVOLUS00332533	EVOLUS00332534	Physician Journey dated February 27, 2019		Withdrawn
CX-1417	C	EVOLUS00336454	EVOLUS00336454	Email string from C. Gores to M. Jafar dated May 7, 2019		Withdrawn
CX-1418	C	EVOLUS00336457	EVOLUS00336460	May Sales Call Questions - JET and Pricing	James Malackowski	Admitted
CX-1419	C	EVOLUS00336615	EVOLUS00336618	Summary of Questions from May 1, 2019 Sales Call re JET and Pricing.		Withdrawn
CX-1420	C	EVOLUS00337255	EVOLUS00337268	Evolus Board Deck by Michael Jafar dated June 4, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1421	C	EVOLUS00339614	EVOLUS00339614	Email from M. Jafar to L. Boff, Janette, J. Federer, Louisawong@gmail.com, C. Rosenberg and J. Lyle dated May 15, 2019		Withdrawn
CX-1422	C	EVOLUS00339921	EVOLUS00339921	Email string from M. Jafar to K. Romine dated May 15, 2019		Withdrawn
CX-1423	C	EVOLUS00341172	EVOLUS00341173	Email string from M. Jafar to C. Gores dated February 27, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1424	C	EVOLUS00341836	EVOLUS00341848	Evolus June Training Slides - The Evolus Movement dated June 2, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1425	C	EVOLUS00342324	EVOLUS00342325	Email string from M. Jafar to D. Moatazedi and B. Clemson dated May 9, 2019		Withdrawn
CX-1426	C	EVOLUS00342566	EVOLUS00342566	Email string from C. Gores to K. Knab dated May 8, 2019		Withdrawn
CX-1427	C	EVOLUS00342569	EVOLUS00342572	Summary of May 1, 2019 Sales Call Questions		Withdrawn
CX-1428	C	EVOLUS00342668	EVOLUS00342681	Evolus J.E.T. FAQ dated May 13, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1429	C	EVOLUS00342804	EVOLUS00342805	Email from C. Gores to AllSale, dated May 7, 2019		Withdrawn
CX-1430	C	EVOLUS00342876	EVOLUS00342876	Email from B. Curry to P. LaSalla and K. Knab dated June 10, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1431	C	EVOLUS00342877	EVOLUS00342877	2019 West Area Top 15 Targets - 2019 Business Plan Template	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1432	C	EVOLUS00343251	EVOLUS00343256	Evolus Recruiting Dashboard - dated February 2019		Withdrawn
CX-1433		N/A	N/A	Products, Metabiologics, https://www.metabiologics.com/products		Withdrawn
CX-1434	C	EVOLUS00344182	EVOLUS00344202	Evolus Strategic Partnership - Ted Porterfield		Withdrawn
CX-1435	C	EVOLUS00344449	EVOLUS00344450	Email string from B. Curry to K. Knab dated May 20, 2019		Withdrawn
CX-1436	C	EVOLUS00344809	EVOLUS00344809	Email string from K. Knab to D. Moatazedi dated December 17, 2018		Withdrawn
CX-1437	C	EVOLUS00344810	EVOLUS00344817	Evolus - Field Compensation dated December 17, 2018		Withdrawn
CX-1438	C	EVOLUS00345366	EVOLUS00345368	Email string to R. Krause dated June 7, 2019		Withdrawn
CX-1439	C	EVOLUS00345580	EVOLUS00345584	Email string from Ray@247spirit.com to B. Fagan dated June 20, 2019		Withdrawn
CX-1440	C	EVOLUS00345603	EVOLUS00345603	Dr. Vanek of Vanek Plastic Surgery is proud to be one of the First Medical Practices in OHIO to introduce NEWTOX!		Withdrawn
CX-1441	C	EVOLUS00345777	EVOLUS00345783	Evolus JET Account Top Level Metrics dated June 20, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1442	C	EVOLUS00347179	EVOLUS00347182	Evolus Draft Jeuveau Media/Influencer Experience Messaging and Q&A dated June 20, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1443	C	EVOLUS00347431	EVOLUS00347431	June 5, 2019 Jeuveau Launch Update - Investor Relations - Key Messages dated June 4, 2019		Withdrawn
CX-1444	C	EVOLUS00347592	EVOLUS00347596	Email from Ray@247spirit.com to B. Fagan dated June 20, 2019		Withdrawn
CX-1445	C	EVOLUS00347597	EVOLUS00347597	Advertisement - Dr. Vanek of Vanek Plastic Surgery is proud to be one of the First Medical Practices in OHIO to introduce Newtox!, June 20, 2019		Withdrawn
CX-1446	C	EVOLUS00348313	EVOLUS00348313	Email from C. Gores to AllSales dated June 12, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1447	C	EVOLUS00348315	EVOLUS00348318	Evolus #Newtox Now FAQ - Jeuveau (prabotulinumtoxinA-xvfs) Injection dated June 12, 2019		Withdrawn
CX-1448	C	EVOLUS00348319	EVOLUS00348334	Marketing updated dated June 12, 2019		Withdrawn
CX-1449	C	EVOLUS00348335	EVOLUS00348335	Evolus Account Pricing Cheat Sheet dated June 12, 2019		Withdrawn
CX-1450	C	EVOLUS00348460	EVOLUS00348494	Evolus Campaign Ideation & Tactical Plans - dated March 4, 2019		Withdrawn
CX-1451	C	EVOLUS00348762	EVOLUS00348763	Jeuveau Sales Team Pricing FAQ, titled "Injection List Price - Background & Key Messages," dated March 18, 2019		Withdrawn
CX-1452	C	EVOLUS00349327	EVOLUS00349327	Email from Scott Peterson to Jenny Wetterau, dated March 28, 2019		Withdrawn
CX-1453	C	EVOLUS00349328	EVOLUS00349342	Sales FAQ (Post-Approval) from Evolus		Withdrawn
CX-1454	C	EVOLUS00349363	EVOLUS00349364	Email string from C. Muilenburg to M. Jafar dated May 30, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1455	C	EVOLUS00350364	EVOLUS00350365	Email string from C. Muilenburg to D. Moatazedi dated May 8, 2019		Withdrawn
CX-1456	C	EVOLUS00350620	EVOLUS00350620	Email string from C. Muilenburg to D. Moatazedi dated April 26, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1457	C	EVOLUS00350875	EVOLUS00350877	Email string from C. Muilenburg to Kiera Carter dated June 17, 2019		Withdrawn
CX-1458	C	EVOLUS00351616	EVOLUS00351635	Evolus slides re Corporate Communications Strategy Discussion dated May 7, 2019		Withdrawn
CX-1459	C	EVOLUS00351795	EVOLUS00351795	Email string from C. Muilenburg to D. Moatazedi dated March 1, 2019		Withdrawn
CX-1460	C	EVOLUS00351860	EVOLUS00351860	Email from C. Muilenburg to Evolus recipients dated June 10, 2019		Withdrawn
CX-1461	C	EVOLUS00360736	EVOLUS00360737	Email string from D. Moatazedi to C. Muilenburg dated May 8, 2019		Withdrawn
CX-1462	C	EVOLUS00360860	EVOLUS00360860	Email string from D. Moatazedi to M. Jafar and K. Knab dated May 4, 2019		Withdrawn
CX-1463	C	EVOLUS00363768	EVOLUS00363770	Email string from B. Curry to K. Knab, D. Moatazedi and M. Jafar dated May 9, 2019		Withdrawn
CX-1464	C	EVOLUS00365411	EVOLUS00365411	Email from S. Stokes to D. Moatazedi dated June 13, 2019		Withdrawn
CX-1465	C	EVOLUS00365669	EVOLUS00365669	Email string from M. Thompson to M. Jafar dated April 25, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1466	C	EVOLUS00365670	EVOLUS00365680	Guidelines for Use dated April 25, 2019		Withdrawn
CX-1467	C	EVOLUS00365803	EVOLUS00365804	Email string from M. Jafar to K. Knab and D. Moatazedi dated April 24, 2019		Withdrawn
CX-1468	C	EVOLUS00371826	EVOLUS00371826	Jeuveau Daily Sales Report dated June 17, 2019		Withdrawn
CX-1469	C	EVOLUS00376176	EVOLUS00376176	Jeuveau Daily Sales Report dated June 18, 2019		Withdrawn
CX-1470	C	EVOLUS00376320	EVOLUS00376321	Email string from K. Knab to D. Moatazedi and M. Jafar dated June 18, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1471	C	EVOLUS00376334	EVOLUS00376342	Evolus Pricing Overview slides dated April 5, 2019		Withdrawn
CX-1472	C	EVOLUS00376675	EVOLUS00376675	Email from K. Knab to D. Moatazedi and M. Jafar dated June 13, 2019		Withdrawn
CX-1473	C	EVOLUS00376676	EVOLUS00376676	Spreadsheet of Revenue Projection		Withdrawn
CX-1474	C	EVOLUS00377379	EVOLUS00377390	Evolus slides re US Jeuveau Launch - Operations Deep Dive Discussion dated January 22, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1475	C	EVOLUS00377530	EVOLUS00377533	Evolus slides re Pricing Guidelines dated May 3, 2019		Withdrawn
CX-1476	C	EVOLUS00380273	EVOLUS00380275	M. Jafar - Evolus Performance Review Form	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1477	C	EVOLUS00384414	EVOLUS00384414	Email string from M. Jafar to K. Knab and D. Moatazedi dated January 10, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1478	C	EVOLUS00388229	EVOLUS00388230	Email string from K. Knab to M. Jafar and D. Moatazedi dated November 9, 2018		Withdrawn
CX-1479	C	EVOLUS00393340	EVOLUS00393340	Email from J. Healy of Healy Plastic Surgery to D. Moatazedi dated May 22, 2019		Withdrawn
CX-1480	C	EVOLUS00393511	EVOLUS00393511	Email from R. Avelar to D. Moatazedi dated August 8, 2018		Withdrawn
CX-1481	C	EVOLUS00395403	EVOLUS00395403	Email string from A. Sabad to D. Moatazedi and M. Jafar dated January 11, 2019		Withdrawn
CX-1482	C	EVOLUS00395491	EVOLUS00395515	Evolus Slides , titled "The Opportunity - Today's Millennial Seeks a Meaningful Practice and Patient Experience - One that is Connected, Simple & Personal," dated July 25, 2018		Withdrawn
CX-1483	C	EVOLUS00396556	EVOLUS00396556	Email string from D. Moatazedi to M. Jafar dated May 30, 2019		Withdrawn
CX-1484	C	EVOLUS00398622	EVOLUS00398629	Evolus Board of Directors Digital Call slides re Enhancing Digital Footprint to Disrupt Launch	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1485	C	EVOLUS00399132	EVOLUS00399141	Evolus Slides, titled "Evolus Creating an Aesthetic Evolution," dated July 12, 2018		Withdrawn
CX-1486	C	EVOLUS00401877	EVOLUS00401878	Daewoong Pharmaceutical Co. Commercial Invoice dated April 09, 2019		Withdrawn
CX-1487	C	EVOLUS00404138	EVOLUS00404139	Email from Jennifer Kim to Rui Avelar, Lauren Silvernail, dated August 23, 2018		Withdrawn
CX-1488	C	EVOLUS00406872	EVOLUS00406873	Email from Rui Avelar to Jennifer Kim and Lauren Silvernail, dated August 23, 2018		Withdrawn
CX-1489	C	EVOLUS00407133	EVOLUS00407136	Email from Eric A. Johnson to Scott Cannizzaro, dated March 11, 2014		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1490	C	EVOLUS00407141	EVOLUS00407145	Email from Eric A. Johnson to Scott Cannizzaro, dated March 24, 2014		Withdrawn
CX-1491	C	EVOLUS00407149	EVOLUS00407150	Email from Eric A. Johnson to Scott Cannizzaro, dated February 25, 2014		Withdrawn
CX-1492	C	EVOLUS00407178	EVOLUS00407179	Email from Scott Cannizzaro to Eric Johnson, dated March 5, 2014		Withdrawn
CX-1493	C	EVOLUS00408391	EVOLUS00408398	Stifel Report re Evolus, "Beauty in Simplicity," dated May 8, 2019		Withdrawn
CX-1494	C	EVOLUS00417886	EVOLUS00417886	Email from R. Felder dated September 14, 2018		Withdrawn
CX-1495	C	EVOLUS00418239	EVOLUS00418242	A. Sabad Resume	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1496	C	EVOLUS00418809	EVOLUS00418855	Evolus June Forecast dated May 30, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1497	C	EVOLUS00421836	EVOLUS00421836	National Account JET Results dated June 18, 2019		Withdrawn
CX-1498	C	EVOLUS00423297	EVOLUS00423302	Email string from D. Moatazedi to Evolus Leadership Team dated March 22, 2019		Withdrawn
CX-1499	C	EVOLUS00425553	EVOLUS00425559	Morgan Stanley report re Allergan, "Botox competitor approved; likely a20-25% discount," dated February 1, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1500	C	EVOLUS00430934	EVOLUS00430953	Goldman Sachs Report "A wrinkle in time Assessing Botox and competitive threats on the horizon" - dated September 4, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1501	C	EVOLUS00448994	EVOLUS00448995	Email string from B. S. Biesman to M. Jafar dated December 9, 2018		Withdrawn
CX-1502	C	EVOLUS00452135	EVOLUS00452136	Email string from B. Clemson to K. t Knab, M. Jafar dated May 9, 2019		Withdrawn
CX-1503	C	EVOLUS00452140	EVOLUS00452151	"Sales Update" dated June 13, 2019		Withdrawn
CX-1504	C	EVOLUS00452177	EVOLUS00452184	Evolus slides titled "DM Sales Update Meeting - BC," dated June 12, 2019		Withdrawn
CX-1505	C	EVOLUS00452186	EVOLUS00452212	"Evolus Loyalty Program - Kickoff" dated June 18, 2019		Withdrawn
CX-1506	C	EVOLUS00452752	EVOLUS00452759	"Evolus Fuse Overview," dated September 2018		Withdrawn
CX-1507	C	EVOLUS00452807	EVOLUS00452824	ZS Slides re DWP-450 Customer Universe Identification Approach Overview dated August 22, 2018		Withdrawn
CX-1508	C	EVOLUS00452845	EVOLUS00452847	Evolus Board of Directors Slides re Sales dated June 11, 2019		Withdrawn
CX-1509	C	EVOLUS00452871	EVOLUS00452871	Guidepoint Tracker U.S. Neurotoxins spreadsheet dated June 17, 2019		Withdrawn
CX-1510	C	EVOLUS00452877	EVOLUS00452910	ZS slides re Evolus Sales Organization Alignment dated October 8, 2018		Withdrawn
CX-1511	C	EVOLUS00452913	EVOLUS00452942	ZS Slides re Evolus Sales Organization Alignment - Project Check In dated September 25, 2018		Withdrawn
CX-1512	C	EVOLUS00452944	EVOLUS00452953	ZS Slides re Evolus Sales Organization Alignment Proposal dated August 31, 2018		Withdrawn
CX-1513	C	EVOLUS00452955	EVOLUS00452964	ZS Slides re Evolus Sales Organization Alignment Proposal dated August 31, 2018		Withdrawn
CX-1514	C	EVOLUS00455070	EVOLUS00455074	Evolus document re Allergan Loyalty dated April 2, 2019		Withdrawn
CX-1515	C	EVOLUS00460348	EVOLUS00460348	Email from Rui Avelar to James Lim, dated August 13, 2018		Withdrawn
CX-1516	C	EVOLUS00460561	EVOLUS00460561	Email from A. Wytish to D. Moatazedi and S. Riharb dated June 15, 2018		Withdrawn
CX-1517	C	EVOLUS00460574	EVOLUS00460575	Evolus LinkedIn/Twitter Header Refresh Mocks dated June 15, 2018		Withdrawn
CX-1518	C	EVOLUS00460576	EVOLUS00460576	Email string From P. Shea to M. Jafar, David Moatazedi dated June 18, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1519	C	EVOLUS00460851	EVOLUS00460851	Email string from K. Knab to D. Moatazedi dated May 30, 2019		Withdrawn
CX-1520	C	EVOLUS00460852	EVOLUS00460856	Evolus Document re Allergan Loyalty		Withdrawn
CX-1521	C	EVOLUS00461903	EVOLUS00461904	Email string from A. Wytish to Evolus recipients dated May 31, 2018		Withdrawn
CX-1522	C	EVOLUS00462000	EVOLUS00462000	"Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer" Press Release, Global Newswire dated June 18, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1523	C	EVOLUS00462583	EVOLUS00462584	Email from K. Green to D. Moatazedi and S. Riharb dated May 31, 2018		Withdrawn
CX-1524	C	EVOLUS00462710	EVOLUS00462711	Email string From D. Moatazedi to K. Green dated June 2, 2018		Withdrawn
CX-1525	C	EVOLUS00463497	EVOLUS00463500	Email from S. Cannizzaro to E. Johnson dated April 18, 2014		Withdrawn
CX-1526	C	BKL-ITC-00000009	BKL-ITC-00000009	Email from Byung Kook Lee to his personal email, dated September 7, 2007		Withdrawn
CX-1527	C	BKL-ITC-00000010	BKL-ITC-00000023	Attachment to email titled Medytox Neuronox CTD 3.2.S.2 dated September 2007		Withdrawn
CX-1528	C	BKL-ITC-00000133	BKL-ITC-00000134	Email from Byung Kook Lee to his personal email, dated December 28, 2007		Withdrawn
CX-1529	C	BKL-ITC-00000135	BKL-ITC-00000156	Attachment to email titled Draft of Medytox Patent Application regarding Method of producing Clostridium botulinum type A toxin using plant derived medium		Withdrawn
CX-1530	C	BKL-ITC-00000157	BKL-ITC-00000157	Email from Byung Kook Lee to his wife, Yeon Hui Yoon's personal email, dated January 3, 2008		Withdrawn
CX-1531	C	BKL-ITC-00000163	BKL-ITC-00000164	Email from Byung Kook Lee to his personal email, dated February 11, 2008		Withdrawn
CX-1532	C	BKL-ITC-00000187	BKL-ITC-00000188	Email from Byung Kook Lee to his personal email and Byung Jae Kim of Lee& Mock, dated February 22, 2008		Withdrawn
CX-1533	C	BKL-ITC-00000189	BKL-ITC-00000210	Attachment to email titled Draft of Medytox Patent Application regarding Method of producing Clostridium botulinum type A toxin using plant derived medium		Withdrawn
CX-1534	C	BKL-ITC-00000213	BKL-ITC-00000213	Email from Byung Kook Lee's personal email account to his Medytox email address, dated March 23, 2008		Withdrawn
CX-1535	C	BKL-ITC-00000214	BKL-ITC-00000239	Attachment to email titled Draft of Medytox Patent Application regarding Method of producing Clostridium botulinum type A toxin using Single Use Bioreactor with plant derived medium without Anaerobic Condition		Withdrawn
CX-1536	C	BKL-ITC-00000281	BKL-ITC-00000281	Email from Byung Kook Lee to his personal email, dated June 24, 2008		Withdrawn
CX-1537	C	BKL-ITC-00000376	BKL-ITC-00000377	Email from Byung Kook Lee to his personal email, dated July 25, 2008		Withdrawn
CX-1538	C	BKL-ITC-00000398	BKL-ITC-00000398	Email from Byung Kook Lee's personal email account to Hyun Ho Jung's personal email account, dated August 25, 2008.		Withdrawn
CX-1539	C	BKL-ITC-00000399	BKL-ITC-00000399	Attachment to email titled Screenshot of a webpage that shows Byung Kook Lee's loan from Medytox		Withdrawn
CX-1540	C	BKL-ITC-00000404	BKL-ITC-00000404	Email from Byung Kook Lee to Chang Woo Suh, dated March 8, 2010	Joint Stipulation (Dkt. No. 701591); Byung Kook Lee	Admitted
CX-1541	C	BKL-ITC-00000417	BKL-ITC-00000419	Email from Won Chul Kim and Byung Kook Lee, dated September 21, 2010		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1542	C	BKL-ITC-0000624	BKL-ITC-0000627	Byung Kook Lee Curriculum Vitae, updated August 17, 2010	Byung Kook Lee	Admitted
CX-1550	C	EJ-ITC-00002289	EJ-ITC-00002292	Email from Claire Kim to Eric Johnson dated May 17, 2017		Withdrawn
CX-1551	C	KHY-ITC-00000001	KHY-ITC-00000003	The Origin of Medytox's Botulinum Strain	Hyun Ho Jung; Kyu Hwan Yang	Admitted
CX-1552	C	MARMO00004126	MARMO00004127	Letter from KwangJun Ryu to Chris Marmo re: confirming Chris's employment history dated December 15, 2018		Withdrawn
CX-1553	C	MARMO00004214	MARMO00006931	"Biosimilar Meeting Package - Evolus, Inc. - DWP-450(botulinum toxin, Type A) Injection"		Withdrawn
CX-1554	C	MARMO00007236	MARMO00007241	"Cosmetic and Therapeutic Neurotoxin Assets - Alphaeon," dated August 2016		Withdrawn
CX-1555	C	MARMO00008990	MARMO00009006	"Separation Agreement and General Release of Claims" between Alphaeon and Chris Marmo dated August 15, 2018		Withdrawn
CX-1556	C	MARMO00009007	MARMO00009013	"Mutual Confidentiality Agreement" between Aphrodite Pharmaceuticals and Medytox dated September 12, 2018		Withdrawn
CX-1575	C	PPD-ITC-00015306	PPD-ITC-00015307	Email from Sierra Webb to John Watkins and Del Stagg and others, dated February 16, 2017		Rejected
CX-1585	C	PPD-ITC-00033857	PPD-ITC-00033857	Email from Del Stagg to Jungin Lee, et al., dated February 15, 2018		Withdrawn
CX-1586	C	PPD-ITC-00033858	PPD-ITC-00033858	Attachment to email titled Day 120 Timeline Tracker		Withdrawn
CX-1593	C	PPD-ITC-00039663	PPD-ITC-00039667	Email from Larry Thieme to Bruce Krattenmaker and Del Stagg, dated March 28, 2018		Withdrawn
CX-1657	C	PPD-ITC-00122784	PPD-ITC-00122784	Email from John Watkins to Joan Boren and Leona Fitzgerald, dated August 27, 2015		Rejected
CX-1659	C	PPD-ITC-00124311	PPD-ITC-00124315	Scientific Advice List of Issues from European Medicines Agency dated January 20, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1664	C	PPD-ITC-00125804	PPD-ITC-00125805	Email from Clare Ryder to John Watkins, dated July 4, 2016	Carla Mulhern	Admitted
CX-1666	C	PPD-ITC-00126905	PPD-ITC-00126906	Email from Clare Ryder to John Watkins and Joan Boren, dated August 16, 2016	Carla Mulhern	Admitted
CX-1671	C	PPD-ITC-00140473	PPD-ITC-00140479	"Reconciliation report for 3-2-s-2-3-control-of-materials US PR1," dated March 9, 2017		Rejected
CX-1672	C	PPD-ITC-00140480	PPD-ITC-00140480	Email from John Watkins to Clare Ryder dated March 10, 2017		Rejected
CX-1682	C	PPD-ITC-00156988	PPD-ITC-00156989	Email from Clare Ryder to John Watkins, dated December 7, 2017		Rejected
CX-1683	C	PPD-ITC-00157022	PPD-ITC-00157024	Email from Clare Ryder to Patricia Hurley, dated December 7, 2017		Rejected
CX-1684	C	PPD-ITC-00157065	PPD-ITC-00157066	Email from Patricia Hurley to Elizabeth Madichie, Leona Fitzgerald, John Watkins, and Clare Ryder, dated December 8, 2017		Rejected
CX-1703	C	PU ITC 0001	PU ITC 0193	Collection of documents from Purdue University College of Engineering relating to Prof. Ki Nam Park and Byung Kook Lee's employment at the University	Byung Kook Lee	Admitted
CX-1704	C	N/A	N/A	Deposition Designation for Alex Sabad, July 17, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1705	C	N/A	N/A	Deposition Designation for David Moatazedi, July 19, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-1706	C	N/A	N/A	Deposition Designation for Kurt Knab, July 19, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-1707	C	N/A	N/A	30(b)(6) Deposition Designation for Kyoung-Yoon Kim, June 20, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted, Scope Subject to Dkt. No. 702965
CX-1708	C	N/A	N/A	Deposition Designation for Michael Jafar, July 12, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-1709	C	N/A	N/A	Deposition Designation for Byung Chan Park, June 22, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1710	C	N/A	N/A	Deposition Designation for Rui Avelar, July 11, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1711	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 1 - Corrections to the Rebuttal Expert Report of Dr. Singh		Withdrawn
CX-1712	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 2 - Expert Rebuttal Report of Bal Ram Singh, Ph.D.		Withdrawn
CX-1713	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 3 - Clostridium Botulinum: The Source of Bioterror and Beauty		Withdrawn
CX-1714	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 4 - Expert Rebuttal Report Brenda A. Wilson, Ph.D.		Withdrawn
CX-1715	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 5 - Singh Lab Notes	Bal Ram Singh	Admitted
CX-1717	C	N/A	N/A	Bal Ram Singh Deposition Exhibit 6 - Singh Lab Notes		Withdrawn
CX-1718	C	N/A	N/A	Brenda Wilson Deposition Exhibit 1 - Expert Rebuttal Report of Brenda A. Wilson, Ph.D.		Withdrawn
CX-1719	C	N/A	N/A	Brenda Wilson Deposition Exhibit 2 - Korean Article titled "About 5000 chickens had died from Marek disease" and English Translation	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1720	C	N/A	N/A	Brenda Wilson Deposition Exhibit 3 - Declaration of Eric A. Johnson		Withdrawn
CX-1721	C	N/A	N/A	Brenda Wilson Deposition Exhibit 4 - Abrams article, The Purification of Toxin From Clostridium Botulinum Type A		Withdrawn
CX-1722	C	N/A	N/A	Brenda Wilson Deposition Exhibit 5 - Daewoong BLA 3.2.S.2.2. Description of Manufacturing Process and Process Controls		Withdrawn
CX-1723	C	N/A	N/A	Brenda Wilson Deposition Exhibit 6 - Duff article, Studies on Immunity to Toxins of Clostridium Botulinum II: Production and Purification of Type B Toxin for Toxoid		Withdrawn
CX-1724	C	N/A	N/A	Brenda Wilson Deposition Exhibit 7 - Culture Record (DWP450)		Withdrawn
CX-1725	C	N/A	N/A	Brenda Wilson Deposition Exhibit 8 - DasGupta Article, Purification and Amino Acid Composition of Type A Botulinum Neurotoxin	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1726	C	N/A	N/A	Brenda Wilson Deposition Exhibit 10 - Malizio Article, Purification of Clostridium Botulinum Type A Neurotoxin		Withdrawn
CX-1727	C	N/A	N/A	Brenda Wilson Deposition Exhibit 11 - U.S. 9,512,418 Patent	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1728	C	N/A	N/A	Brenda Wilson Deposition Exhibit 13 - Promega Culture Medium		Withdrawn
CX-1729	C	N/A	N/A	Brenda Wilson Deposition Exhibit 14 - Expert Rebuttal Report of Bal Ram Singh, Ph.D.		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1730		N/A	N/A	Brenda Wilson Deposition Exhibit 15 - Paper, Current Application and Future Perspectives of Molecular Typing Methods to Study Clostridium Difficile Infections		Withdrawn
CX-1731	C	N/A	N/A	Carla Mulhern Deposition Exhibit 1 - Expert Rebuttal Report of Carla S. Mulhern		Withdrawn
CX-1732	C	N/A	N/A	Carla Mulhern Deposition Exhibit 2 - Malackowski Expert Report		Withdrawn
CX-1733		N/A	N/A	Carla Mulhern Deposition Exhibit 3 - Cantor Fitzgerald - Investment Analyst Report		Withdrawn
CX-1734	C	N/A	N/A	Chung Sei Kim Deposition Exhibit 47 - June 21, 2019 email from Jaden Lee		Withdrawn
CX-1735		N/A	N/A	Chung Sei Kim Exhibit No. 53 - U.S. Patent and Trademark Office Action Summary In Response to Daewoong Patent Application dated May 5, 2016		Withdrawn
CX-1736	C	N/A	N/A	David Sherman Deposition Exhibit 1 - Expert Report of Dr. Keim		Withdrawn
CX-1737	C	N/A	N/A	David Sherman Deposition Exhibit 2 - Expert Rebuttal Report of David H. Sherman, Ph.D.		Withdrawn
CX-1738	C	N/A	N/A	David Sherman Deposition Exhibit 3 - File Information		Withdrawn
CX-1739	C	N/A	N/A	David Sherman Deposition Exhibit 4 - Sherman Handwritten Drawing		Withdrawn
CX-1740		N/A	N/A	David Sherman Deposition Exhibit 5 - Printout from PharmaForensics Website		Withdrawn
CX-1741	C	N/A	N/A	David Sherman Deposition Exhibit 6 - Handwritten Notes		Withdrawn
CX-1742		N/A	N/A	David Sherman Deposition Exhibit 7 - VCFtools Webpage		Withdrawn
CX-1743	C	N/A	N/A	David Sherman Deposition Exhibit 8 - Corrections to the Rebuttal Expert Report of Dr. David H. Sherman, Ph.D.		Withdrawn
CX-1744		N/A	N/A	Jaе Seung Yoon Deposition Exhibit 57- Jaе Seung Yoon - Korea Biomedical Review		Withdrawn
CX-1745		N/A	N/A	Jong Wook Lee Deposition Exhibit 80 - SBS CNBC News Article dated April 16, 2014	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1746		N/A	N/A	Jong Wook Lee Deposition Exhibit 81 - Yakup.com News Article dated January 18, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1747		N/A	N/A	Michael Jafar Deposition Exhibit 1 - M. Jafar LinkedIn Profile	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1748	C	N/A	N/A	Ryan Sullivan Deposition Exhibit 1 - Expert Rebuttal Report of Ryan Sullivan, Ph.D.		Withdrawn
CX-1749		N/A	N/A	Ryan Sullivan Deposition Exhibit 2 - 18 USC 1839(3)		Withdrawn
CX-1750		N/A	N/A	Ryan Sullivan Deposition Exhibit 3 - In the Matter of Certain Processes for the Manufacture of Skinless Sausage Casings and Resulting Product		Withdrawn
CX-1751		N/A	N/A	Ryan Sullivan Deposition Exhibit 4 - Declaration of Theresa J. Smith, M.S.	Ryan Sullivan	Admitted
CX-1752	C	N/A	N/A	Ryan Sullivan Deposition Exhibit 5 - Expert Report of Dr. Keim		Withdrawn
CX-1753		N/A	N/A	Ryan Sullivan Deposition Exhibit 8 - University of Wisconsin Madison Fall 2007 Article, A New Wrinkle, Cals Research Launches a Rival to Botox		Withdrawn
CX-1754		N/A	N/A	Ryan Sullivan Deposition Exhibit 9 - Metabiologics Webpage Printout		Withdrawn
CX-1755		N/A	N/A	Ryan Sullivan Deposition Exhibit 10 - Metabiologics Catalog	Ryan Sullivan	Admitted
CX-1756		N/A	N/A	Ryan Sullivan Deposition Exhibit 11 - Minutes and Other Documents Concerning a Meeting of the Board of Regents of the University of Wisconsin 31 Oct. 2001		Withdrawn
CX-1757	C	N/A	N/A	Ryan Sullivan Deposition Exhibit 12 - Deposition Transcript of Eric A. Johnson, Sc. D.		Withdrawn
CX-1758		N/A	N/A	Ryan Sullivan Deposition Exhibit 14 - Wisconsin Article		Withdrawn
CX-1759		N/A	N/A	Ryan Sullivan Deposition Exhibit 15 - List Biological Laboratories Website Printout		Withdrawn
CX-1760		N/A	N/A	Ryan Sullivan Deposition Exhibit 16 - Letter of Assurance	Ryan Sullivan	Admitted
CX-1761		N/A	N/A	Ryan Sullivan Deposition Exhibit 17 - Amendment Number 2 to the Revance S-1 from 2014		Withdrawn
CX-1762		N/A	N/A	Ryan Sullivan Deposition Exhibit 18 - Printout from www.btxa.com Website		Withdrawn
CX-1763		N/A	N/A	Ryan Sullivan Deposition Exhibit 19 - Product Information Sheet for Strain Ending 17863		Withdrawn
CX-1764		N/A	N/A	Ryan Sullivan Deposition Exhibit 20 - ATCC Material Transfer Agreement		Withdrawn
CX-1765		N/A	N/A	Ryan Sullivan Deposition Exhibit 21 - Printout from ATCC Website, Commercial Use		Withdrawn
CX-1766		N/A	N/A	Ryan Sullivan Deposition Exhibit 22 - Terms and Conditions of Supply - Public Health England Website		Withdrawn
CX-1767		N/A	N/A	Ryan Sullivan Deposition Exhibit 23 - Public Health England Website, ATCC 3502, Reference Number NCTC13319		Withdrawn
CX-1768		N/A	N/A	Ryan Sullivan Deposition Exhibit 24 - Respondent Evolus' Identification of Expert Witnesses		Withdrawn
CX-1769	C	N/A	N/A	Evolus Inc.'s Objections and Responses to Complainants Allergan's First Set of Requests for Admissions to Respondent Evolus, Inc. (Nos. 1-22) dated July 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1770		AGN-ITC-00133313	AGN-ITC-00133329	Evolus' Investor Relations Presentation dated November 2019		Withdrawn
CX-1771	C	N/A	N/A	Evolus' Objections and Responses to Complainant Medytox Inc.'s First Set of Requests for Documents and Tangible Things to Respondents Daewoong Pharmaceuticals Co., LTD and Evolus, Inc. (Nos. 1-60) dated March 22, 2019		Withdrawn
CX-1772	C	N/A	N/A	Evolus' Objections and Responses to Complainant Medytox Inc.'s Request for Entry Upon Land for Inspection to Respondents Daewoong Pharmaceuticals Co., LTD and Evolus, Inc. (Nos. 1-11) dated March 22, 2019		Withdrawn
CX-1773	C	N/A	N/A	Evolus' Objections and Responses to Complainant Medytox Inc.'s Second Set of Requests for Documents and Tangible Things to Respondents Daewoong Pharmaceuticals Co., LTD and Evolus, Inc. (Nos. 61-62) dated May 15, 2019		Withdrawn
CX-1774	C	N/A	N/A	Evolus' Objections and Responses to Complainants' First Set of Requests for Documents and Tangible Things to Respondents Daewoong Pharmaceuticals Co., LTD and Evolus, Inc. (Nos. 1-49) dated March 22, 2019		Withdrawn
CX-1775	C	N/A	N/A	Evolus, Inc.'s Supplemental Objections and Responses to Complainant Medytox Inc.'s First Set of Requests for Documents and Tangible Things Nos. 14-20, 24-26, and 34-37 to Respondents Daewoong Pharmaceuticals Co., Ltd. and Evolus, Inc. dated May 14, 2019		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1776	C	N/A	N/A	Evolus's Responses and Objections to Staff's First Set of Requests for the Production of Documents and Things to Respondent Evolus, Inc. (1-40) dated April 8, 2019		Withdrawn
CX-1777	C	N/A	N/A	Evolus's Supplemental Objections and Responses to Complainant Medytox Inc.'s Third Set of Interrogatories to Respondent Evolus, Inc. (Nos. 30) dated June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1778	C	N/A	N/A	Evolus's Supplemental Responses and Objections to Staff's First Set of Requests for the Production of Documents and Things to Respondent Evolus, Inc. (No. 12) dated May 14, 2019		Withdrawn
CX-1781	C	N/A	N/A	Complainant Medytox, Inc.'s Supplemental Responses and Objections to Respondent Daewoong Pharmaceuticals Co., LTD.'s Contention Interrogatories to Medytox, Inc. dated June 1, 2019	Order No. 37	Admitted
CX-1783	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s First Supplemental Responses and Objections to Complainant Medytox Inc.'s First Set of Requests for Documents and Tangible Things (Nos. 1-60) dated May 14, 2019		Withdrawn
CX-1784	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s First Supplemental Responses and Objections to Staff's First Set of Requests for Production of Documents and Things to Daewoong Pharmaceuticals Co., LTD. (Nos. 1-68) dated May 29, 2019		Withdrawn
CX-1785	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s First Request for Entry Upon Land for Inspection (Nos. 1-11) dated March 22, 2019		Withdrawn
CX-1786	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 1-74) dated April 3, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1787	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s First Set of Requests for Documents and Tangible Things (Nos. 1-60) dated March 22, 2019		Withdrawn
CX-1788	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Fourth Set of Requests for Documents and Tangible Things (Nos. 66-67) dated June 28, 2019		Withdrawn
CX-1789	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Second Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (No. 75) dated May 13, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1790	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Second Set of Requests for Documents and Tangible Things (Nos. 61-62) dated May 15, 2019		Withdrawn
CX-1791	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainant Medytox Inc.'s Third Set of Requests for Documents and Tangible Things (Nos. 63-65) dated May 23, 2019		Withdrawn
CX-1792	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainants' First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 1-32) dated April 3, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1793	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Complainants' First Set of Requests for Documents and Tangible Things to Respondents (Nos. 1-49) dated March 22, 2019		Withdrawn
CX-1794	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Staff's First Set of Interrogatories to Daewoong Pharmaceuticals Co., LTD. (Nos. 1 - 78), April 8, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1795	C	N/A	N/A	Respondent Daewoong Pharmaceuticals Co., LTD.'s Responses and Objections to Staff's First Set of Requests for Production of Documents and Things to Daewoong Pharmaceuticals Co., LTD. (Nos. 1-68) dated April 9, 2019		Withdrawn
CX-1796		N/A	N/A	A.C.R. Dean, The adaption of bacterial cultures during the lag phase in media containing new substrates or antibacterial agents 147 Proc. Of the Royal Soc'y B, 247-257 (1957).	Andrew Pickett	Admitted
CX-1797		N/A	N/A	Agendas and supporting documents for meetings of the Board and Committees, Board of Regents at the University of Wisconsin System (October 31, 2001), https://www.wisconsin.edu/regents/download/meeting_materials/2001/november/november.pdf	Andrew Pickett	Admitted
CX-1798		N/A	N/A	Alan Scott, Botulinum toxin injection of eye muscles to correct strabismus, 79 Transactions of the Am. Ophthalmological Soc'y, 734-770 (1981)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1799		N/A	N/A	Alan Scott, Development of botulinum toxin, 29 Disability and Rehabilitation, 1757-1758 (2007)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1800		N/A	N/A	Alberto S. Ciccarelli et al., Cultural and physiological characteristics of Clostridium botulinum type G and the susceptibility of certain animals to its toxin, Applied Envtl. Microbiology 843-48 (1977)		Withdrawn
CX-1801		N/A	N/A	Testimony of Defendants' Expert Witness, Dr. David Howard Sherman in Allergan, Inc., Plaintiff-Appellee, v. Barr Laboratories, Inc., Civ. No. 09-333-SLR, 808 F.Supp.2d 715 (D.Del. 2011)		Withdrawn
CX-1802		N/A	N/A	Altana Pharma AG and Wyeth, v. Teva Pharmaceuticals USA, INC., et al. 532 F.Supp.2d 666 (2007)		Withdrawn
CX-1803		N/A	N/A	Amy Vogler, The Effect of Repeat Copy Number on Variable-Number Tandem Repeat Mutation in Escherichia coli O157:H7, 188 J. of Bacteriology, 4253-4263 (2006)		Withdrawn
CX-1804		N/A	N/A	Anastasia Litvintseva et al., Whole-Genome Analysis of Exserohilum rostratum from an Outbreak of Fungal Meningitis and Other Infections, 52 J. of Clinical Microbiology, 3216-3222 (2014)	Paul Keim	Admitted
CX-1805		N/A	N/A	Andrew Pickett, Botulinum Toxin as a Clinical Product- Manufacture and Pharmacology, Clinical Applications of Botulinum Neurotoxin 7-49 (Keith Foster ed., 2014)	Andrew Pickett	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1806		N/A	N/A	Andrew Pickett, Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype?, <i>The Botulinum J.</i> , 176-178 (2013).		Withdrawn
CX-1807		N/A	N/A	Andrew Pickett, Historical aspects of botulinum toxin used clinically: part II: overcoming resistance, <i>The Botulinum J.</i> , 34-40 (2015)		Withdrawn
CX-1808		N/A	N/A	Andy Pickett, Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology, <i>Clinical Applications of Cobotulinum Neurotoxin 7-49</i> (K.A. Foster ed., 2014)		Withdrawn
CX-1809		N/A	N/A	<i>Bacterial Toxins: Methods and Protocols</i> (Otto Holst ed., 2000)		Withdrawn
CX-1810		N/A	N/A	Bal Ram Singh et al., Clostridium botulinum: The Source of Bioterror and Beauty, <i>Microbes: Health and Environment</i> (Ashok K. Chauhan & Ajit Varma eds., 2006)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1811		N/A	N/A	Roshan Kukreja and Bal Ram Singh, The botulinum toxin as a therapeutic agent: molecular and pharmacological insights, <i>5 Research and Reports in Biochemistry</i> 173 (2015)		Withdrawn
CX-1812		N/A	N/A	Benjamin D. Kaehler et al., Species abundance information improves sequence taxonomy classification accuracy, <i>10 Nature Comm.</i> , 1 (Oct. 2019)		Withdrawn
CX-1813		N/A	N/A	Boards of Appeal of the European Patent Office, Decision of the Technical Board of Appeal 3.3.02 of 11 January 2012, <i>Sandra Pohlman v. Alcon Laboratories, Inc.</i> No. T 0197/08 - 3.3.02		Withdrawn
CX-1814		N/A	N/A	Bob Mitchell, A New Wrinkle: Cals Research Launches a Rival to Botox (Fall 2007), https://grow.cals.wisc.edu/deprecated/health/a-new-wrinkle		Withdrawn
CX-1815		N/A	N/A	Botulinum Neurotoxin Type A Complex from Clostridium botulinum, List Biological Laboratories, Inc., https://www.listlabs.com/products/buy-botulinum-neurotoxin-type-a-complex-from-clostridium-botulinum		Withdrawn
CX-1816		N/A	N/A	Brenda A. Wilson et al., Cargo-Delivery Platforms for Targeted Delivery of Inhibitor Cargos Against Botulism, <i>14 Current Topics in Medicinal Chemistry</i> 2081 (2014)		Withdrawn
CX-1817		N/A	N/A	Brenda A. Wilson et al., Evolutionary aspects of toxin-producing bacteria, <i>The Comprehensive Sourcebook of Bacterial Protein Toxins</i> , 1-39 (Michel R. Popoff eds., 2015)		Withdrawn
CX-1818		N/A	N/A	Brenda A. Wilson et al., Evolutionary aspects of toxin-producing bacteria, <i>The Comprehensive Sourcebook of Bacterial Protein Toxins</i> , 25-43 (Michel R. Popoff eds., 2006)		Withdrawn
CX-1819		N/A	N/A	Brenda A. Wilson and Mengfei Ho, The Biosecurity Threat Posed by Biological Toxins, <i>Handbooks in Toxinology: Biological Toxins and Bioterrorism</i> , 142-181 (P. Gopalakrishnakone eds., 2006)		Withdrawn
CX-1820		N/A	N/A	C. W. Knetesch et al., Current application and future perspectives of molecular typing methods to study Clostridium difficile infections, <i>18 Eurosurveillance</i> 1 (2013)		Withdrawn
CX-1821		N/A	N/A	Caporaso et al., QIME allows analysis of high-throughput community sequencing data, <i>7 Nature Methods</i> 335-36 (2010)		Withdrawn
CX-1822		N/A	N/A	Chase M. Fredrick et al., Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502, <i>83 Applied Environl. Microbiology</i> (2017)		Withdrawn
CX-1823		N/A	N/A	Clostridium botulinum A str. Hall, complete genome GenBank CP000727.1, https://www.ncbi.nlm.nih.gov/nucleotide/CP000727 (last visited Nov. 6, 2019)	Order No. 37	Admitted
CX-1824		N/A	N/A	CMC and GMP Guidances, U.S. Food & Drug Administration, https://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/cmc-and-gmp-guidances		Withdrawn
CX-1825		N/A	N/A	Corrected Declaration of David H. Sherman Ph.D. in Support of Plaintiff's Responsive Claim Construction Briefs Regarding the '405 Patent, the '180 Patent, and the '197 Patent, Enzo Life Sciences, Inc. v. Gen-Probe, Inc., No. 1:12-cv-0014-LPS (D. Del. Aug. 14, 2014), ECF No. 123		Withdrawn
CX-1826		N/A	N/A	Daewoong's U.S. Application No. 14654819 Patent File Wrapper	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1827		N/A	N/A	Daiqing Liao, Gene Conversion Drives Within Genic Sequences: Concerted Evolution of Ribosomal RNA Genes in Bacteria and Archaea, <i>51 J. Molecular Evolution</i> 305-17 (2000)	Paul Keim	Admitted
CX-1828		N/A	N/A	Daniel Madar et al., Promoter activity dynamics in the lag phase of Escherichia coli, <i>7 BMC Sys Biology</i> , 2-13 (2013).	Andrew Pickett	Admitted
CX-1829		N/A	N/A	David J. Kihm et al., Zinc Stimulates Sporulation in Clostridium botulinum 113B, <i>17 Current Microbiology</i> 193-98 (1988)		Rejected
CX-1830		N/A	N/A	David Rasko et al., <i>Bacillus anthracis</i> comparative genome analysis in support of the Amerithrax investigation, <i>108 Proc. of the Nat'l Acad. Sci of the United States of Am.</i> , 5027-5032 (2010)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1831		N/A	N/A	David Rasko et al., Origins of the E. coli Strain Causing an Outbreak of Hemolytic-Uremic Syndrome in Germany, <i>365 New England J. of Med.</i> , 709-717 (2011).	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1832		N/A	N/A	Decision in Korean Criminal Case dated October 28, 2019	Chung Sei Kim	Admitted
CX-1833		N/A	N/A	Declaration of David H. Sherman, Ph.D. in Support of Defendants' Joint Opening Claim Construction Brief, <i>Kowa Co. v. Sawai USA, Inc.</i> , No. 14-CV-5575 (PAC) (S.D.N.Y. May 8, 2015), ECF No. 79		Withdrawn
CX-1834		N/A	N/A	Declaration of David H. Sherman, Ph.D., Use of fluprostenol isopropyl ester for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension, Alcon Research, Ltd. Application No. 94 305 752.1		Withdrawn
CX-1835		N/A	N/A	Deposition of David H. Sherman, Enzo Biochem, Inc. v. Applera Corp., 2007 WL 6375276 (D. Conn. June 20, 2007)		Withdrawn
CX-1836		N/A	N/A	Ding et al., Genome-based Characterization of Two Prenylation Steps in the Assembly of the Stephacidin and Notoamide Anticancer Agents in a Marine-derived Aspergillus sp. <i>132 J. Am. Chem. Society</i> 12733-12740 (2010)		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1837		N/A	N/A	Dirk Dressler & Roberto Eleopra, Clinical use of non-A botulinum toxins: botulinum toxin type B, 9 Neurotoxicity Res. 121-25 (2006)		Withdrawn
CX-1838		N/A	N/A	Dirk Dressler et al., Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use, J. Neural Transmission (2019)		Withdrawn
CX-1839		N/A	N/A	Domingo F. Gimenez & Alberto S. Ciccarelli, Clostridium botulinum type F in the soil of Argentina, 16 Applied Microbiology 732-34 (1968)		Withdrawn
CX-1840		N/A	N/A	E. Boylen et al., Reproducible, interactive, scalable, and extensible microbiome data science using QIIME 2, 37 Nature Biotechnology 852-85 (2019)		Withdrawn
CX-1841		N/A	N/A	Electronic Common Technical Document (eCTD), U.S. Food & Drug Administration, https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd		Withdrawn
CX-1842		N/A	N/A	Enzo Biochem, Inc. v. Applera Corp., 2007 WL 2669025 (D. Conn. Sept. 6, 2007)		Withdrawn
CX-1843		N/A	N/A	Eric A. Johnson and Marite Bradshaw, Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective, 39 Toxicon 1703-1722 (2001)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1844		N/A	N/A	Eric A. Johnson, Clostridium botulinum, Food microbiology: Fundamentals and frontiers (M. P. Doyle & R. L. Buchanan eds., 4th ed. 2013)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1845		N/A	N/A	Eric S. Donkor, Sequencing of Bacterial Genomes: Principles and Insights into Pathogenesis and Development of Antibiotics, 4 Genes 556-72 (2013)		Withdrawn
CX-1846		N/A	N/A	Eric A. Johnson, Manufacture of Commercial Botulinum Neurotoxins for Human Treatment, Treatment for Dystonia 120-27 (Dirk Dressler et al. eds., 2018)	Andrew Pickett	Admitted
CX-1847		N/A	N/A	Eva R. Kashket & Zhi-Yi Cao, Clostridial strain degeneration, 17 FEMS Microbiology Reviews 397-315 (1995)		Withdrawn
CX-1848		AGN-ITC-00133346	AGN-ITC-00133351	Evolus 2019 Q3 Earnings Press Release dated November 4, 2019		Withdrawn
CX-1849		AGN-ITC-00133330	AGN-ITC-00133345	Evolus' Q3 2019 Earnings Call Transcript, Motley Fool dated November 4, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-1850		N/A	N/A	Expert Report of Dr. David H. Sherman, PH.D., Pursuant to Federal Rule of Civil Procedure 26(a)(2)(B), Allergan, Inc. v. Apotex Inc., No. 1:10-CV-681 (M.D.N.C. Oct. 19, 2012), ECF No. 140-1		Withdrawn
CX-1851		N/A	N/A	Expert Report of Dr. David H. Sherman, Roche Diagnostics GMBH v. Enzo Biochem, Inc., 992 F.Supp.2d 213 (S.D.N.Y. Dec. 6, 2013) ECF No. 332-3		Withdrawn
CX-1853		N/A	N/A	G. G. Knock, Survey of soils for spores of Clostridium botulinum (union of South Africa and South West Africa), 3 J. Sci. Food & Agriculture 86-91 (1952)		Withdrawn
CX-1854		N/A	N/A	G.R. Smith and Angela M. Young, Clostridium botulinum in British soil, 85 J. Hyg., Camb., 271-274 (1980)		Withdrawn
CX-1855		N/A	N/A	George Fox et al., How Close Is Close: 16S rRNA Sequence Identity May Not Be Sufficient To Guarantee Species Identity, 42 Int'l J. of Systematic Bacteriology 166 (1992)		Withdrawn
CX-1856		N/A	N/A	Haim M. Solomon and Timonty Lilly, Jr, Bacteriological Analytical Manual- Chapter 17: Clostridium botulinum (January 2001), https://www.fda.gov/food/laboratory-methods-food/bam-clostridium-botulinum		Withdrawn
CX-1857	C	N/A	N/A	Handwritten labnotes of Brenda Wilson, Part I dated July 13, 2019		Withdrawn
CX-1858		N/A	N/A	History and Mileston, BTXA Botulinum Toxin Type A, https://www.btxa.com/discover/milestone/		Withdrawn
CX-1859		N/A	N/A	J.K. Tsui et al., A pilot study on the use of botulinum toxin in spasmodic torticollis, 12 The Canadian J. of Neurological Sci, 314-316 (1985).		Withdrawn
CX-1860		N/A	N/A	James Staley – The bacterial species dilemma and the genomic-phylogenetic species concept, Phil. Transactions of the Royal Soc'y, 1899-1909 (2006)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1861		N/A	N/A	Janda and Abbott, 16S rRNA Gene Sequencing for Bacterial Identification in the Diagnostic Laboratory Pluses, Perils, and Pitfalls, 45 J. of Clinical Microbiology 2761-64 (2007).	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1862		N/A	N/A	Jasmin Strotmeier et al., Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity, 586 FEBS Letters, 310-313 (2012)		Withdrawn
CX-1863		N/A	N/A	Jason Sahl et al., NASP: an accurate, rapid method for identification of SNPs in WGS datasets that supports flexible input and output formats, 2 Microbial Genomics, 1-12 (2016)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1864		N/A	N/A	Jeremy Pearce, Edward J. Schantz, Pioneering Researcher of Toxins, Including Botox, Dies at 96, The New York Times (May 4, 2005), https://www.nytimes.com/2005/05/04/us/edward-j-schantz-pioneering-researcher-of-toxins-including-botox-dies-at.html		Withdrawn
CX-1865		N/A	N/A	Jessica L. Halpin et al., Finished Whole-Genome Sequence of Clostridium argentinense Producing Botulinum Neurotoxin Type G, 5 Genome Announcement, 1 (2017)		Withdrawn
CX-1866		N/A	N/A	Jianbo Dong et al., A Single Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic Alpha-Exosite Binding Region, 397 J. Molecular Biology 1106 (2010)		Withdrawn
CX-1867		N/A	N/A	Jianbo Dong et al., A Single Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic Alpha-Exosite Binding Region, 394(4) J. Mol. Biol. 1106-1108 (2010)		Withdrawn
CX-1868		N/A	N/A	JMP Securities Life Sciences Conference Transcript dated June 19, 2019	James Malackowski	Admitted
CX-1869		N/A	N/A	U.S. Patent No. 5,512,547, Johnson et al. dated April 30, 1996	Brenda Wilson	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1870		N/A	N/A	Joint Statement Regarding Identification of Accused Products, April 5, 2019		Withdrawn
CX-1871		N/A	N/A	Joint Technology Stipulation, July 26, 2019		Withdrawn
CX-1872		N/A	N/A	Jospeh L. Stone, A Modified Mueller Medium Without Native Protein for Tetanus Toxin Production, 1(4) Appl. Microbiol. 166-68 (1953)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1873		N/A	N/A	Judgment, DSM Anti-Infectives BV v. SmithKline Beecham plc, [2004] EWCA Civ 1199, No. A3/2004/1302		Withdrawn
CX-1874		N/A	N/A	Karin Kleigrew et al., Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria, 78 J. Nat. Products 1671-682 (2015)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1875		N/A	N/A	Keith H. Lewis & Edwin V. Hill, Practical Media and Control Measures for Producing Highly Toxic Cultures of Clostridium botulinum, Type A, 53 J. Bacteriology 213-30 (1947)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1876		N/A	N/A	Koji Hayashi et al., Highly accurate genome sequences of Escherichia coli K-12 strains MG 1655 and W3110, 2 Molecular Systems Biology 1-5 (2006)		Withdrawn
CX-1878		N/A	N/A	Korean patent application no. 10-2008-0046152 titled, 'Method of Producing Clostridium botulinum Toxin Using a Media Containing Plant-Derived Components and a Flexible Closed Container', submitted to Korean Intellectual Property Office on May 19, 2008	Chang Hoon Rhee	Admitted
CX-1879		N/A	N/A	Korean patent application no. 10-2011-0072576 titled, 'Method of Producing Clostridium botulinum Toxin Using a Media Containing Plant-Derived Components and a Flexible Closed Container', submitted to Korean Intellectual Property Office on July 21, 2011	Chang Hoon Rhee	Admitted
CX-1880		N/A	N/A	L. D., Smith, The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States, 15 Health Lab Sci., 74-80 (1978)		Withdrawn
CX-1881		N/A	N/A	Laurent Pons et al., Outcomes of the first-in-human study with a recombinant botulinum toxin type E (rBoNT-E): Safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA (Dysport®), 156 Toxicol., S93 (2015).		Withdrawn
CX-1882		N/A	N/A	Lee SO, Hong EK, Lysis Induction for Botulinum Neurotoxin of Clostridium botulinum, KSBB, Proceedings of Current Biotechnology and Bioengineering, 2004, XV:380-383.		Withdrawn
CX-1883		N/A	N/A	Lee SO, Lee GD, Hong EK, Effects of various culture conditions on cell mass in liquid culture of Clostridium botulinum. Proceedings of Current Biotechnology and Bioengineering, 2004, XIV:186-189.		Withdrawn
CX-1884		N/A	N/A	M4: The Common Technical Document, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), https://www.ich.org/page/ctd .		Withdrawn
CX-1885		N/A	N/A	Marite Bradshaw et al., Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System, 80 Applied and Environmental Microbiology, 7415-422 (2014)	Andrew Pickett	Admitted
CX-1886	C	N/A	N/A	Summary of Medytox R&D Documents Produced	Seong Hun Chang	Admitted
CX-1887		N/A	N/A	Melissa Pires-Alves et al., Tandem Fluorescent Proteins as Enhanced FRET-based Substrates for Botulinum Neurotoxin Activity, 53 Toxicol 392 (2009)		Withdrawn
CX-1888		N/A	N/A	Mengfei Ho et al., Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A, 21 Protein Science 318 (2011)		Withdrawn
CX-1889		N/A	N/A	Merck Sharp & Dohme Corp. v. Sandoz, No. 3:12-cv-03289-PGS-LHG, 2015 WL 5089543 (D.N.J. Aug. 27, 2015)	David Sherman	Admitted
CX-1890		N/A	N/A	Michael D. Barton & Hazel A. Barton, Scarfholder - software for manual genome scaffolding, 7 Source Code for Biology and Medicine 1-6 (2012)		Withdrawn
CX-1891		N/A	N/A	Michael J. Mansfield et al., Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins, 9 Sci. Rep. 1-11 (2019)		Withdrawn
CX-1892		N/A	N/A	Michael J. Mansfield et al., Botulinum neurotoxin homologs in non-Clostridium species, 589 FEBS Letters, 342-348 (2015)		Withdrawn
CX-1893		N/A	N/A	Michael Peck et al., Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature, 9 Toxins, 1-21 (2017)		Withdrawn
CX-1894		N/A	N/A	Michael R. Baldwin et al., Characterization of the Antibody Response to the Receptor Binding Domain of Botulinum Neurotoxin Serotypes A and E, 73 Infection and Immunity 6998 (Oct. 2005)		Withdrawn
CX-1895		N/A	N/A	Michael Schofield et al., Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743, 17 Env't Microbiology (2015)		Withdrawn
CX-1896		N/A	N/A	Microbial Forensics, 259-276 (Bruce Budowle et al. eds., 2nd ed. 2011)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1897		N/A	N/A	Microbial Forensics, 545-559 (Bruce Budowle et al. eds., 2nd ed. 2011)		Withdrawn
CX-1898		N/A	N/A	Nagarajan Thirunavukkarasu et al., Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance, 6 Frontiers in Bioengineering and Biotechnology 1 (2018)		Withdrawn
CX-1899		N/A	N/A	Nathan Olson et al., Best Practices for Evaluating Single Nucleotide Variant Calling Methods for Microbial Genomics, 6 Frontiers in Genetics, 1-15 (2015)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1900		N/A	N/A	Nicholas Bokulich et al., Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin, 6 Microbiome (2018)		Withdrawn
CX-1901		N/A	N/A	Notice of Institution of Investigation, February 28, 2019		Withdrawn
CX-1902		N/A	N/A	Object Pharma Announces Strategic Acquisition of Metabiologics, Object (January 28, 2014), https://www.objectpharma.com/pressreleases-test/2019/5/28/metalogics		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1903		N/A	N/A	Order Re: Webster, Spormann/Lievense, And Sherman Daubert Motions, Kaneka Corp. v. Zhejiang Medicine Co., Ltd., No. CV 11-02389-SJO-SS (C.D. Cal. Feb. 22, 2017), ECF No. 696	David Sherman	Admitted
CX-1904		N/A	N/A	Our History, List Biological Laboratories, Inc., https://www.listlabs.com/our-history/		Withdrawn
CX-1905		N/A	N/A	Our Products, List Biological Laboratories, Inc., https://www.listlabs.com/	Ryan Sullivan	Admitted
CX-1906		N/A	N/A	P. S. G. Chain et al., Genome Project Standards in a New Era of Sequencing, 326 Science 236-37 (2009)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1907		N/A	N/A	P.H. A. Sneath, Letter to the Editor: Evidence from Aeromonas for Genetic Crossing-Over in Ribosomal Sequences, 43 Int'l J. of Systematic Bacteriology, 626-629 (1993)		Withdrawn
CX-1908		N/A	N/A	Pablo Yarza et al., The All-Species Living Tree project: A 16S rRNA-based phylogenetic tree of all sequences type strains, 31 Systematic and Applied Microbiology, 241-250 (2008)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1909		N/A	N/A	Park Report Submitted in Korean Civil Litigation		Withdrawn
CX-1910		N/A	N/A	Peter Hambleton et al., A high containment polymodal pilot plant fermenter-design concepts, 50 J. Chemical Tech. Biotechnology 167-80 (1991)		Withdrawn
CX-1911		N/A	N/A	PharmaForensics, Genomics and Microbiology, https://www.pharmaforensicslabs.com/what-we-do/genomics-microbiology/		Withdrawn
CX-1912		N/A	N/A	Ping-Ke Fang et al., Analysis of genomic differences among <i>Clostridium botulinum</i> type A1 strains, 11 BMC Genomics 725-732 (2010)		Withdrawn
CX-1913		N/A	N/A	Raina M. Maier, Bacterial Growth, Environmental Microbiology 37-54 (Raina M. Maier eds., 2nd ed. 2009)	Andrew Pickett	Admitted
CX-1914		N/A	N/A	Raj Kumar et al., Evolutionary Traits of Toxins, The Comprehensive Sourcebook of Bacterial Protein Toxins (P. Gopalakrishnakone eds., 2015)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1915		N/A	N/A	Read et al., Comparative Genome Sequencing for Discovery of Novel Polymorphisms in Bacillus anthracis, Science 2028-2033 (2002)		Withdrawn
CX-1916		N/A	N/A	Rene S. Hendriksen et al., Population genetics of Vibrio cholerae from Nepal in 2010: Evidence on the Origin on the Haitian outbreak, 2 mBio 1-6 (2011)	Joint Stipulation (Dkt. No. 701591); Paul Keim	Admitted
CX-1917		N/A	N/A	Richard J. Simmons & Ralph N. Costilow, Enzymes of Glucose and Pyruvate Catabolism In Cells, Spores, and Germinated Spores of Clostridium Botulinum, 84 J. Bacteriology 1274-1281 (1962)	Andrew Pickett	Admitted
CX-1918		N/A	N/A	Robert L. Bertrand, Lag Phase Is a Dynamic, Organized, Adaptive, and Evolvable Period That Prepares Bacteria for Cell Division, 201 J. Bacteriology 1-21 (2019)	Andrew Pickett	Admitted
CX-1919		N/A	N/A	Roberto Eleopra et al., Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human, 2 Neuroscience Letters 91-94 (1997)		Withdrawn
CX-1920		N/A	N/A	Roberto Eleopra et al., Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study, 124 Clinical Neurophysiology 999-1004 (2013)		Withdrawn
CX-1921		N/A	N/A	Roberto Eleopra et al., Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F, 9 Neurotoxicity Res. 127-31 (2006)		Withdrawn
CX-1922		N/A	N/A	Ruth Koepke et al., Global Occurrence of Infant Botulism, 122 Pediatrics e73-e82 (2008)		Withdrawn
CX-1923		N/A	N/A	S. Dineen et al., Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in <i>Clostridium botulinum</i> , 235 FEMS Microbiology Letters 9-16 (2004)		Withdrawn
CX-1924		N/A	N/A	S.K. Sharma et al., Separation of the components of type A botulinum neurotoxin complex by electrophoresis, 41 Toxicol., 321-331 (2003)		Withdrawn
CX-1925	C	N/A	N/A	2019.07.19 - Medytox's Second Set of Supplemental Responses and Objections to Daewoong's First Set of Interrogatories	Order No. 37	Admitted
CX-1926		N/A	N/A	Sicai Zhang et al., Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium, 23 Cell Host Microbe, 169-176 (2018)		Withdrawn
CX-1927		N/A	N/A	Sida Wang, Characterizing Microbial Communities Using Droplet Microfluidic Technology (2017) (unpublished Ph.D. dissertation, University of Michigan)		Withdrawn
CX-1928		N/A	N/A	Sigma-Aldrich, The Aldrich Handbook of Organic Chemicals (1972)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1929		N/A	N/A	Steve Yoelin et al., Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin in Subjects with Glabellar Frown Lines: Results of Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study, 142 Plastic and Reconstructive Surgery, 847-855 (2018)		Withdrawn
CX-1931		N/A	N/A	Sujay Paul et al., High-quality draft genome sequence of a biofilm forming lignocellulolytic Aspergillus niger strain ATCC 10864, Standards in Genomic Sci. 1-8 (2017)		Withdrawn
CX-1932		N/A	N/A	Sujay Paul et al., Insights from the genome of a high alkaline cellulose producing Aspergillus fumigatus strain obtained from Peruvian Amazon rainforest, 251 J. of Biotechnology, 53-58 (2015)		Withdrawn
CX-1933		N/A	N/A	Suzanne R. Kalb et al., Functional Characterization of Botulinum Neurotoxin Serotype H as a hybrid of known serotypes D and A (BoNT F/A), 87 Analytical Chemistry 3911-3017 (2015)		Withdrawn
CX-1934		N/A	N/A	T.J. Smith et al., Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization, 73 Infection and Immunity, 5450-5457 (2005)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1935		N/A	N/A	Technical Consulting and Advising of David H. Sherman, Kowa Company, Ltd. V. Sawai USA, Inc., 2016 WL 3681459 (S.D.N.Y. July 5, 2016) ECF No. 79-1		Withdrawn
CX-1936		N/A	N/A	Testimony of Defendants' Expert Witness, Dr. David Howard Sherman, Allergan, Inc. v. Barr Laboratories, Inc., No. 09CV00333, 2011 WL 8183947 (D.Del. Feb. 4, 2011)		Withdrawn
CX-1937		N/A	N/A	Testimony of Plaintiffs' Expert Witness, David Howard Sherman, Ph.D., Enzo Biochem, Inc. v. Applera Corp., 2012 WL 10634096 (D. Conn. Oct. 24, 2012)		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1938		N/A	N/A	The Science Behind The Litigation: Our Founders, PharmaForensics Laboratories, https://www.pharmaforensicslabs.com/	David Sherman	Admitted
CX-1939		N/A	N/A	Theresa J. Smith et al., Analysis of the Neurotoxin Complex Genes in <i>Clostridium botulinum</i> A1-A4 and B1 Strains: BoNT/A3/Ba4 and /B1 Clusters Are Located within Plasmids, 2(12) PLoS ONE, e1271 (2007)	David Sherman; Paul Keim	Admitted
CX-1940		N/A	N/A	Theresa Smith et al., Botulinum Neurotoxin-Producing Bacteria. Isn't It Time that We Called a Species Species? 9 Am. Soc'y for Microbiology, 1-5 (2018)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1941		N/A	N/A	Tim Dufree , et al., The Complete Genome Sequence of <i>Escherichia coli</i> DH10B: Insights into the Biology of a Laboratory Workhouse, 190 J. of Bacteriology, 2597-2606 (2008)		Withdrawn
CX-1942		N/A	N/A	Todd Treangen & Steven L. Salzberg, Repetitive DNA and next-generation sequencing: computational challenges and solutions, 13 Nature Revs. Genetics, 36-46 (2013)		Withdrawn
CX-1943		N/A	N/A	Transcript of Proceedings: Volume 4, Atlanta Pharma AG & Wyeth v. tEVA Pharm. USA, Inc., No. 04-2355(JLL) (D.N.J. Apr. 8, 2010), ECF No. 860		Withdrawn
CX-1944		N/A	N/A	Transcript of Proceedings: Volume 5, Atlanta Pharma AG & Wyeth v. tEVA Pharm. USA, Inc., No. 04-2355(JLL) (D.N.J. Apr. 9, 2010), ECF No. 861		Withdrawn
CX-1945		N/A	N/A	Trial Tr. Day 6, Jan. 10, 2018, Zhejiang Medicine Co., Ltd., v. Kaneka Corp., F.Appx. 1000 (Mem. May 13, 2019) ECF No. 392		Withdrawn
CX-1946	C	N/A	N/A	Handwritten notes on documents from Promega and Sigma Aldrich as well as a typed up protocol of Brenda Wilson (Brenda Wilson Lab Notes, Part II)		Withdrawn
CX-1947		N/A	N/A	U.S. Patent No. 4,943,523, Stavrianopoulos dated July 4, 1990		Withdrawn
CX-1948		N/A	N/A	Virginia Ng & Wei-Jen Lin, Comparison of Assembled <i>Clostridium botulinum</i> A1 Genomes Revealed Their Evolutionary Relationship, 103 Genomics, 94-106 (2014)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1949		N/A	N/A	Welcome to the ICH Official Website, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), https://www.ich.org/		Withdrawn
CX-1950		N/A	N/A	Xavier Estivill et al., Chromosomal regions containing high-density and ambiguously mapped putative single nucleotide polymorphisms (SNPs) correlate with segmental duplications in the human genome, 11 Human Molecular Genetics 1987 (2002)		Withdrawn
CX-1951		N/A	N/A	Yongfeng Fan et al., Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity, 10 PLOS ONE (2015)		Withdrawn
CX-1952		N/A	N/A	Yongfeng Fan et al., Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B, 7 toxins 3405 (2015)		Withdrawn
CX-1953		N/A	N/A	Yongtai Zhou et al., The Genes for the <i>Clostridium botulinum</i> Type G Toxin Complex Are on a Plasmid 63 Infection and Immunity, 2087-2091 (1995)		Withdrawn
CX-1954		N/A	N/A	Yoshikazu Inukai, Effect of carbohydrate on toxin production by <i>Clostridium botulinum</i> type A, 10 Japanese J. Veterinary Res. 64-71 (1962)		Withdrawn
CX-1955		N/A	N/A	Jaе-Won Byun et al., Devastating botulism outbreak in cattle, associated with contaminated soil, 37 J. of the Preventative Veterinary Med., 87-91 (2013)		Withdrawn
CX-1956		N/A	N/A	Zhejiang Medicine Co., Ltd. V. Kaneka Corp., 676 F.App'x. 962 (Fed. Cir. Jan. 23, 2017)		Withdrawn
CX-1957		N/A	N/A	Zuo Guanghong et al., Polyphyly in 16S rRNA-based LVTree Versus Monophyly in Whole-genome-based CVTree, 16 Genomics, Proteomics & Bioinformatics, 310-319 (2018)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1958	C	N/A	N/A	Deposition Transcript of BK Lee Pursuant to 28 U.S.C. § 1782		Withdrawn
CX-1959	C	N/A	N/A	Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis		Withdrawn
CX-1960	C	N/A	N/A	Ex. A to Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis	Paul Keim; David Sherman	Admitted
CX-1961	C	N/A	N/A	Ex. B to Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis	Paul Keim	Admitted
CX-1962	C	N/A	N/A	Ex. C to Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis	Paul Keim	Admitted
CX-1963	C	N/A	N/A	Ex. D to Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis	Paul Keim	Admitted
CX-1964	C	N/A	N/A	Ex. E to Dr. Paul Keim's Review of Dr. David Sherman's Alternative Analysis	Paul Keim	Admitted
CX-1965	C	N/A	N/A	Corrections to the Expert Report of Dr. Paul Keim		Withdrawn
CX-1967	C	N/A	N/A	2019.04.30 - Medytox's Supplemental Responses and Objections to the Staff's First Set of Interrogatories	Order No. 37	Admitted
CX-1969		N/A	N/A	P.F. Bonventre and Lloyd L. Kempe, Physiology of toxin production by <i>Clostridium botulinum</i> types A and B. I. Growth, autolysis, and toxin production, J. Bacteriol 18-23 (1960).	Andrew Pickett	Admitted
CX-1970		N/A	N/A	Samuel Slocum, Biochemical Studies of Polyketide Beta-Branching and Polyketide Synthase Module Architecture (2017) (unpublished Ph.D. dissertation, University of Michigan)		Withdrawn
CX-1971	C	N/A	N/A	2019.08.14 - Medytox's Third Set of Supplemental Responses and Objections to Daewoong's First Set of Interrogatories	Order No. 37	Admitted
CX-1972		N/A	N/A	Sang-On Lee et al., Effects of various culture conditions on cell mass in liquid culture of <i>Clostridium botulinum</i> , 4 The Korean Society for Biotechnology and Bioengineering, 186-189 (2004), http://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE02313793		Withdrawn
CX-1973		N/A	N/A	Praveen Nadukkalam Ravindran et al., PMERGE: Computational filtering of paralogous sequences from RAD-seq data, 8 Ecology and Evolution, 7002-7013 (2018)		Withdrawn
CX-1974		N/A	N/A	Ashish Bhushan et al., Insights into the Origin of <i>Clostridium botulinum</i> Strains: Evolution of Distinct Restriction Endonuclease Sites in rrs (16S rRNA gene), 55 Indian J. Microbiology, 140 - 150 (2015)		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-1975		N/A	N/A	Charles H. D. Williamson et al., Differentiating Botulinum Neurotoxin- Producing Clostridia with a Simple, Multiplex PCR Assay, 83 Applied and Environmental Microbiology, 1 (2017)		Withdrawn
CX-1976	C	DAEWOONG000618480	DAEWOONG000618480	Daewoong's log of lab notebook issuance from 2006 to 2013		Withdrawn
CX-1977		N/A	N/A	Joseph L. Ferreira et al., Immunodiffusion Method for Description of Type A Clostridium botulinum, 42 Applied and Environmental Microbiology, 1057-1061 (1981)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1978		N/A	N/A	H. Sugiyama et al., Growth Potential of Clostridium botulinum in Fresh Mushrooms Packaged in Semipermeable Plastic Film, 30 Applied Microbiology, 964-969 (1975)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1979		N/A	N/A	Charles H. D. Williamson et al., Comparative genomic analyses reveal broad diversity in botulinum-toxin producing Clostridia, 17 BMC Genomics 180-199 (2016)		Withdrawn
CX-1980		N/A	N/A	George K. York II and Reese H. Vaughn, Use of Sorbic Acid Enrichment Media for Species of Clostridium, 68 J. Bacteriol. 739-744 (1954)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1981		N/A	N/A	Narjol Gonzalez-Escalona et al., Whole-Genome Single-Nucleotide-Polymorphism Analysis for Discrimination of Clostridium botulinum Group I Strains, 80 Applied and Environmental Microbiology, 2125-2132, (2014)		Withdrawn
CX-1982		N/A	N/A	Melody J. Jensen et al., Probability of Growth of Clostridium Botulinum as Affected by Strain, Cell and Serologic Type, Inoculum Size and Temperature and Time of Incubation in a Model Broth System, 8 Journal of Food Safety 109-126 (1987)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1983		N/A	N/A	Mia Lindstrom et al., Multiplex PCR Assay for Detection and Identification of Clostridium botulinum Types A, B, E, and F in Food and Fecal Material, 67 Applied and Environmental Microbiology, 5694-5699, (2001)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1984		N/A	N/A	H. M. Solomon et al., Antigenic Relationships Among the Proteolytic and Nonproteolytic Strains of Clostridium botulinum, 21 Applied Microbiology, 295-299, (1971)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1985		N/A	N/A	Rene S. Hendriksen et al., Population Genetics of Vibrio cholerae from Nepal in 2010: Evidence on the Origin of the Haitian Outbreak, 2 mBio e00157-11 (2011)		Withdrawn
CX-1986		N/A	N/A	GenBank report of Clostridium botulinum CFSAN002369 isolate 69A, whole genome shotgun sequencing project		Withdrawn
CX-1987		N/A	N/A	Nathan D. Olson et al., Best practices for evaluating single nucleotide variant calling methods for microbial genomics, 6 Frontiers in Genetics, 1-15, (2015).		Withdrawn
CX-1988		N/A	N/A	Mohammed Sebahia et al., Genome sequence of a proteolytic (Group 1) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes, 17 Genome Research 1082-1092, (2007)		Withdrawn
CX-1989		N/A	N/A	Arthur W. Pightling et al., Interpreting Whole-Genome Sequence Analyses of Foodborne Bacteria for Regulatory Applications and Outbreak Investigations, 9 Frontiers in Microbiology, 1-13, (2018)		Withdrawn
CX-1990		N/A	N/A	Theresa J. Smith et al., Analysis of the Neurotoxin Complex Genes in Clostridium botulinum A1-A4 and B1 Strains: BoNT/A3/Ba4 and /B1 Clusters Are Located within Plasmids, 12 PLoS ONE, e1271, (2007)		Withdrawn
CX-1991		N/A	N/A	Ruth E. Timme et al., Benchmark datasets for phylogenomic pipeline validation, applications for foodborne pathogen surveillance, 5 PeerJ, 1-13, (2017)		Withdrawn
CX-1992	C	N/A	N/A	2019.11.13 - Medytox Production Cover Letter		Withdrawn
CX-1993		N/A	N/A	Transcript of Dubai Audio Conference Part II	Hyun Ho Jung	Admitted
CX-1995		N/A	N/A	Transcript of Dubai Audio Conference Part I	Hyun Ho Jung	Admitted
CX-1996	C	DAEWOONG000153383	DAEWOONG000153397	Daewoong Terms of Document Management (Daewoong Group Document Management Regulation), dated March 15, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-1997	C	AGN-ITC-00004879	AGN-ITC-00004881	JSC Meeting Agenda, dated February 3, 2014	Sesha Neervannan	Admitted
CX-1998	C	AGN-ITC-00004882	AGN-ITC-00004898	JSC Meeting Slides, dated February 3, 2014	Joint Stipulation (Dkt. No. 701591); Carla Mulhern; Sesha Neervannan	Admitted
CX-1999	C	AGN-ITC-00004903	AGN-ITC-00004940	JSC Meeting Slides, dated June 20, 2014	Carla Mulhern; Sesha Neervannan	Admitted
CX-2000	C	AGN-ITC-00004990	AGN-ITC-00004990	JSC Meeting Minutes, dated September 22-23, 2014	Sesha Neervannan	Admitted
CX-2001	C	AGN-ITC-00004999	AGN-ITC-00005002	JSC Meeting Minutes, dated October 14, 2014	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2002	C	AGN-ITC-00005074	AGN-ITC-00005077	JSC Meeting Minutes, dated March 11-12, 2015	Joint Stipulation (Dkt. No. 701591); Carla Mulhern; Sesha Neervannan	Admitted
CX-2003	C	AGN-ITC-00005149	AGN-ITC-00005151	JSC Meeting Agenda, dated December 15, 2015	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2004	C	AGN-ITC-00005179	AGN-ITC-00005183	JSC Meeting Minutes, dated June 6, 2016	Joint Stipulation (Dkt. No. 701591); Carla Mulhern; Sesha Neervannan	Admitted
CX-2005	C	AGN-ITC-00005184	AGN-ITC-00005191	JSC Meeting Minutes, dated April 19, 2017	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2006	C	AGN-ITC-00005192	AGN-ITC-00005198	JSC Meeting Minutes, dated December 7, 2017	Sesha Neervannan	Admitted
CX-2007	C	AGN-ITC-00005199	AGN-ITC-00005205	JSC Meeting Minutes, dated February 13, 2018	Sesha Neervannan	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2008	C	AGN-ITC-00005206	AGN-ITC-00005218	JSC Meeting Minutes, dated May 24, 2018	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2009	C	AGN-ITC-00005219	AGN-ITC-00005228	JSC Meeting Slides (Allergan), dated November 19, 2018	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2010	C	AGN-ITC-00005229	AGN-ITC-00005246	JSC Meeting Slides (Medytox), dated November 19-20, 2018	Carla Mulhern; Sesha Neervannan	Admitted
CX-2011	C	EJ-ITC-00001189	EJ-ITC-00001194	Email from Sung Wan Lee to Eric Johnson, dated December 19, 2016		Withdrawn
CX-2012	C	LL00001	LL00005	Letter from Linda Eaton to Dr. Bibhuti DasGupta, dated March 13, 1992		Withdrawn
CX-2013	C	LL00006	LL00006	List Labs Select Agent Non-Retail Inventory		Withdrawn
CX-2014		N/A	N/A	Verified Complaint of Medytox and Allergan Under Section 337 of the Tariff Act of 1930, as Amended		Withdrawn
CX-2015		N/A	N/A	Complaint Exhibit B - Daewoong Business Report, dated June 29, 2010		Withdrawn
CX-2016	C	N/A	N/A	Complaint Exhibit D - Medytox Orientation Material for New Hires - Introduction to Our Security System	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2017	C	N/A	N/A	Complaint Exhibit E - Medytox PC Security Management Rules	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2018	C	N/A	N/A	Complaint Exhibit F - Medytox Information Security System Establishment Project	Seong Hun Chang	Admitted
CX-2019	C	N/A	N/A	Complaint Exhibit G - Isolation and Characterization of Daewoong Clostridium botulinum Type A Hall strain		Withdrawn
CX-2020	C	N/A	N/A	Complaint Exhibit H - Daewoong Submission to Director of Korea Centers for Disease Control and Prevention. Re: Notification of the high-risk pathogen isolation, July 19, 2010		Withdrawn
CX-2021	C	N/A	N/A	Complaint Exhibit I - Byung Kook Lee Letter of Resignation, dated Aug. 13, 2008	Hyun Ho Jung	Admitted
CX-2022	C	N/A	N/A	Complaint Exhibit J - Email from Byung Kook Lee to Byung Kook Lee, re "Here is the draft specification," Dec. 26, 2007	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2023	C	N/A	N/A	Complaint Exhibit K - Medytox Record of Emails Sent by Byung Kook Lee on July 24, 2008		Withdrawn
CX-2024		N/A	N/A	Complaint Exhibit L - Declaration of Byung Kook Lee in Support of Specially Appearing Byung Kook Lee's Notice of Motion and Motion to Quash Service of Summons for Lack of Personal Jurisdiction and Joinder in Daewoong Defendants' Motion to Dismiss for Forum Non Conveniens, submitted in Medytox v. Daewoong Pharmaceuticals Co., Ltd, 30-2017- 00924912-CU-IP-CJC, July 25, 2017		Withdrawn
CX-2025	C	N/A	N/A	Complaint Exhibit M - Excerpt of Daewoong Answer to Medytox's Korean Civil Complaint, submitted in Medytox Co. Ltd v. Daewoong Pharm. Co., Ltd, 2017GAHAP574026, Jan. 26, 2018		Withdrawn
CX-2026		N/A	N/A	Complaint Exhibit N - Daewoong U.S. Patent No. 9,512,418 B2, Dec. 6, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2027		N/A	N/A	Complaint Exhibit O - Letter from Health Canada to Counsel for Medytox, regarding response to Medytox' s request under the Access to Information Act, Nov. 28, 2018	Hyun Ho Jung	Admitted
CX-2028		N/A	N/A	Complaint Exhibit P - Daewoong Press Release, "'Nabota" successfully exported to US, Europe, South America, Argentina and Iran! Daewoong people contribute to the global advancement"	Joint Stipulation (Dkt. No. 701591); Chung Sei Kim	Admitted
CX-2029		N/A	N/A	Complaint Exhibit Q - Daewoong Pharmaceuticals Presentation, "The Current State of Biological Pharmaceutical Product Research and Development Using Botulinum Toxin," Sept. 7, 2012	Hyun Ho Jung	Admitted
CX-2030		N/A	N/A	Complaint Exhibit R - Excerpts of Doctoral Dissertation of Byung Kook Lee, "Fabrication of Biosensors and Cell Arrays by Inkjet Printing of Polymers and Biomolecules," Aug. 2012		Withdrawn
CX-2031		N/A	N/A	Complaint Exhibit S - Slide Deck and Transcript of Evolus Investor Presentation at Cantor Fitzgerald Global Healthcare Conference, Oct. 1, 2018	Joint Stipulation (Dkt. No. 701591); Colleen McKenna	Admitted
CX-2032		N/A	N/A	Complaint Exhibit T - Transcript of Evolus Earnings Call, Nov. 5, 2018		Withdrawn
CX-2033		N/A	N/A	Complaint Exhibit W - Daewoong Press Release, "Daewoong Pharmaceutical built 2nd plant for Nabota with annual capacity of 4.5 million vials for international expansion," Oct. 10, 2017		Withdrawn
CX-2034	C	N/A	N/A	Complaint Exhibit Y - Declaration of Dr. Chang Hoon Rhee		Withdrawn
CX-2035	C	N/A	N/A	Complaint Exhibit Z - Declaration of Dr. Hung Ho Jung		Withdrawn
CX-2036	C	N/A	N/A	Complaint Exhibit AA - Declaration of Woo Han Kim	Seong Hun Chang	Admitted
CX-2037	C	N/A	N/A	Complaint Exhibit BB - Declaration of KwangJun Ryu	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2038	C	N/A	N/A	Complaint Exhibit CC - Declaration of Charles Schultes III		Withdrawn
CX-2039	C	N/A	N/A	Complaint Exhibit DD - Declaration of Dr. Mitchell Brin	Carla Mulhern	Admitted
CX-2040	C	N/A	N/A	Response of Daewoong Pharmaceutical to Complaint and Notice of Investigation		Withdrawn
CX-2041		Medytox-ITC-00000268	Medytox-ITC-00000268	Kyu Hwan Yang's affidavit submitted in Korean civil litigation, dated March 31, 2017	Hyun Ho Jung	Admitted
CX-2042	C	Medytox-ITC-00003994	Medytox-ITC-00003996	Report Title: "HPLC Analysis of BTA Substance", dated September 4, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted
CX-2043	C	Medytox-ITC-00003997	Medytox-ITC-00003999	Report Title: "IEF Analysis of BTA Substance", dated September 4, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted
CX-2044	C	Medytox-ITC-00004000	Medytox-ITC-00004002	Report Title: "2DE analysis of BTA stock solution (SDS-PAGE analysis of BTA Substance)," dated September 6, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted
CX-2045	C	Medytox-ITC-00004003	Medytox-ITC-00004007	Report Title: "SDS-PAGE analysis of BTA stock solution (SDS-PAGE analysis of BTA substance)," dated September 6, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2046	C	Medytox-ITC-00004037	Medytox-ITC-00004047	Report Title: "Peptide Mapping Analysis of BTA Substance," dated by September 6, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted
CX-2047	C	Medytox-ITC-00004051	Medytox-ITC-00004149	Experimental Batch Record dated November 8, 2007		Withdrawn
CX-2048	C	Medytox-ITC-00006670	Medytox-ITC-00006678	PowerPoint Presentation for Progress Report 20071005, dated October 5, 2007	Seong Hun Chang	Admitted
CX-2049	C	Medytox-ITC-00006679	Medytox-ITC-00006687	PowerPoint Presentation for Progress Report 20070921, dated September 21, 2007	Seong Hun Chang	Admitted
CX-2050	C	Medytox-ITC-00006688	Medytox-ITC-00006696	PowerPoint Presentation for Progress Report 20070831, dated August 31, 2007	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2051	C	Medytox-ITC-00006744	Medytox-ITC-00006753	PowerPoint Presentation titled "Progress Report 20070726" dated July 26, 2007	Hack Woo Kim; Seong Hun Chang	Admitted
CX-2052	C	Medytox-ITC-00006808	Medytox-ITC-00006926	Byung Kook Lee Lab Notebook, dated December 14, 2004 to January 8, 2007	Seong Hun Chang; Andrew Pickett	Admitted
CX-2053	C	Medytox-ITC-00006927	Medytox-ITC-00007077	Byung Kook Lee Lab Notebook, dated May 9, 2006 to April 19, 2007	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2054	C	Medytox-ITC-00007078	Medytox-ITC-00007209	Byung Kook Lee Lab Notebook, dated August 6, 2007 to July 10, 2008	Joint Stipulation (Dkt. No. 701591); Hack Woo Kim; Seong Hun Chang; Andrew Pickett; Byung Kook Lee	Admitted
CX-2055	C	Medytox-ITC-00013233	Medytox-ITC-00013248	Notice of examination result by the Head of KFDA, dated August 21, 2001	Hyun Ho Jung	Admitted
CX-2056	C	Medytox-ITC-00013524	Medytox-ITC-00013524	SecuPrint Log for Byung Kook Lee	Seong Hun Chang; Andrew Pickett; Byung Kook Lee	Admitted
CX-2057	C	Medytox-ITC-00013525	Medytox-ITC-00013525	Email from Byung Kook Lee to his personal email, dated November 2, 2007	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2058	C	Medytox-ITC-00013526	Medytox-ITC-00013526	Attachment to email titled Preliminary Agenda of Meeting at Medy-Tox, dated November 7-8th	Seong Hun Chang; Brenda Wilson	Admitted
CX-2059	C	Medytox-ITC-00013527	Medytox-ITC-00013528	Attachment to email titled Process Parameters and In-Process Control Limits version 1	Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2060	C	Medytox-ITC-00013529	Medytox-ITC-00013531	Attachment to email titled List of Materials and Containers version 1	Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2061	C	Medytox-ITC-00013532	Medytox-ITC-00013532	Attachment to email titled Process Block Diagram version 1	Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2062	C	Medytox-ITC-00013533	Medytox-ITC-00013533	Attachment to email titled Process Flow Diagram version 1	Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2063	C	Medytox-ITC-00013534	Medytox-ITC-00013551	Attachment to email titled Experimental Batch Record Version No. 04, dated January 11, 2006	Joint Stipulation (Dkt. No. 701591); Chang Hoon Rhee; Hack Woo Kim; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2064	C	Medytox-ITC-00013552	Medytox-ITC-00013578	Attachment to email titled Project and Quality Plan for Construction of Botulinum Toxin Type A Complex Facility	Joint Stipulation (Dkt. No. 701591); Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2065	C	Medytox-ITC-00013579	Medytox-ITC-00013678	License Agreement between Medytox and Allergan	Chang Hoon Rhee	Admitted
CX-2066	C	Medytox-ITC-00013796	Medytox-ITC-00013797	Master Cell Bank Management Log for CBAM0301 - Clostridium botulinum type A, Hall	Seong Hun Chang	Admitted
CX-2067	C	Medytox-ITC-00014487	Medytox-ITC-00014488	SecuPrint image of report titled "Characterization Report of Botulinum Toxin Type A," Doc. No./Ver. No. OOO-06000/00	Joint Stipulation (Dkt. No. 701591); Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2068	C	Medytox-ITC-00014489	Medytox-ITC-00014505	SecuPrint image of Batch Record version no. 05, version date 9/11/06	Joint Stipulation (Dkt. No. 701591); Chang Hoon Rhee; Seong Hun Chang; Andrew Pickett; Brenda Wilson	Admitted
CX-2069	C	Medytox-ITC-00014605	Medytox-ITC-00014605	SecuPrint image of report titled "HPLC Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06019/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2070	C	Medytox-ITC-00014606	Medytox-ITC-00014606	SecuPrint image of report titled "SDS-PAGE Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06022/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2071	C	Medytox-ITC-00014607	Medytox-ITC-00014607	SecuPrint image of report titled "IEF Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06020/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2072	C	Medytox-ITC-00014608	Medytox-ITC-00014608	SecuPrint image of report titled "Mass analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06023/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2073	C	Medytox-ITC-00014609	Medytox-ITC-00014609	SecuPrint image of report titled "HPLC Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06019/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2074	C	Medytox-ITC-00014610	Medytox-ITC-00014610	SecuPrint image of report titled "HPLC Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06019/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2075	C	Medytox-ITC-00014611	Medytox-ITC-00014611	SecuPrint image of report titled "Peptide mapping analysis of BTA Drug Substance," Doc. No./Ver. No. OVR 06024/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2076	C	Medytox-ITC-00014612	Medytox-ITC-00014612	SecuPrint image of report titled "Mass Measurement for BTA Drug Substance," Doc. No./Ver. No. OVR-06023/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2077	C	Medytox-ITC-00014613	Medytox-ITC-00014613	SecuPrint image of report titled "2DE (SDS-PAGE) Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06021/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2078	C	Medytox-ITC-00014614	Medytox-ITC-00014614	SecuPrint image of report titled "2DE (SDS-PAGE) Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06021/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2079	C	Medytox-ITC-00014615	Medytox-ITC-00014615	SecuPrint image of report titled "Mass analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06023/00	Seong Hun Chang; Chang Hoon Rhee	Admitted
CX-2080	C	Medytox-ITC-00014616	Medytox-ITC-00014616	SecuPrint image of report titled "SDS-PAGE Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06022/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2081	C	Medytox-ITC-00014617	Medytox-ITC-00014617	SecuPrint image of report titled "IEF Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06020/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2082	C	Medytox-ITC-00014618	Medytox-ITC-00014618	SecuPrint image report titled "IEF Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06020/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2083	C	Medytox-ITC-00014619	Medytox-ITC-00014619	SecuPrint image of report titled "IEF Analysis of BTA Drug Substance," Doc. No./Ver. No. OVR-06020/00	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2084	C	Medytox-ITC-00014620	Medytox-ITC-00014620	SecuPrint image of report titled "Peptide mapping analysis of BTA Drug Substance," Doc. No./Ver. No. OVR 06023/00	Seong Hun Chang; Chang Hoon Rhee	Admitted
CX-2085	C	Medytox-ITC-00014621	Medytox-ITC-00014626	Byung Kook Lee contract for payment of annual salary and other remuneration	Seong Hun Chang	Admitted
CX-2086	C	Medytox-ITC-00014627	Medytox-ITC-00014651	Master Cell Bank Management Log for CBAM0802 - Clostridium botulinum type A, Hall	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2087	C	Medytox-ITC-00014679	Medytox-ITC-00014679	Spreadsheet of Medytox Employee Salary/Benefits Information for 2006 and 2007	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2088	C	Medytox-ITC-00014680	Medytox-ITC-00014680	Spreadsheet of Medytox Employee Salary/Benefits Information for 2008	Seong Hun Chang Byung Kook Lee	Admitted
CX-2089	C	Medytox-ITC-00086355	Medytox-ITC-00086360	Mass Analysis of BTA Substance, dated September 6, 2006	Chang Hoon Rhee; Andrew Pickett	Admitted
CX-2090	C	Medytox-ITC-00086672	Medytox-ITC-00086683	Experimental Batch Record, Version No. 15, dated March 18, 2008	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2091	C	Medytox-ITC-00086684	Medytox-ITC-00086762	Batch Record, Version No. 04, dated January 11, 2006	Chang Hoon Rhee; Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2092	C	Medytox-ITC-00086763	Medytox-ITC-00086828	Batch Record, Version No. 05, dated August 7, 2008	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2093	C	Medytox-ITC-00086866	Medytox-ITC-00086894	Characterization Report of Botulinum Toxin Type A, dated April 6, 2007	Chang Hoon Rhee; Seong Hun Chang	Admitted
CX-2094	C	Medytox-ITC-00086964	Medytox-ITC-00086966	Standard Operating Procedure titled "Potency Test for Stock Solution," No. QB2201, dated August 2006	Seong Hun Chang	Admitted
CX-2095	C	Medytox-ITC-00086967	Medytox-ITC-00086969	Standard Operating Procedure titled "Specific Potency Test for Stock Solution," No. QB2401, dated August 2006	Seong Hun Chang	Admitted
CX-2096	C	Medytox-ITC-00092146	Medytox-ITC-00092205	"Common Technical Document: MT10109L (Clostridium botulinum toxin type A)", dated January 13, 2014	Joint Stipulation (Dkt. No. 701591); Brenda Wilson	Admitted
CX-2097	C	Medytox-ITC-00100762	Medytox-ITC-00100776	Presentation titled "Progress Report 20071005" dated October 5, 2007	Seong Hun Chang; Andrew Pickett	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2098	C	Medytox-ITC-00102553	Medytox-ITC-00102553	Development of Botulinum Toxin Type A Process Flow chart	Hack Woo Kim	Admitted
CX-2099	C	Medytox-ITC-00105644	Medytox-ITC-00105644	Manufacturing and research schedule, dated March 2005 to December 2005	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2100	C	Medytox-ITC-00107759	Medytox-ITC-00107761	Meeting Minutes regarding Second TFT process improvement, dated February 22, 2005	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2101	C	Medytox-ITC-00109906	Medytox-ITC-00109906	Minutes of the meeting on October 8, 2007 relating to improving manufacturing process	Seong Hun Chang; Andrew Pickett	Admitted
CX-2102	C	Medytox-ITC-00123529	Medytox-ITC-00123603	Batch Record Version No. 05, dated September 11, 2006	Joint Stipulation (Dkt. No. 701591); Hack Woo Kim; Byung Kook Lee	Admitted
CX-2103	C	Medytox-ITC-00132759	Medytox-ITC-00132759	DNA Sequencing Data for CBAM0301		Withdrawn
CX-2104	C	Medytox-ITC-00132760	Medytox-ITC-00132760	DNA Sequencing Data for CBAM0301		Withdrawn
CX-2105	C	Medytox-ITC-00132761	Medytox-ITC-00132761	DNA Sequencing Data for CBAM0804		Withdrawn
CX-2106	C	Medytox-ITC-00132762	Medytox-ITC-00132762	DNA Sequencing Data for CBAM0804		Withdrawn
CX-2107	C	Medytox-ITC-00132763	Medytox-ITC-00132763	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2108	C	Medytox-ITC-00132764	Medytox-ITC-00132764	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2109	C	Medytox-ITC-00132765	Medytox-ITC-00132765	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2110	C	Medytox-ITC-00132766	Medytox-ITC-00132766	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2111	C	Medytox-ITC-00132767	Medytox-ITC-00132767	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2112	C	Medytox-ITC-00132768	Medytox-ITC-00132768	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2113	C	Medytox-ITC-00132769	Medytox-ITC-00132769	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2114	C	Medytox-ITC-00132770	Medytox-ITC-00132770	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2115	C	Medytox-ITC-00132771	Medytox-ITC-00132771	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2116	C	Medytox-ITC-00132772	Medytox-ITC-00132772	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2117	C	Medytox-ITC-00132773	Medytox-ITC-00132773	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2118	C	Medytox-ITC-00132774	Medytox-ITC-00132774	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2119	C	Medytox-ITC-00132775	Medytox-ITC-00132775	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2120	C	Medytox-ITC-00132776	Medytox-ITC-00132776	DNA Sequencing Data for CBAW1310		Withdrawn
CX-2121	C	Medytox-ITC-00132832	Medytox-ITC-00132832	Email from Byung Kook Lee to Seong Hun Chang, dated February 25, 2008		Withdrawn
CX-2122	C	Medytox-ITC-00132836	Medytox-ITC-00132836	Email from Byung Kook Lee to Hyun Ho Jung and Gi Hyuk Yang, dated July 15, 2008	Hyun Ho Jung	Admitted
CX-2123	C	Medytox-ITC-00132863	Medytox-ITC-00132863	Email from Byung Kook Lee to Gi Hyuk Yang, dated October 16, 2007		Withdrawn
CX-2124	C	Medytox-ITC-00132866	Medytox-ITC-00132866	Email from Sung Hun Chang to Byung Kook Lee, dated October 10, 2007	Seong Hun Chang	Admitted
CX-2125	C	Medytox-ITC-00133113	Medytox-ITC-00133113	Email from Byung Kook Lee email to his personal email, dated December 12, 2007	Seong Hun Chang	Admitted
CX-2126	C	Medytox-ITC-00133807	Medytox-ITC-00133807	Email from Byung Kook Lee email to his personal email, dated July 17, 2008	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2127	C	Medytox-ITC-00133892	Medytox-ITC-00133907	Collection of documents relating to Kyu-Hwan Yang's research and the origin of Medytox strain	Hyun Ho Jung; Seong Hun Chang	Admitted
CX-2128	C	Medytox-ITC-00135200	Medytox-ITC-00135207	Attachment to email titled Seoul Scholarship Application for Byung Kook Lee's Ph.D. study dated December 12, 2007	Seong Hun Chang	Admitted
CX-2129	C	Medytox-ITC-00137174	Medytox-ITC-00137196	Attachment to email titled "Progress Report 20070626" dated June 26, 2007	Hack Woo Kim; Seong Hun Chang; Andrew Pickett	Admitted
CX-2130	C	Medytox-ITC-00139039	Medytox-ITC-00139039	Attachment to email containing spreadsheet of Byung Kook Lee's credit card and loan debts	Seong Hun Chang	Admitted
CX-2131	C	Medytox-ITC-00153359	Medytox-ITC-00153365	Presentation slides titled "Purification condition design" dated September 28, 2007	Seong Hun Chang; Andrew Pickett	Admitted
CX-2132	C	Medytox-ITC-00153669	Medytox-ITC-00153683	Presentation slides titled "Process Development team"		Withdrawn
CX-2133	C	Medytox-ITC-00160101	Medytox-ITC-00160115	Presentation titled "Progress Report 20070322" dated March 22, 2007	Seong Hun Chang; Andrew Pickett	Admitted
CX-2134	C	Medytox-ITC-00165280	Medytox-ITC-00165336	Report on a Meditoxin injectible clinical trial for hemifacial spasm patients	Hyun Ho Jung	Admitted
CX-2135	C	Medytox-ITC-00202000	Medytox-ITC-00202004	Minutes of meeting between Medytox and Q-med occurring on November 7th and 8th, 2007 dated November 12, 2007	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2136	C	Medytox-ITC-00219822	Medytox-ITC-00219871	Handout titled "Disclosure of Whole Genome Sequence of Medytox's C. Botulinum Strain"		Withdrawn
CX-2137	C	Medytox-ITC-00232507	Medytox-ITC-00232508	Byung Kook Lee Confidentiality Agreement dated March 2, 2005	Seong Hun Chang Byung Kook Lee	Admitted
CX-2138	C	Medytox-ITC-00233979	Medytox-ITC-00233983	Document titled "Studies on immunity to toxins of Clostridium botulinum"	Hack Woo Kim; Andrew Pickett	Admitted
CX-2139	C	Medytox-ITC-00234524	Medytox-ITC-00234527	Origin and development details (history)		Withdrawn
CX-2140	C	Medytox-ITC-00234530	Medytox-ITC-00234531	The Request for Examination of Standards and Testing Methods, dated June 14, 2001		Withdrawn
CX-2141	C	Medytox-ITC-00234532	Medytox-ITC-00234533	Summary Table of Botulinum toxin Type A three-time test productions, dated April 2001		Withdrawn
CX-2142	C	Medytox-ITC-00234539	Medytox-ITC-00234552	Document titled "Clostridium Botulinum Toxin Type A" summarizing properties of C. botulinum toxin		Withdrawn
CX-2143	C	Medytox-ITC-00234563	Medytox-ITC-00234569	Document titled "Batch Production & Control Record" dated November 20, 2000	Hyun Ho Jung; Hack Woo Kim; Seong Hun Chang	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2144	C	Medytox-ITC-00234571	Medytox-ITC-00234577	Document titled "Attachment 1. Drug Substance and its Quantity" showing manufacturing method and test method for C. botulinum toxin		Withdrawn
CX-2145	C	Medytox-ITC-00234578	Medytox-ITC-00234584	Raw material medicine and quantity; Efficacy Effect		Withdrawn
CX-2146	C	Medytox-ITC-00234591	Medytox-ITC-00234601	Test Report for Meditoxin, dated April 15, 2001.		Withdrawn
CX-2147	C	Medytox-ITC-00234602	Medytox-ITC-00234605	Batch Production & Control Record for Meditoxin, dated 2001		Withdrawn
CX-2148	C	Medytox-ITC-00234606	Medytox-ITC-00234616	Test Report for Botulinum toxin type A, dated March 18, 2001		Withdrawn
CX-2149	C	Medytox-ITC-00234617	Medytox-ITC-00234617	Test Report for Botulinum toxin type A Standard Preparation, dated March 14, 2001		Withdrawn
CX-2150	C	Medytox-ITC-00234618	Medytox-ITC-00234621	Anti-Botulinum toxin type A Rabbit Serum Standard Preparation		Withdrawn
CX-2151	C	Medytox-ITC-00234632	Medytox-ITC-00234638	Production Method		Withdrawn
CX-2152	C	Medytox-ITC-00260722	Medytox-ITC-00260879	Young Sook Yoon's Lab Notebook - RN-07038 (July 23, 2007 - November 30, 2007)	Seong Hun Chang	Admitted
CX-2153	C	Medytox-ITC-00260880	Medytox-ITC-00261031	Young Sook Yoon's Lab Notebook - RN-07039 (March 22, 2007 - July 13, 2007)	Seong Hun Chang	Admitted
CX-2154	C	Medytox-ITC-00261032	Medytox-ITC-00261183	Young Sook Yoon's Lab Notebook - RN-07050 (December 3, 2007 - August 8, 2008)	Seong Hun Chang; Byung Kook Lee	Admitted
CX-2155	C	DAEWOONG00001004	DAEWOONG000001019	DWP-450 CTD Section 2.3.S.2 Manufacture		Withdrawn
CX-2156	C	DAEWOONG000001459	DAEWOONG000001514	DWP-450 CTD Section 3.2.A.1 Facilities and Equipment		Withdrawn
CX-2157	C	DAEWOONG000140896	DAEWOONG000140915	DWP-450 CTD Section 1.11.1 Quality Information Amendment	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2158	C	DAEWOONG000141245	DAEWOONG000141281	DWP450-32s23-REP-006E Study Report for Manufacturing of DWP450 WCB	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2159	C	DAEWOONG000141282	DAEWOONG000141308	DWP450-REP-069: Report for DWP450 EPC Characterization (English)		Withdrawn
CX-2160	C	DAEWOONG000141309	DAEWOONG000141357	DWP450-REP-110: Sporeforming test of MCB (English)		Withdrawn
CX-2161	C	DAEWOONG000143376	DAEWOONG000143490	DWP-450 CTD Section 1.11.1 Quality Information Amendment	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2162	C	DAEWOONG000149148	DAEWOONG000149469	DWP-450 CTD Section 3.2.S.2.6: Manufacturing Process Development (322 pages)	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
CX-2163	C	DAEWOONG000149658	DAEWOONG000149675	DWP450-32s26-REP-023: Test Result Report of Possible Spore during DWP450 Undiluted Solution Production Process (English)	Kyoung Yun Kim	Admitted
CX-2164	C	DAEWOONG000151748	DAEWOONG000151797	DWP-450 CTD Section 3.2.S.2.3: Control of Materials	Andrew Pickett	Admitted
CX-2165		DAEWOONG000153417	DAEWOONG000153417	Certificate of Good Manufacturing Practice for Daewoong from the Korea Food and Drug Administration dated July 26, 2010		Withdrawn
CX-2166	C	DAEWOONG000156063	DAEWOONG000156065	Letter from the Korean Ministry of Knowledge Economy (MKE) to Daewoong regarding "Issuing Certificate of Completion of Declaration for Manufacture of Biological Agents, etc.," dated October 29, 2010		Withdrawn
CX-2167	C	DAEWOONG000157083	DAEWOONG000157176	DWP450-REP-003: DWP 450 MCB Manufacturing Report	David Sherman; Kyoung Yun Kim	Admitted
CX-2168	C	DAEWOONG000164040	DAEWOONG000164093	Korean DWP450 Module 3, Section 3.2.S.2	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2169	C	DAEWOONG000213786	DAEWOONG000213852	Daewoong Annual Business Report from April 2009 to March 2010	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2170	C	DAEWOONG000218017	DAEWOONG000218021	DWP450-32s23-REP-026 (Addendum): Results of Spore Formation Test	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2171	C	DAEWOONG000218022	DAEWOONG000218034	DWP450-32s23-REP-026E: Study Report on Spore Formation Test of Daewoong Clostridium Botulinum Strain Under Stress Conditions	Joint Stipulation (Dkt. No. 701591); Kyoung Yun Kim	Admitted
CX-2172	C	DAEWOONG000218400	DAEWOONG000218411	New Drug Submission - Response to Quality Clarifax of 19-February-2018		Withdrawn
CX-2173		DAEWOONG000218696	DAEWOONG000218696	GenBank C. botulinum 16S ribosomal RNA gene, partial sequence	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2174	C	DAEWOONG000230316	DAEWOONG000230327	Daewoong Study Report by researchers Ji Sung Park and Seungju Choo, for the period April 9, 2018 to May 14, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2175	C	DAEWOONG000243058	DAEWOONG000243090	Email attachment titled Nabota Business Plan by Seongsoo Park, Division Head / Executive director dated December 3, 2018	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2176	C	DAEWOONG000294763	DAEWOONG000294775	DWP450-REP-012: Report of setting the context coverage of DWP450 Botulinum Toxin Injection	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2177	C	DAEWOONG000294776	DAEWOONG000294789	DWP450-REP-012E: Report of setting the context coverage of DWP450 Botulinum Toxin Injection	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2178	C	DAEWOONG000339378	DAEWOONG000339380	Jeon Ye-Jin, Korea Economy, "Daewoong Pharmaceutical 'Nabota' 2 plant approved by FDA ... Green light to proceed," October 10, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2179	C	DAEWOONG000444579	DAEWOONG000444608	Presentation titled "Botulinum Toxin Development Strategies (Overview, draft 1)," dated January 2010	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chang Woo Suh	Admitted
CX-2180	C	DAEWOONG000444609	DAEWOONG000444615	Memo titled "Comprehensive Report on BTA Development Project," dated November 4, 2009	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chang Woo Suh	Admitted
CX-2181	C	DAEWOONG000445515	DAEWOONG000445560	"DWP-450 Botulinum toxin injected drug development," dated September 26, 2012		Withdrawn
CX-2182	C	DAEWOONG000523243	DAEWOONG000523271	Jeong Eun Choo Lab Notebook Excerpt (pgs. 137-188)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2183	C	DAEWOONG000523693	DAEWOONG000524085	Daewoong U.S. Patent Application for "Method for Production of Botulinum Toxin" and related documents		Withdrawn
CX-2184	C	DAEWOONG000524106	DAEWOONG000524106	Spore Images from Study Report on Spore Formation Test of Daewoong Clostridium Botulinum Strain Under Stress Conditions (DWP450-32s23-REP-026E, DAEWOONG000218022)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2185	C	DAEWOONG000524107	DAEWOONG000524107	Spore Images from Study Report on Spore Formation Test of Daewoong Clostridium Botulinum Strain Under Stress Conditions (DWP450-32s23-REP-026E, DAEWOONG000218022)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2186	C	DAEWOONG000524108	DAEWOONG000524108	Spore Images from Study Report on Spore Formation Test of Daewoong Clostridium Botulinum Strain Under Stress Conditions (DWP450-32s23-REP-026E, DAEWOONG000218022)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2187	C	DAEWOONG000524109	DAEWOONG000524109	Spore Images from Study Report on Spore Formation Test of Daewoong Clostridium Botulinum Strain Under Stress Conditions (DWP450-32s23-REP-026E, DAEWOONG000218022)	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2188	C	DAEWOONG000524110	DAEWOONG000524182	Letter from Wayne Seifert, FDA, to June Kim, Daewoong, Reference No. FEI 3012333115, May 8, 2018		Withdrawn
CX-2189	C	DAEWOONG000524234	DAEWOONG000524236	Record of Payments to Chung Sei Kim	Chung Sei Kim	Admitted
CX-2190	C	DAEWOONG000546120	DAEWOONG000546120	Email attachment containing spreadsheet titled "2016 Joint Investment Plan"		Withdrawn
CX-2191	C	DAEWOONG000552848	DAEWOONG000552848	Investment progress layout: Investment Plan Development Plan	Chung Sei Kim	Admitted
CX-2192	C	DAEWOONG000552854	DAEWOONG000552854	Investment Progress Plan: Investment Plan Progress Report		Withdrawn
CX-2193	C	DAEWOONG000617018	DAEWOONG000617020	Personnel Record Card for Chang Woo Suh	Chang Woo Suh	Admitted
CX-2194	C	DAEWOONG000617371	DAEWOONG000617377	"Submission of [information on] current retention of highly dangerous pathogens (HDPs) (for electronic document)," submitted by Jong Wook Lee, Daewoong Pharmaceuticals, for the following periods: Second half of 2013 (submitted January 6, 2014); first half of 2014 (submitted July 14, 2014); second half of 2014 (submitted January 2, 2015); second half of 2015 (submitted January 20, 2016). "Declaration of Information on our Current Retention of Highly Dangerous Pathogens," submitted by Jong Wook Lee, Daewoong Pharmaceuticals, on January 5, 2017 and January 12, 2018, and submitted by Seung Ho Jeon and Jae Choon Youn on January 30, 2019.		Withdrawn
CX-2195	C	DAEWOONG000617378	DAEWOONG000617388	"Submission of [information on] current retention of highly dangerous pathogens (HDPs) (for electronic document)," submitted by Jong Wook Lee, Daewoong Pharmaceuticals, for the following periods: Second half of 2011; first half of 2012. "Declaration of Information on our Current Retention of highly dangerous pathogens (HDPs)," submitted by Jong Wook Lee, Daewoong Pharmaceuticals, for the following periods: second half of 2012; first half of 2013; second half of 2013; first half of 2014; second half of 2014; second half of 2015. "Declaration of Information on our Current Retention of Highly Dangerous Pathogens," submitted by Jong Wook Lee, Daewoong Pharmaceuticals, on January 5, 2017 and January 17, 2018, and submitted by Seung Ho Jeon and Jae Choon Youn on January 18 2019.		Withdrawn
CX-2196	C	DAEWOONG000617391	DAEWOONG000617394	"High Risk Pathogen Transfer Report," dated July 18, 2013, March 4, 2015, and May 28, 2018		Withdrawn
CX-2197	C	DAEWOONG000617603	DAEWOONG000617604	Letter from Shawn Park to Christopher J Marmo, CEO, Evolus, RE: Providing Information about Daewoong's Official Position on the Recent Botulinum Issues dated November 11, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2198	C	DAEWOONG000617605	DAEWOONG000617804	Ji Seong Park Lab Notebook (No. 2018-156)	Joint Stipulation (Dkt. No. 701591); Kyoung Yun Kim	Admitted
CX-2199	C	DAEWOONG000617812	DAEWOONG000617823	DWP450-32s26-REP-023: Test Result Report of Possible Spore during DWP450 Undiluted Solution Production Process (Korean)	Joint Stipulation (Dkt. No. 701591); Kyoung Yun Kim	Admitted
CX-2200	C	DAEWOONG000617827	DAEWOONG000617828	Personnel Record Card for Chung Sei Kim	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2201	C	DAEWOONG000619566	DAEWOONG000619667	Ji Seong Park Lab Notebook (No. 2018-070)		Withdrawn
CX-2202	C	DAEWOONG000620192	DAEWOONG000620193	Personnel Record Card for Yeon Tae Jung	Andrew Pickett	Admitted
CX-2203	C	DAEWOONG000620261	DAEWOONG000620264	Technical Guidance Consulting Service Agreement between Daewoong Pharmaceutical Co., Ltd. and Byung Kook Lee	Byung Kook Lee; Chang Woo Suh	Admitted
CX-2204	C	DAEWOONG000621183	DAEWOONG000621183	Record of Payslips of Kyung Min Min (From onboarding until present); Record of Payslips of Kwan Young Song (From onboarding until present); Record of Payslips of Yeon Tae Jung (From onboarding until present)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2205	C	DAEWOONG000621184	DAEWOONG000621186	Personnel Record Card for Kyung Min Min	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2206	C	DAEWOONG000621187	DAEWOONG000621188	Personnel Record Card for Song Kwan Young	Andrew Pickett	Admitted
CX-2207	C	DAEWOONG000621192	DAEWOONG000621192	Record of Payslips of Chang Woo Suh (From onboarding until present)		Withdrawn
CX-2208	C	DAEWOONG000623884	DAEWOONG000623924	Report by Michael R. Popoff	Paul Keim; Andrew Pickett; Kyoung Yun Kim	Admitted
CX-2209	C	DAEWOONG000623942	DAEWOONG000623942	Biosafety Manager Certificate awarded to Chung Sei Kim by KOBSA (Korea Biosafety Association)		Withdrawn
CX-2210	C	AGN-ITC-00002783	AGN-ITC-00002794	Allergen-Daewoong Distributorship Agreement	Joint Stipulation (Dkt. No. 701591); Chang Woo Suh; Sesha Neervannan	Admitted
CX-2211		AGN-ITC-00002795	AGN-ITC-00002804	Evolus, Inc. Q3 2018 Earnings Call Transcript dated November 5, 2018		Withdrawn
CX-2212	C	AGN-ITC-00002876	AGN-ITC-00002895	Distribution Agreement between Allergan and Daewoong	Joint Stipulation (Dkt. No. 701591); Chang Woo Suh	Admitted
CX-2213	C	AGN-ITC-00002896	AGN-ITC-00002913	Settlement Agreement between Allergan and Daewoong	Joint Stipulation (Dkt. No. 701591); Chang Woo Suh	Admitted
CX-2214	C	AGN-ITC-00002915	AGN-ITC-00002915	Allergan payment to Medytox		Withdrawn
CX-2215		AGN-ITC-00002939	AGN-ITC-00002959	Evolus' January 2019 "Creating an Aesthetic Evolution" Investor Presentation Deck		Withdrawn
CX-2216	C	AGN-ITC-00002960	AGN-ITC-00003016	Allergan situational analysis deck, dated May 2018	Colleen McKenna	Admitted
CX-2217	C	AGN-ITC-00003017	AGN-ITC-00003052	U.S. Facial Aesthetic Bimonthly News Update, SAI MedPartners dated July-August 2018	Colleen McKenna	Admitted
CX-2218	C	AGN-ITC-00003053	AGN-ITC-00003136	BOTOX Competitor Analysis, dated December 8, 2015	Colleen McKenna	Admitted
CX-2219	C	AGN-ITC-00003137	AGN-ITC-00003246	BOTOX Competitor Analysis, dated November 2016	Colleen McKenna	Admitted
CX-2220	C	AGN-ITC-00003247	AGN-ITC-00003338	2018 Facial Injectable Dosing Records NTX Report	Colleen McKenna	Admitted
CX-2221	C	AGN-ITC-00003339	AGN-ITC-00003512	Facial Injectable MD Landscape Study dated April 19, 2018	Colleen McKenna	Admitted
CX-2222	C	AGN-ITC-00003513	AGN-ITC-00003587	Allergan Report, dated March 2018	Colleen McKenna	Admitted
CX-2223		AGN-ITC-00003610	AGN-ITC-00003611	Clinicaltrial.gov Search Results	Sesha Neervannan	Admitted
CX-2224		AGN-ITC-00003612	AGN-ITC-00003616	Clinicaltrial.gov Search Result 1:MT10109L in the Treatment of Glabellar Lines	Sesha Neervannan	Admitted
CX-2225		AGN-ITC-00003617	AGN-ITC-00003621	Clinicaltrial.gov Search Result 2:MT10109L in the Treatment of Lateral Canthal Lines	Sesha Neervannan	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2226		AGN-ITC-00003622	AGN-ITC-00003627	Clinicaltrial.gov Search Result 3:MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines	Sesha Neervannan	Admitted
CX-2227		AGN-ITC-00003628	AGN-ITC-00003633	Clinicaltrial.gov Search Result 4:MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines	Sesha Neervannan	Admitted
CX-2228		AGN-ITC-00003634	AGN-ITC-00003641	Clinicaltrial.gov Search Result 5:Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line	Sesha Neervannan	Admitted
CX-2229	C	AGN-ITC-00004120	AGN-ITC-00004125	FDA IND Acknowledgement Letter	Sesha Neervannan	Admitted
CX-2230	C	AGN-ITC-00004126	AGN-ITC-00004128	FDA IND Submission Letter	Joint Stipulation (Dkt. No. 701591); Sesha Neervannan	Admitted
CX-2231	C	AGN-ITC-00004794	AGN-ITC-00004797	Allergan Pricing List	James Malackowski; Colleen McKenna	Admitted
CX-2232		AGN-ITC-00007315	AGN-ITC-00007340	Evolus' Creating an Aesthetic Evolution deck dated May 2019		Withdrawn
CX-2233		AGN-ITC-00007341	AGN-ITC-00007346	"Evolus Reports First Quarter 2019 Financial Results," Evolus Press Release dated April 30, 2019		Withdrawn
CX-2234		AGN-ITC-00007347	AGN-ITC-00007359	Evolus' FQ1 2019 Earnings Call Transcript, S&P Global dated April 30, 2019	James Malackowski	Admitted
CX-2235		AGN-ITC-00007360	AGN-ITC-00007365	Katie Thomas, "A Rival to Botox Invites Doctors to Party in Cancun, With Fireworks, Confetti and Social Media Posts," The New York Times dated May 15, 2019	James Malackowski	Admitted
CX-2236	C	AGN-ITC-00007491	AGN-ITC-00007491	Allergan Sales Analysis for Q1 2019		Withdrawn
CX-2237	C	AGN-ITC-00007586	AGN-ITC-00007587	Allergan email dated March 6, 2018	James Malackowski	Admitted
CX-2238	C	AGN-ITC-00008237	AGN-ITC-00008313	Competitor Assessment Final Report – 2018	Colleen McKenna	Admitted
CX-2239	C	AGN-ITC-00008672	AGN-ITC-00008673	Allergan email dated March 15, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2240	C	AGN-ITC-00008697	AGN-ITC-00008699	Allergan email dated April 28, 2017		Withdrawn
CX-2241	C	AGN-ITC-00008803	AGN-ITC-00008804	Allergan email dated December 3, 2016		Withdrawn
CX-2242	C	AGN-ITC-00008805	AGN-ITC-00008806	Allergan email dated December 3, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2243	C	AGN-ITC-00009123	AGN-ITC-00009126	Allergan email dated May 17, 2018		Withdrawn
CX-2244	C	AGN-ITC-00009618	AGN-ITC-00009619	Allergan email dated December 14, 2018		Withdrawn
CX-2245	C	AGN-ITC-00009737	AGN-ITC-00009738	Allergan email dated February 4, 2019		Withdrawn
CX-2246	C	AGN-ITC-00009925	AGN-ITC-00009925	Allergan Internal Data re Evolus	Colleen McKenna	Admitted
CX-2247	C	AGN-ITC-00009931	AGN-ITC-00009964	Social media analysis, dated May 17, 2019	Colleen McKenna	Admitted
CX-2248	C	AGN-ITC-00010159	AGN-ITC-00010159	BOTOX Cost of Goods	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2249	C	AGN-ITC-00010160	AGN-ITC-00010160	Allergan Financial Modeling, dated May 24, 2019	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2250	C	AGN-ITC-00010161	AGN-ITC-00010161	Botox Cost of Goods		Withdrawn
CX-2251	C	AGN-ITC-00010162	AGN-ITC-00010162	Botox Units Data 2014-2018	James Malackowski; Carla Mulhern; Ben Marzouk	Admitted
CX-2252	C	AGN-ITC-00010163	AGN-ITC-00010163	Botox Sales Data 2013-2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2253	C	AGN-ITC-00010164	AGN-ITC-00010164	Allergan Revenue Model for 2014-2019	Carla Mulhern; Ben Marzouk	Admitted
CX-2254	C	AGN-ITC-00010165	AGN-ITC-00010165	Allergan Sales Analysis for 2014-2019	Ben Marzouk	Admitted
CX-2255		AGN-ITC-00010166	AGN-ITC-00010197	Evolus, Inc. Corporate Analyst Meeting Transcript, Thomson Reuters dated May 8, 2019	James Malackowski	Admitted
CX-2256		AGN-ITC-00010198	AGN-ITC-00010261	Evolus Investor and Analyst Day presentation dated May 2019	James Malackowski	Admitted
CX-2257	C	AGN-ITC-00010262	AGN-ITC-00010262	Allergan field inquiry re Evolus, dated May 20, 2019	Carla Mulhern; Colleen McKenna	Admitted
CX-2258	C	AGN-ITC-00010266	AGN-ITC-00010266	Allergan trend report re Evolus, for week of May 13, 2019	Colleen McKenna	Admitted
CX-2259	C	AGN-ITC-00010269	AGN-ITC-00010269	Allergan trend report re Evolus, for week of May 20, 2019	Colleen McKenna	Admitted
CX-2260	C	AGN-ITC-00010272	AGN-ITC-00010272	Allergan trend report re Evolus, for week of April 29, 2019	Colleen McKenna	Admitted
CX-2261	C	AGN-ITC-00010275	AGN-ITC-00010275	Allergan trend report re Evolus, for week of May 6, 2019	Colleen McKenna	Admitted
CX-2262	C	AGN-ITC-00010308	AGN-ITC-00010310	Allergan email dated May 20, 2019	Colleen McKenna	Admitted
CX-2263	C	AGN-ITC-00010313	AGN-ITC-00010346	Social media analysis, dated May 17, 2019		Withdrawn
CX-2264	C	AGN-ITC-00010377	AGN-ITC-00010377	Allergan email dated April 25, 2019		Withdrawn
CX-2265	C	AGN-ITC-00010378	AGN-ITC-00010382	Allergan email dated April 30, 2019		Withdrawn
CX-2266	C	AGN-ITC-00010383	AGN-ITC-00010390	Allergan email dated May 23, 2019	Colleen McKenna	Admitted
CX-2267	C	AGN-ITC-00010391	AGN-ITC-00010393	Allergan email dated May 7, 2019		Withdrawn
CX-2268		AGN-ITC-00010399	AGN-ITC-00010401	"Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox," The Street dated February 4, 2019		Withdrawn
CX-2269		AGN-ITC-00010402	AGN-ITC-00010403	"Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines," NASDAQ.com dated February 5, 2019		Withdrawn
CX-2270		AGN-ITC-00010404	AGN-ITC-00010407	Botox Rivals Create New Wrinkles for Allergan, Wall Street, Journal dated April 8, 2019	James Malackowski	Admitted
CX-2271	C	AGN-ITC-00010408	AGN-ITC-00010433	Neurotoxin Tracker Report April 2017		Withdrawn
CX-2272	C	AGN-ITC-00010620	AGN-ITC-00010644	Neurotoxin Tracker Report December 2018		Withdrawn
CX-2273	C	AGN-ITC-00011169	AGN-ITC-00011170	NTX Market Share Presentation	Colleen McKenna	Admitted
CX-2274	C	AGN-ITC-00011171	AGN-ITC-00011179	Neurotoxin presentation	Colleen McKenna	Admitted
CX-2275	C	AGN-ITC-00011180	AGN-ITC-00011182	Allergan report re Neurotoxin dated May 24, 2019		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2276	C	AGN-ITC-00011183	AGN-ITC-00011183	2014 HR Data	James Malackowski; Ben Marzouk	Admitted
CX-2277	C	AGN-ITC-00011184	AGN-ITC-00011184	2015 HR data	James Malackowski; Ben Marzouk	Admitted
CX-2278	C	AGN-ITC-00011185	AGN-ITC-00011185	2016 HR Data	James Malackowski; Ben Marzouk	Admitted
CX-2279	C	AGN-ITC-00011186	AGN-ITC-00011186	2017 HR Data	James Malackowski; Ben Marzouk	Admitted
CX-2280	C	AGN-ITC-00011187	AGN-ITC-00011187	2018 HR Data	James Malackowski; Ben Marzouk	Admitted
CX-2281	C	AGN-ITC-00011188	AGN-ITC-00011188	MT10109L Vendor Transactions		Withdrawn
CX-2282	C	AGN-ITC-00011189	AGN-ITC-00011199	Allergan internal tracker re Evolus, dated November 9, 2016	Colleen McKenna James Malackowski	Admitted
CX-2283	C	AGN-ITC-00011209	AGN-ITC-00011209	Allergan internal tracker re Evolus, dated February 9, 2018		Withdrawn
CX-2284	C	AGN-ITC-00011210	AGN-ITC-00011210	Allergan Financial Projections for 2017, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2285	C	AGN-ITC-00011211	AGN-ITC-00011211	Botox R&D Data	James Malackowski	Admitted
CX-2286	C	AGN-ITC-00011212	AGN-ITC-00011216	ACER Report 1588	James Malackowski; Ben Marzouk	Admitted
CX-2287	C	AGN-ITC-00011217	AGN-ITC-00011221	ACER Report 1951	James Malackowski; Ben Marzouk	Admitted
CX-2288	C	AGN-ITC-00011222	AGN-ITC-00011226	ACER Report 2659	James Malackowski; Ben Marzouk	Admitted
CX-2289	C	AGN-ITC-00011227	AGN-ITC-00011232	ACER Report 3730	James Malackowski; Ben Marzouk	Admitted
CX-2290	C	AGN-ITC-00011233	AGN-ITC-00011237	ACER Report 3754	James Malackowski; Ben Marzouk	Admitted
CX-2291	C	AGN-ITC-00011238	AGN-ITC-00011242	ACER Report 3762	James Malackowski; Ben Marzouk	Admitted
CX-2292	C	AGN-ITC-00011243	AGN-ITC-00011243	Revised ACER Report dated May 29, 2019	Ben Marzouk	Admitted
CX-2293	C	AGN-ITC-00011244	AGN-ITC-00011244	Botox C P&L		Withdrawn
CX-2294	C	AGN-ITC-00011245	AGN-ITC-00011245	Botox Tx P&L		Withdrawn
CX-2295	C	AGN-ITC-00011246	AGN-ITC-00011246	Allergan Capital Expenses	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2296	C	AGN-ITC-00011247	AGN-ITC-00011247	Allergan Operating Costs for 2012-2019	James Malackowski; Ben Marzouk	Admitted
CX-2297	C	AGN-ITC-00011248	AGN-ITC-00011250	Aesthetic Toxin Commentary from Investor Conference Mizuho Securities Koffler, Irina dated March 12, 2018	Colleen McKenna	Admitted
CX-2298	C	AGN-ITC-00011251	AGN-ITC-00011255	"Put the Iron Down; New Treatments Could Be A Better Way To Smooth Out Those Wrinkles," Cantor Fitzgerald dated May 7, 2018	James Malackowski; Colleen McKenna	Admitted
CX-2299	C	AGN-ITC-00011256	AGN-ITC-00011271	"A wrinkle in time: Assessing Botox and competitive threats on the horizon," Goldman Sachs dated September 4, 2018	James Malackowski; Colleen McKenna	Admitted
CX-2300	C	AGN-ITC-00011272	AGN-ITC-00011289	"Our two BOTOX cosmetic surveys both surprised; deep dive look, reason for caution," RBC Capital Markets dated February 3, 2019	James Malackowski; Colleen McKenna	Admitted
CX-2301	C	AGN-ITC-00011290	AGN-ITC-00011299	"Survey Suggests That Jeuneau Clearly Has The Attention of Dermatologists," Piper Jaffray dated February 18, 2019	Colleen McKenna	Admitted
CX-2302	C	AGN-ITC-00011300	AGN-ITC-00011300	Allergan BOTOX and HR Information		Withdrawn
CX-2303		AGN-ITC-00011301	AGN-ITC-00011301	Screenshot re Evolus		Withdrawn
CX-2304		AGN-ITC-00011302	AGN-ITC-00011302	Screenshot re Evolus		Withdrawn
CX-2305		AGN-ITC-00011303	AGN-ITC-00011303	Photos re Evolus		Withdrawn
CX-2306		AGN-ITC-00011304	AGN-ITC-00011304	Photos re Evolus		Withdrawn
CX-2307		AGN-ITC-00011305	AGN-ITC-00011305	Photos re Evolus		Withdrawn
CX-2308	C	AGN-ITC-00011310	AGN-ITC-00011310	Allergan Capital through Q1 2019	James Malackowski; Ben Marzouk	Admitted
CX-2309		AGN-ITC-00011311	AGN-ITC-00011313	"Aeon Biopharma Appoints BOTOX Therapeutic Head as President and CEO," Alphaeon Corporation Press Release dated May 13, 2019		Withdrawn
CX-2310	C	AGN-ITC-00015101	AGN-ITC-00015102	Allergan email dated February 20, 2019		Withdrawn
CX-2311	C	AGN-ITC-00015103	AGN-ITC-00015110	Allergan internal deck		Withdrawn
CX-2312	C	AGN-ITC-00015113	AGN-ITC-00015173	Allergan deck dated February 21, 2019	James Malackowski	Admitted
CX-2313	C	AGN-ITC-00015175	AGN-ITC-00015188	Allergan deck dated March 7, 2019		Withdrawn
CX-2314	C	AGN-ITC-00016111	AGN-ITC-00016111	Botox Manufactured Units, for 2014 - Q1 2019		Withdrawn
CX-2315	C	AGN-ITC-00016112	AGN-ITC-00016112	Allergan Expenses 2014-2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2316	C	AGN-ITC-00016120	AGN-ITC-00016135	"Aesthetics survey suggests headwinds for Botox Cosmetic," Cool Sculpting dated June 11, 2019		Withdrawn
CX-2317	C	AGN-ITC-00018184	AGN-ITC-00018227	Medytox Opportunity Assessment - Interim US Report dated September 30, 2015	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2318	C	AGN-ITC-00020075	AGN-ITC-00020082	Allergan deck dated February 19, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski; Carla Mulhern; Colleen McKenna	Admitted
CX-2319	C	AGN-ITC-00020085	AGN-ITC-00020086	Allergan email dated February 20, 2019		Withdrawn
CX-2320	C	AGN-ITC-00020087	AGN-ITC-00020094	Allergan deck dated February 20, 2019		Withdrawn
CX-2321	C	AGN-ITC-00020153	AGN-ITC-00020153	Allergan marketing budget	Colleen McKenna	Admitted
CX-2322	C	AGN-ITC-00020154	AGN-ITC-00020154	Botox Tx P&L	Joint Stipulation (Dkt. No. 701591); James Malackowski; Ben Marzouk	Admitted
CX-2323	C	AGN-ITC-00020155	AGN-ITC-00020155	Botox C P&L	James Malackowski; Carla Mulhern; Ben Marzouk	Admitted
CX-2324	C	AGN-ITC-00020156	AGN-ITC-00020161	Allergan's Agreement for Protection of Company Information		Withdrawn
CX-2325	C	AGN-ITC-00030180	AGN-ITC-00030180	Analysource Report - BOTOX Price Changes for 2010-2019		Withdrawn
CX-2326	C	AGN-ITC-00030186	AGN-ITC-00030186	Brand Price Change Document		Withdrawn
CX-2327	C	AGN-ITC-00030574	AGN-ITC-00030574	Botox R&D Data	Joint Stipulation (Dkt. No. 701591); James Malackowski; Ben Marzouk	Admitted
CX-2328	C	AGN-ITC-00031270	AGN-ITC-00031290	Allergan internal material dated May 29, 2019		Withdrawn
CX-2329	C	AGN-ITC-00033157	AGN-ITC-00033267	Competitor Assessment, dated April 2019	James Malackowski	Admitted
CX-2330	C	AGN-ITC-00033668	AGN-ITC-00033680	Allergan Financial Modeling dated May 1, 2019	Carla Mulhern	Admitted
CX-2331	C	AGN-ITC-00034627	AGN-ITC-00034627	Allergan Financial Projections for 2019, dated May 13, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski; Carla Mulhern; Colleen McKenna	Admitted
CX-2332	C	AGN-ITC-00034632	AGN-ITC-00034658	Allergan Financial Projections dated May 13, 2019	James Malackowski; Colleen McKenna	Admitted
CX-2333	C	AGN-ITC-00035085	AGN-ITC-00035104	Allergan Internal Analysis re Evolus, dated July 17, 2019	James Malackowski; Colleen McKenna	Admitted
CX-2334	C	AGN-ITC-00038872	AGN-ITC-00038872	Allergan Financial Projections dated June 12, 2019	Carla Mulhern	Admitted
CX-2335	C	AGN-ITC-00042969	AGN-ITC-00043067	"Pediatric Spasticity Advisory Board" Presentation dated May 4, 2019	James Malackowski	Admitted
CX-2336	C	AGN-ITC-00050484	AGN-ITC-00050602	Allergan's "Medical Aesthetics Day Presentation" dated September 14, 2018	James Malackowski; Colleen McKenna	Admitted
CX-2337	C	AGN-ITC-00052261	AGN-ITC-00052262	Allergan email dated March 22, 2019		Withdrawn
CX-2338	C	AGN-ITC-00058945	AGN-ITC-00058945	Allergan email dated June 22, 2019	James Malackowski Colleen McKenna	Admitted
CX-2339	C	AGN-ITC-00073500	AGN-ITC-00073523	Investment Presentation	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2340	C	AGN-ITC-00074199	AGN-ITC-00074199	Allergan HR Information	James Malackowski; Carla Mulhern; Ben Marzouk	Admitted
CX-2341	C	AGN-ITC-00074220	AGN-ITC-00074259	Neurotoxin Presentation		Withdrawn
CX-2342	C	AGN-ITC-00087130	AGN-ITC-00087172	Neurotoxin Strategy Presentation	James Malackowski	Admitted
CX-2343	C	AGN-ITC-00093723	AGN-ITC-00093854	Allergan presentation dated May 2019	James Malackowski; Colleen McKenna	Admitted
CX-2344	C	AGN-ITC-00093900	AGN-ITC-00093900	BOTOX Cost Centers		Withdrawn
CX-2345	C	AGN-ITC-00094384	AGN-ITC-00094384	Fixed Asset Register June 2019	James Malackowski; Carla Mulhern; Ben Marzouk	Admitted
CX-2346	C	AGN-ITC-00095128	AGN-ITC-00095128	P05 2019 - FA Detail for Assets	James Malackowski; Ben Marzouk	Admitted
CX-2347	C	AGN-ITC-00095129	AGN-ITC-00095129	Allergan email dated July 2, 2019	Joint Stipulation (Dkt. No. 701591); Carla Mulhern; Ben Marzouk	Admitted
CX-2348	C	AGN-ITC-00095130	AGN-ITC-00095130	Asset Register June 2019	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2349	C	AGN-ITC-00095132	AGN-ITC-00095132	Allergan HR Information		Withdrawn
CX-2350	C	AGN-ITC-00106932	AGN-ITC-00106932	Allergan Financial Projections through Q1 2019	James Malackowski; Ben Marzouk	Admitted
CX-2351		AGN-ITC-00132720	AGN-ITC-00132721	"Allergan, Inc. and Medytox, Inc. to Enter into Licensing Agreement," Business Wire dated September 25, 2013		Withdrawn
CX-2352		AGN-ITC-00132990	AGN-ITC-00133004	Virginia Ng, et al., "Comparison of Transcriptomes and Sporulation of Two Clostridium botulinum A1 Strains," Advances in Biotechnology & Microbiology, Volume 11 Issue 5, November 16, 2018		Withdrawn
CX-2353		EVOLUS00003895	EVOLUS00003918	Evolus "Creating an Aesthetic Evolution" Presentation		Withdrawn
CX-2354		EVOLUS00003919	EVOLUS00003958	Evolus "Jeuneau™ FDA Approval Conference Call" Presentation		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2355		EVOLUS00004732	EVOLUS00004746	Transcript of February 4, 2019 Evolus Conference Call re Jeuveau™ FDA Approval	Order No. 37	Admitted
CX-2356		EVOLUS00004771	EVOLUS00004783	Transcript of June 8, 2018 Evolus Presentation at Jefferies 2018 Global Healthcare Conference		Withdrawn
CX-2357	C	EVOLUS00006206	EVOLUS00006207	Email from Chris Marmo to Larry Thieme, dated August 23, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2358	C	EVOLUS00014946	EVOLUS00014946	Evolus 2017 - 2022 Strategic Plan	James Malackowski	Admitted
CX-2359	C	EVOLUS00016611	EVOLUS00016611	DWP-450 Forecasted Financial Information		Withdrawn
CX-2360	C	EVOLUS00042096	EVOLUS00042145	DWP-450 CTD Section 3.2.S.2.3. Control of Materials	Joint Stipulation (Dkt. No. 701591); Christopher Marmo	Admitted
CX-2361	C	EVOLUS00042246	EVOLUS00042270	Management of WCB (Working Cell Bank) by Daewoong		Withdrawn
CX-2362	C	EVOLUS00046441	EVOLUS00046441	Changes Being Effected Submission		Withdrawn
CX-2363	C	EVOLUS00047090	EVOLUS00047096	September 8, 2014 Letter to D. Stagg from FDA		Withdrawn
CX-2364	C	EVOLUS00047097	EVOLUS00047139	Minutes of Meeting between Evolus and FDA on October 19, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2365	C	EVOLUS00047140	EVOLUS00047148	Discussion Points and Agreements Reached during Meeting between Evolus and FDA on October 19, 2016		Withdrawn
CX-2366	C	EVOLUS00047149	EVOLUS00047160	Minutes of Teleconference between Evolus and FDA on March 11, 2015		Withdrawn
CX-2367	C	EVOLUS00047168	EVOLUS00047206	Background Materials for Meeting between Evolus and FDA on October 19, 2016		Withdrawn
CX-2368	C	EVOLUS00047207	EVOLUS00047211	August 4, 2016 Letter to D. Stagg from FDA		Withdrawn
CX-2369	C	EVOLUS00047724	EVOLUS00047727	Letter from S. Blank of Alphaeon to M. Simhambhatla of Evolus "Re: Therapeutic Option"		Withdrawn
CX-2370	C	EVOLUS00049654	EVOLUS00049654	Email from C. Marmo to S. Cannizzaro and J. Gross dated February 5, 2013	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2371	C	EVOLUS00049662	EVOLUS00049663	Email string from SengHo Jeon (Daewoong) to C. Marmo and Daewoong recipients, dated February 6, 2013		Withdrawn
CX-2372	C	EVOLUS00065320	EVOLUS00065322	Second Amendment to Agreement between Daewoong and Evolus		Withdrawn
CX-2373	C	EVOLUS00077398	EVOLUS00077433	Alphaeon slides re Therapeutic Neurotoxin Asset	James Malackowski	Admitted
CX-2374	C	EVOLUS00077467	EVOLUS00077470	Alphaeon slides re Botulinum Toxin Competitive Landscape	James Malackowski	Admitted
CX-2375	C	EVOLUS00105384	EVOLUS00105389	Attachment to email titled Letter from Kelly Ballard at the Center of Drug Evaluation and Research to Del Stagg re: biologics license application for DWP-450 dated February 9, 2018	Christopher Marmo	Admitted
CX-2376	C	EVOLUS00141922	EVOLUS00141924	Email from Chris Marmo to John Gross and Scott Cannizzaro, dated April 5, 2017	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
CX-2377	C	EVOLUS00207391	EVOLUS00207401	Summary of Evolus Leadership Summit - General Session	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2378	C	EVOLUS00207402	EVOLUS00207408	Summary of Evolus Leadership Summit - Consumer Workshop	James Malackowski	Admitted
CX-2379	C	EVOLUS00207461	EVOLUS00207524	Slides for Evolus Investor & Analyst Day	Joint Stipulation (Dkt. No. 701591); David Moatazedi	Admitted
CX-2380	C	EVOLUS00207525	EVOLUS00207550	Evolus Investor Presentation, titled "Creating an Aesthetic Evolution"	Joint Stipulation (Dkt. No. 701591); David Moatazedi; James Malackowski	Admitted
CX-2381	C	EVOLUS00207572	EVOLUS00207606	Transcript of May 8, 2019 Evolus Analyst/Investor Day Call	James Malackowski	Admitted
CX-2382	C	EVOLUS00207637	EVOLUS00207642	Summary of March 23, 2019 Evolus Advisory Board (Next Gen Advisors)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2383	C	EVOLUS00207660	EVOLUS00207669	Summary of February 28, 2019 Evolus Digital Marketing Advisory Board Meeting	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2384	C	EVOLUS00207746	EVOLUS00207826	Alphaeon Neurotoxin Quantitative Research Slide Deck	James Malackowski	Admitted
CX-2385	C	EVOLUS00207846	EVOLUS00207846	Pricing Spreadsheet	James Malackowski	Admitted
CX-2386	C	EVOLUS00210132	EVOLUS00210631	Medical Insight June 2018 THE Global Aesthetic Market Study: Version XVI		Withdrawn
CX-2387	C	EVOLUS00210632	EVOLUS00210637	Evolus "Guidepoint Data" Slide Deck	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2388	C	EVOLUS00210893	EVOLUS00210898	Discount and Rebate Agreement between Evolus and Dermatology Management, LLC	James Malackowski	Admitted
CX-2389	C	EVOLUS00210899	EVOLUS00210904	Discount and Rebate Agreement between Evolus and US Dermatology	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2390	C	EVOLUS00210905	EVOLUS00210910	Discount and Rebate Agreement between Evolus and Happy Clinic		Withdrawn
CX-2391	C	EVOLUS00210911	EVOLUS00210916	Discount and Rebate Agreement between Evolus and Phynet		Withdrawn
CX-2392	C	EVOLUS00210917	EVOLUS00210923	Discount and Rebate Agreement between Evolus and Skin by Lovely		Withdrawn
CX-2393	C	EVOLUS00210924	EVOLUS00210929	Discount and Rebate Agreement between Evolus and Premier Aesthetic Solutions		Withdrawn
CX-2394	C	EVOLUS00210930	EVOLUS00210993	Slides for May 2019 Evolus Investor & Analyst Day	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2395	C	EVOLUS00211003	EVOLUS00211003	Jeuveau Importation Documents (5/7/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2396	C	EVOLUS00211004	EVOLUS00211004	Jeuveau Importation Documents (5/1/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2397	C	EVOLUS00211005	EVOLUS00211005	Jeuveau Importation Documents (4/12/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2398	C	EVOLUS00211006	EVOLUS00211006	Jeuveau Importation Documents (3/29/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2399	C	EVOLUS00211007	EVOLUS00211007	Jeuveau Importation Documents (5/21/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2400	C	EVOLUS00211008	EVOLUS00211009	Evolus Entry Summary (Imported 5/21/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2401	C	EVOLUS00211010	EVOLUS00211011	Evolus Entry Summary (Imported 5/7/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2402	C	EVOLUS00211012	EVOLUS00211013	Evolus Entry Summary (Imported 5/1/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2403	C	EVOLUS00211014	EVOLUS00211015	Evolus Entry Summary (Imported 4/12/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2404	C	EVOLUS00211016	EVOLUS00211017	Evolus Entry Summary (Imported 3/29/2019)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2405	C	EVOLUS00287569	EVOLUS00287595	Alphaeon December 2016 Slide Deck titled "DWP-450 Market Share Analysis & Daewoong License Agreement"		Withdrawn
CX-2406	C	EVOLUS00342542	EVOLUS00342558	Evolus slides re Sales Team updated dated June 12, 2019		Withdrawn
CX-2407	C	EVOLUS00342559	EVOLUS00342559	Evolus Account Pricing Cheat Sheet dated June 12, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2408	C	EVOLUS00342560	EVOLUS00342562	#NEWTOX Now FAQ dated June 12, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2409	C	EVOLUS00342644	EVOLUS00342645	Email string from B. Clemson to B. Curry, M. Jafar, K. Knab dated May 8, 2019		Withdrawn
CX-2410	C	EVOLUS00345323	EVOLUS00345325	Draft document re Jeuneau Pricing - Key Messages dated March 11, 2019		Withdrawn
CX-2411	C	EVOLUS00345605	EVOLUS00345607	Talking Points for June 19, 2019 Lauren Silvernail Presentation and Fireside Chat	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2412	C	EVOLUS00347185	EVOLUS00347193	#NEWTIX Now FAQ dated June 19, 2019		Withdrawn
CX-2413	C	EVOLUS00347439	EVOLUS00347452	Evolus slides re June 2019 Investor Relations update dated May 22, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2414	C	EVOLUS00348458	EVOLUS00348458	Email from J. Axelrod to C. Muilenburg dated March 4, 2019		Withdrawn
CX-2415	C	EVOLUS00349848	EVOLUS00349848	Email string from C. Muilenburg to A. Agarwal dated June 5, 2019		Withdrawn
CX-2416	C	EVOLUS00350600	EVOLUS00350600	Evolus Account Pricing Cheat Sheet dated June 12, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski; Carla Mulhern	Admitted
CX-2417	C	EVOLUS00353422	EVOLUS00353422	Inventory Reconciliation dated June 7, 2019	James Malackowski	Admitted
CX-2418	C	EVOLUS00361551	EVOLUS00361553	Email string from D. Moatazedi to R. Sigal dated March 21, 2019	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2419	C	EVOLUS00373289	EVOLUS00373290	Evolus Board slides, including slide titled "At the gates of Allergan," dated February 9, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2420	C	EVOLUS00373515	EVOLUS00373519	Slides for Evolus Board Meeting - Operations Materials dated February 5, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2421	C	EVOLUS00386611	EVOLUS00386612	Daewoong Pharmaceutical Co. Commercial Invoice dated May 31, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2422	C	EVOLUS00386613	EVOLUS00386614	Daewoong Pharmaceutical Co. Commercial Invoice dated May 16, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2423	C	EVOLUS00386615	EVOLUS00386616	Daewoong Pharmaceutical Co. Commercial Invoice dated May 2, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2424	C	EVOLUS00390609	EVOLUS00390609	Email from K. Knab to Evolus recipients dated May 24, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2425	C	EVOLUS00397171	EVOLUS00397172	Email string from D. Moatazedi to M. Jafar, C. Fukuoka and C. Gores dated May 28, 2019		Withdrawn
CX-2426	C	EVOLUS00401462	EVOLUS00401463	Daewoong Pharmaceutical Co. Commercial Invoice dated April 25, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2427	C	EVOLUS00401895	EVOLUS00401896	Daewoong Pharmaceutical Co. Commercial Invoice dated April 09, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2428	C	EVOLUS00402181	EVOLUS00402192	Evolus Commercial Strategy slides dated April 7, 2018	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted
CX-2429	C	EVOLUS00407463	EVOLUS00407509	Slides re Evolus June Forecast - LT Review dated May 30, 2019	Joint Stipulation (Dkt. No. 701591); James Malackowski; Carla Mulhern	Admitted
CX-2430		EVOLUS00411125	EVOLUS00411171	Evolus June Forecast dated May 30, 2019	Joint Stipulation (Dkt. No. 701591); David Moatazedi	Admitted
CX-2431	C	EVOLUS00433667	EVOLUS00433668	Email from James Lin to Rui Avelar, dated August 13, 2018		Withdrawn
CX-2432	C	EVOLUS00449180	EVOLUS00449180	Evolus Purchase Order for DWP-450 dated September 12, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2433	C	EVOLUS00451895	EVOLUS00451895	Guidepoint Tracker "U.S. Neurotoxins - Tracker Survey Data" - Prepared by Evolus	James Malackowski; Carla Mulhern; David Moatazedi	Admitted
CX-2434	C	EVOLUS00452229	EVOLUS00452240	Evolus slides re YTD May 2019 Financials dated May 22, 2019		Withdrawn
CX-2435	C	EVOLUS00453096	EVOLUS00453114	Cantor Fitzgerald Equity - Company Update Specialty Pharmaceuticals "True Love Stories Don't End; We Expect Doctors to Stick with Jeuneau Post J.E.T." dated June 9, 2019	James Malackowski	Admitted
CX-2436	C	EVOLUS00454976	EVOLUS00454977	Daewoong Pharmaceutical Co. Commercial Invoice dated March 25, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2437	C	EVOLUS00455060	EVOLUS00455064	"What counts as proof of loyalty"		Withdrawn
CX-2438	C	EVOLUS00463677	EVOLUS00463677	Evolus 12 Month Rolling Forecast - U.S. Canada Market dated April 16, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2439	C	EVOLUS00463678	EVOLUS00463678	Evolus 12 Month Rolling Forecast - U.S. Canada Market dated May 30, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2440	C	EVOLUS00463679	EVOLUS00463679	Evolus 12 Month Rolling Forecast - U.S. Canada Market dated June 20, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2441	C	EVOLUS00463680	EVOLUS00463680	Evolus 12 Month Rolling Forecast - U.S. Canada Market dated January 15, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2442	C	EVOLUS00463681	EVOLUS00463681	Evolus 12 Month Rolling Forecast - U.S. Canada Market dated February 15, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2443	C	EVOLUS00463682	EVOLUS00463682	Evolus Purchase Order PO-EVO-402 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2444	C	EVOLUS00463683	EVOLUS00463683	Evolus Purchase Order PO-EVO-403 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2445	C	EVOLUS00463684	EVOLUS00463684	Evolus Purchase Order PO-EVO-405 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2446	C	EVOLUS00463685	EVOLUS00463685	Evolus Purchase Order PO-EVO-406 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2447	C	EVOLUS00463686	EVOLUS00463686	Evolus Purchase Order PO-EVO-407 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2448	C	EVOLUS00463687	EVOLUS00463687	Evolus Purchase Order PO-EVO-408 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2449	C	EVOLUS00463688	EVOLUS00463688	Evolus Purchase Order PO-EVO-552 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2450	C	EVOLUS00463689	EVOLUS00463689	Evolus Purchase Order PO-EVO-553 - Ship to Cardinal Health - La Vergne Warehouse	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2451	C	EVOLUS00463709	EVOLUS00463710	Email from J. Lehr to Leadership Team dated July 17, 2019	James Malackowski; Carla Mulhern	Admitted
CX-2452	C	BKL-ITC-00000053	BKL-ITC-00000053	Email from Byung Kook Lee to his personal email, dated November 2, 2007	Byung Kook Lee; Brenda Wilson	Admitted
CX-2453	C	BKL-ITC-00000054	BKL-ITC-00000066	Attachment to email titled Experimental Batch Record Version No. 04, Version Date January 11, 2006	Brenda Wilson	Admitted
CX-2454	C	BKL-ITC-00000067	BKL-ITC-00000067	Attachment to email titled Preliminary Agenda of Meeting at Medytox, November 7-8	Brenda Wilson	Admitted
CX-2455	C	BKL-ITC-00000068	BKL-ITC-00000069	Attachment to email titled Attachment 10 to the Medytox Project and Quality Plan (Process Parameters and In-Process Control Limits)	Brenda Wilson	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2456	C	BKL-ITC-0000070	BKL-ITC-0000071	Attachment to email titled Attachment 6 to the Medytox Project and Quality Plan (List of Materials and Containers)	Brenda Wilson	Admitted
CX-2457	C	BKL-ITC-0000072	BKL-ITC-0000099	Attachment to email titled Medytox Project and Quality Plan for Construction of Botulinum Toxin Type A Complex Facility	Brenda Wilson	Admitted
CX-2458	C	BKL-ITC-00000100	BKL-ITC-00000100	Attachment to email titled Attachment 8 to the Medytox Project and Quality Plan (Process Flow Diagram)	Brenda Wilson	Admitted
CX-2459	C	BKL-ITC-00000101	BKL-ITC-00000101	Attachment to email titled Attachment 7 to the Medytox Project and Quality Plan (Process Block Diagram)	Brenda Wilson	Admitted
CX-2460	C	BKL-ITC-00000400	BKL-ITC-00000401	Email from imamuro@medy-tox.co.kr to Byung Kook Lee's personal account, dated August 28, 2008		Withdrawn
CX-2461	C	BKL-ITC-00000405	BKL-ITC-00000406	Attachment to email titled Hee Seok Yoon Letter of Job Application	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2462	C	BKL-ITC-00000407	BKL-ITC-00000409	Attachment to email titled Hee Seok Yoon Career Description	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2463	C	BKL-ITC-00000410	BKL-ITC-00000411	Attachment to email titled Hee Seok Yoon Personal Statement	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2464	C	BKL-ITC-00000412	BKL-ITC-00000412	Email from Byung Kook Lee's personal account to himself, dated August 8, 2010	Joint Stipulation (Dkt. No. 701591); BK Lee	Admitted
CX-2465	C	BKL-ITC-00000413	BKL-ITC-00000413	Attachment to email titled Requesting support for overseas academic conference attendance on behalf of Byung Kook Lee	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2466	C	MARMO00003952	MARMO00003978	DWP-450 Market Share Analysis & Daewoong License Agreement, December 2016		Withdrawn
CX-2467	C	MARMO00007151	MARMO00007207	"License and Supply Agreement" between Daewoong and Evolus dated September 30, 2013		Withdrawn
CX-2468	C	MARMO00008884	MARMO00008948	Handwritten notes from journal, unknown author, undated		Withdrawn
CX-2469	C	PPD-ITC-00001376	PPD-ITC-00001391	Evolus DWP-450 CMC Update Meeting Minutes dated February 15, 2017	Andrew Pickett	Admitted
CX-2470	C	N/A	N/A	Expert Report of Dr. Andrew Pickett	Andrew Pickett; Brenda Wilson	Admitted
CX-2471		N/A	N/A	Expert Report of Dr. Andrew Pickett - Exhibit 1	Andrew Pickett	Admitted
CX-2472	C	N/A	N/A	Expert Report of Dr. Andrew Pickett - Exhibit 2		Withdrawn
CX-2473	C	N/A	N/A	Expert Report of Dr. Andrew Pickett - Exhibit 3		Withdrawn
CX-2474	C	N/A	N/A	Expert Report of Dr. Andrew Pickett - Exhibit 4	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
CX-2475	C	N/A	N/A	Expert Report of Dr. Andrew Pickett - Exhibit 4A		Withdrawn
CX-2476	C	N/A	N/A	Corrections to the Expert Report of Dr. Andrew Pickett		Withdrawn
CX-2477	C	N/A	N/A	Expert Report of James Malackowski and appendices		Withdrawn
CX-2478	C	N/A	N/A	Expert Report of Dr. Paul Keim		Withdrawn
CX-2479	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 1	Paul Keim	Admitted
CX-2480	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 2	Paul Keim	Admitted
CX-2481	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 3	Paul Keim	Admitted
CX-2482	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4	Paul Keim	Admitted
CX-2483	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4A	Paul Keim	Admitted
CX-2484	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4B	Paul Keim	Admitted
CX-2485		N/A	N/A	Mark A. Schoenbaum et al., An outbreak of type C botulism in 12 horses and a mule, 217 JAVMA 365 (2000)		Withdrawn
CX-2486	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4D	Paul Keim	Admitted
CX-2487	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4E	Paul Keim	Admitted
CX-2488	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4F	Paul Keim	Admitted
CX-2489	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4G	Paul Keim	Admitted
CX-2490	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4H	Paul Keim	Admitted
CX-2491	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 5	Paul Keim	Admitted
CX-2492	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 6	Paul Keim	Admitted
CX-2493	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 7	Paul Keim; David Sherman	Admitted
CX-2494	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 8	Paul Keim	Admitted
CX-2495	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 9	Paul Keim	Admitted
CX-2496	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 10	Paul Keim	Admitted
CX-2497	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 11	Paul Keim	Admitted
CX-2499	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 13	Paul Keim	Admitted
CX-2500	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 14	Paul Keim	Admitted
CX-2502	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 16	Paul Keim	Admitted
CX-2503	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17	Chang Hoon Rhee; Paul Keim; David Sherman	Admitted
CX-2504	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17A	Chang Hoon Rhee; Paul Keim	Admitted
CX-2505	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17B	Chang Hoon Rhee; Paul Keim	Admitted
CX-2506	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17C	Chang Hoon Rhee; Paul Keim	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2507	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17D	Chang Hoon Rhee; Paul Keim	Admitted
CX-2508	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17E	Paul Keim	Admitted
CX-2509	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 17F	Chang Hoon Rhee; Paul Keim; David Sherman	Admitted
CX-2510	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 18	Paul Keim	Admitted
CX-2511	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 19	Paul Keim	Admitted
CX-2512	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 20	Paul Keim	Admitted
CX-2513	C	N/A	N/A	Expert Rebuttal Report of Bal Ram Singh		Withdrawn
CX-2514	C	N/A	N/A	Expert Rebuttal Report of Brenda A. Wilson, Ph.D.		Withdrawn
CX-2515	C	N/A	N/A	Expert Rebuttal Report of Carla S. Mulhern		Withdrawn
CX-2516	C	N/A	N/A	Expert Rebuttal Report of David H. Sherman, Ph.D.	Paul Keim; David Sherman	Admitted
CX-2517	C	N/A	N/A	Expert Rebuttal Report of Ryan Sullivan, Ph.D.		Withdrawn
CX-2519	C	N/A	N/A	Deposition Designation for Byung Kook Lee, July 13, 2019		Withdrawn
CX-2520	C	N/A	N/A	Deposition Designation for Byung Kook Lee, July 6, 2019		Withdrawn
CX-2521	C	N/A	N/A	Deposition Designation for Byung Kook Lee, July 7, 2019		Withdrawn
CX-2522	C	N/A	N/A	30(b)(6) Deposition Designation for Chang Woo Suh, June 27, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted, Scope Subject to Dkt. No. 702965
CX-2523	C	N/A	N/A	30(b)(6) Deposition Designation for Chang Woo Suh, June 28, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted, Scope Subject to Dkt. No. 702965
CX-2524	C	N/A	N/A	30(b)(6) Deposition Designation for Chung Sei Kim, July 11, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted, Scope Subject to Dkt. No. 702965
CX-2525	C	N/A	N/A	30(b)(6) Deposition Designation for Chung Sei Kim, June 25, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted, Scope Subject to Dkt. No. 702965
CX-2526	C	N/A	N/A	Deposition Designation for Eric A. Johnson, July 8, 2019		Withdrawn
CX-2527	C	N/A	N/A	Deposition Designation for Han Woo Chun, June 23, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2528	C	N/A	N/A	Deposition Designation for J. Christopher Marmo, July 9, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2529	C	N/A	N/A	Deposition Designation for Jae Choon Yoon, June 18, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2530	C	N/A	N/A	Deposition Designation for Jaeseung Yoon, June 26, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2531	C	N/A	N/A	Deposition Designation for Jongeun Choo, June 21, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2532	C	N/A	N/A	Deposition Designation for Jong Wook Lee, June 29, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2533	C	N/A	N/A	Deposition Designation for Kim Seon Kyum, June 28, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2534	C	N/A	N/A	Deposition Designation for Kim Yoo Chang, June 28, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2535	C	N/A	N/A	Deposition Designation for Kim Yoo Chang, June 30, 2019	Joint Stipulation (Dkt. No. 701591); Carla Mulhern	Admitted
CX-2536	C	N/A	N/A	30(b)(6) Deposition Designation for Kyoung-Yoon Kim, June 29, 2019	Joint Stipulation (Dkt. No. 701591); Kyung Yoon Kim	Admitted, Scope Subject to Dkt. No. 702965
CX-2537	C	N/A	N/A	Deposition Designation for Park Ji Seong, June 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2538	C	N/A	N/A	Deposition Designation for Park Ji Seong, June 30, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2539	C	N/A	N/A	Brenda Wilson Deposition Exhibit 9 - U.S. 5,512,547 Patent		Withdrawn
CX-2540	C	N/A	N/A	Brenda Wilson Deposition Exhibit 12 - Wilson Lab Notebook		Withdrawn
CX-2541		N/A	N/A	Ryan Sullivan Deposition Exhibit 6 - Article, Practical Media and Control Measures for Pro-Ducing Highly Toxic Cultures of Clostridium Botulinum, Type A		Withdrawn
CX-2542		N/A	N/A	Ryan Sullivan Deposition Exhibit 7 - Article, Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine		Withdrawn
CX-2543		N/A	N/A	Ryan Sullivan Deposition Exhibit 13 - Metabiotics and Mentor Services Agreement		Withdrawn
CX-2544	C	N/A	N/A	Evolus Inc.'s Objections and Responses to Complainants' First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 1-31) dated April 3, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2545	C	N/A	N/A	Evolus, Inc. Objections and Responses to Staff's First Set of Interrogatories (Nos. 1-57) dated April 8, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2546	C	N/A	N/A	Evolus, Inc.'s Supplemental Objections and Responses to Staff's First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 12, 15-21, 33, 35, 37, 51, 57) dated May 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2547	C	N/A	N/A	Evolus, Inc.'s Supplemental Objections and Responses to Staff's First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 40-43, 46-49) dated June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2548	C	N/A	N/A	Evolus, Inc.'s Supplemental Objections and Responses to Staff's First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 44-45) dated May 31, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2549	C	N/A	N/A	Evolus's Objections and Responses to Complainant Medytox Inc.'s First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 1-28) dated April 3, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2550	C	N/A	N/A	Evolus's Objections and Responses to Complainant Medytox Inc.'s Second Set of Interrogatories to Respondent Evolus, Inc. (No. 29) dated May 13, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2551	C	N/A	N/A	Evolus's Objections and Responses to Complainant Medytox Inc.'s Third Set of Interrogatories to Respondent Evolus, Inc. (Nos. 30 - 32) dated June 10, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2552	C	N/A	N/A	Evolus's Objections and Responses to Complainants Allergan PLC's and Allergan, Inc.'s First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 1-29) dated July 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2553	C	N/A	N/A	Evolus's Second Supplemental Objections and Responses to Complainants' First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 1, 3-9, 13, 14, 16-21, 23-25, 27, 29-30) dated July 23, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2554	C	N/A	N/A	Evolus's Supplemental Objections and Responses to Allergan's First Set of Interrogatories (Nos. 8, 10, 25, 28) dated October 15, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2555	C	N/A	N/A	Evolus's Supplemental Objections and Responses to Complainant Medytox Inc.'s First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 8 - 18) dated May 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2556	C	N/A	N/A	Evolus's Supplemental Objections and Responses to Complainant Medytox Inc.'s First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 17, 18, 28) dated July 19, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2557	C	N/A	N/A	Evolus's Supplemental Objections and Responses to Complainants' First Set of Interrogatories to Respondent Evolus, Inc. (Nos. 9-12, 18-19) dated June 14, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2558	C	N/A	N/A	Allergan's Responses and Objections to Daewoong Pharmaceuticals Co., LTD.'s First Set of Requests for Admissions to Allergan (Nos. 1-99) dated July 15, 2019		Withdrawn
CX-2559	C	N/A	N/A	Allergan's Responses and Objections to Daewoong Pharmaceuticals Co., LTD.'s Second Set of Requests for Admissions to Allergan (Nos. 100-109) dated July 19, 2019	Order No. 37	Admitted
CX-2561	C	N/A	N/A	Complainant Allergan's First Supplemental Responses and Objections to Respondent Daewoong Pharmaceuticals, Co., LTD.'s First Set of Interrogatories to Allergan PLC and Allergan Inc. (Nos. 2, 7, 8, 24, 29, 38, 43, 47, 48, 55, 59-61, 64, 65, 68, 71, 72, 78, 85-88) dated May 31, 2019	Order No. 37	Admitted
CX-2562	C	N/A	N/A	Complainant Allergan's First Supplemental Responses and Objections to Staff's First Set of Interrogatories to Complainants Allergan PLC and Allergan, Inc. (Nos. 1, 4, 5, 6, 7, 11, 12, 27, 32, 43, 50, 53, 54, 56-58, 60, 61) dated May 31, 2019		Withdrawn
CX-2564	C	N/A	N/A	Complainant Allergan's Responses and Objections to Respondent Daewoong Pharmaceuticals, Co., LTD.'s Second Set of Interrogatories to Allergan PLC and Allergan Inc. (Nos. 91-95) dated June 7, 2019	Order No. 37	Admitted
CX-2565	C	N/A	N/A	Complainant Allergan's Responses and Objections to Respondent Daewoong Pharmaceuticals, Co., LTD.'s Third Set of Interrogatories to Allergan PLC and Allergan Inc. (Nos. 96-102) dated July 19, 2019	Order No. 37	Admitted
CX-2568	C	N/A	N/A	Complainant Allergan's Second Supplemental Responses and Objections to Respondent Daewoong Pharmaceuticals, Co., LTD.'s First Set of Interrogatories to Allergan PLC and Allergan Inc. (Nos. 8, 59, 64, 68, 71, 85-88) dated July 19, 2019	Order No. 37	Admitted
CX-2569	C	N/A	N/A	Complainant Allergan's Second Supplemental Responses and Objections to Staff's First Set of Interrogatories to Complainants Allergan PLC and Allergan, Inc. (Nos. 1, 4-7, 12-14, 47, 51, 53, 62 & 66-68) dated June 25, 2019	Order No. 37	Admitted
CX-2570	C	N/A	N/A	Complainant Allergan's Third Supplemental Responses and Objections to Respondent Daewoong Pharmaceuticals Co., LTD.'s First Set of Interrogatories to Allergan PLC and Allergan Inc. (Nos. 24, 29, 78 & 84) dated July 30, 2019	Order No. 37	Admitted
CX-2571	C	N/A	N/A	Complainant Allergan's Third Supplemental Responses and Objections to Staff's First Set of Interrogatories to Complainants Allergan PLC and Allergan, Inc. (Nos. 1, 4-7, 11-13, 50, 53-61) dated July 19, 2019	Order No. 37	Admitted
CX-2572	C	N/A	N/A	Complainant Medytox Inc.'s Disclosure Pursuant to Order 17	Brenda Wilson	Admitted
CX-2573	C	N/A	N/A	Complainant Medytox Inc.'s Responses and Objections to Respondent Daewoong's Pharmaceuticals Co. LTD.'s First Set of Interrogatories to Medytox, Inc. dated April 4, 2019		Withdrawn
CX-2574	C	N/A	N/A	Complainant Medytox Inc.'s Responses and Objections to Respondent Evolus, Inc.'s First Set of Interrogatories dated July 19, 2019	Order No. 37	Admitted
CX-2575	C	N/A	N/A	Complainant Medytox Inc.'s Responses and Objections to The Staff's First Set of Interrogatories dated April 8, 2019	Carla Mulhern	Admitted
CX-2578	C	N/A	N/A	Complainant Medytox Inc.'s Responses and Objections to Respondent Daewoong Pharmaceuticals Co., LTD.'s Third Set of Requests for Admissions to Medytox Inc. dated July 15, 2019		Withdrawn
CX-2579	C	N/A	N/A	Complainant Medytox, Inc.'s Supplemental Responses and Objections to Respondent Daewoong Pharmaceuticals Co., LTD.'s First Set of Interrogatories to Medytox, Inc. dated April 22, 2019	Order No. 37	Admitted
CX-2581		N/A	N/A	Revance Therapeutics, Inc. 10-K for FYE December 31, 2018	Andrew Pickett	Admitted
CX-2582	C	N/A	N/A	Exhibit 1 to Complaint Exhibit AA	Seong Hun Chang	Admitted
CX-2583		Medytox-ITC-00237527	Medytox-ITC-00237527	Part 2 of audio file of conversation between Chung Sei Kim and Hyung Ho Jung at Dubai conference	Hyun Ho Jung	Admitted
CX-2585		Medytox-ITC-00244551	Medytox-ITC-00244551	Part 1 of audio file of conversation between Chung Sei Kim and Hyun Ho Jung at Dubai conference	Hyun Ho Jung	Admitted
CX-2586		AGN-ITC-00011306	AGN-ITC-00011306	Photos re Evolus		Withdrawn
CX-2587		AGN-ITC-00011307	AGN-ITC-00011307	Video re Evolus		Withdrawn
CX-2588		AGN-ITC-00011308	AGN-ITC-00011308	Video re Evolus		Withdrawn
CX-2589		AGN-ITC-00133272	AGN-ITC-00133272	Mad Money - Evolus mp3 file, Cramer, CNBC		Withdrawn
CX-2590		N/A	N/A	Fiercely Fighting Company K1 (KBS1 television broadcast interview Mar. 25, 2010)	Hyun Ho Jung	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2591	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 4C	Paul Keim	Admitted
CX-2592	C	N/A	N/A	Expert Report of Dr. Paul Keim - Exhibit 15	Paul Keim	Admitted
CX-2593	C	N/A	N/A	Picture of Ochang I Entrance of Cell Bank	Seong Hun Chang	Admitted
CX-2594	C	N/A	N/A	Picture of Entrance of Ochang I Production Site	Seong Hun Chang	Admitted
CX-2595	C	N/A	N/A	Picture of Ochang I Cell bank Deep Freezer	Order No. 37; Seong Hun Chang	Admitted
CX-2596	C	AGN-ITC-00050731	AGN-ITC-00050731	Allergan Financial Projections for 2018-2029, dated June 12, 2019	James Malackowski; Colleen McKenna	Admitted
CX-2597	C	N/A	N/A	Corrections to Dr. Keim's Review of Dr. Sherman's Alternative Analysis		Withdrawn
CX-2598	C	DAEWOONG000620982	DAEWOONG000621182	Hoon Yoon Lab Notebook	James Malackowski	Admitted
CX-2599	C	N/A	N/A	The testimony of David Engelthaler in United States v. Barry J. Cadden	Paul Keim	Admitted
CX-2600	C	EVOLUS00256970	EVOLUS00256995	Rui Avelar Deposition Exhibit 4 - PrabotulinumtoxinA Clinical Overview	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2601	C	N/A	N/A	David Moatazedí Deposition Exhibit 20 - Evolus: Creating an Aesthetic Evolution, dated October 1, 2018	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2602	C	DAEWOONG000621193	DAEWOONG000621193	List of DWP450 Reports		Withdrawn
CX-2603	C	N/A	N/A	Witness Statement Errata of Dr. Paul Keim	Paul Keim	Admitted
CX-2604	C	N/A	N/A	Corrected Witness Statement Errata of James E. Malackowski	James Malackowski	Admitted
CX-2605	C	N/A	N/A	Deposition Errata of Dr. Andrew Pickett		Withdrawn
CX-2606	C	N/A	N/A	Witness Statement Errata of Dr. Hyun Ho Jung	Hyun Ho Jung	Admitted
CX-2607	C	N/A	N/A	Deposition Errata of Dr. Paul Keim		Withdrawn
CX-2608	C	N/A	N/A	Deposition Transcript of Dr. Paul Keim, November 19, 2019		Withdrawn
CX-2609	C	N/A	N/A	Deposition Transcript of Dr. Paul Keim, November 20, 2019		Withdrawn
CX-2610	C	N/A	N/A	Contingent Rebuttal Witness Statement of Dr. Seong Hun Chang	Seong Hun Chang	Admitted
CX-2611	C	N/A	N/A	Contingent Rebuttal Witness Statement of Hack Woo Kim	Hack Woo Kim	Admitted
CX-2612	C	N/A	N/A	Contingent Rebuttal Witness Statement of Dr. Hyun Ho Jung	Hyun Ho Jung	Admitted
CX-2613	C	N/A	N/A	Metadata of Medytox Email Exhibits		Withdrawn
CX-2614	C	N/A	N/A	Declaration of Metabiologics, Inc. dated July 2, 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2615	C	N/A	N/A	Metadata for Medytox-ITC-00132909		Withdrawn
CX-2616	C	N/A	N/A	Verification of Daewoong's Interrogatory Responses		Withdrawn
CX-2617	C	N/A	N/A	"Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year Revenue," Press Release, Global Newswire dated January 9, 2020	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2618	C	Medytox-ITC-00264714	Medytox-ITC-00264714	Medytox Lab Photo	Byung Kook Lee	Admitted
CX-2619	C	Medytox-ITC-00264715	Medytox-ITC-00264715	BK Lee Lab Photo	Byung Kook Lee	Admitted
CX-2620	C	Medytox-ITC-00264716	Medytox-ITC-00264716	Medytox Lab Photo	Byung Kook Lee	Admitted
CX-2621	C	Medytox-ITC-00264717	Medytox-ITC-00264717	Medytox Lab Photo	Byung Kook Lee	Admitted
CX-2622	C	Medytox-ITC-00264718	Medytox-ITC-00264718	Medytox Lab Photo		Withdrawn
CX-2623	C	Medytox-ITC-00264719	Medytox-ITC-00264719	BK Lee Lab Photo	Byung Kook Lee	Admitted
CX-2624	C	Medytox-ITC-00264720	Medytox-ITC-00264720	BK Lee Lab Photo	Byung Kook Lee	Admitted
CX-2625	C	Medytox-ITC-00159950	Medytox-ITC-00159951	Translation for RX-2322C	Seong Hun Chang	Admitted
CX-2626	C	Medytox-ITC-00167682	Medytox-ITC-00167683	Translation for RX-2183C	Hyun Ho Jung	Admitted
CX-2627	C	Medytox-ITC-00191195	Medytox-ITC-00191201	Translation for RX-2117C		Withdrawn
CX-2628	C	Medytox-ITC-00212677	Medytox-ITC-00212678	Translation for RX-2071C	Hack Woo Kim; Seong Hun Chang	Admitted
CX-2629	C	Medytox-ITC-00264721	Medytox-ITC-00264721	Strain vial photo		Withdrawn
CX-2630	C	Medytox-ITC-00264722	Medytox-ITC-00264722	Strain vial photo		Withdrawn
CX-2631	C	Medytox-ITC-00264723	Medytox-ITC-00264723	Strain vial photo		Withdrawn
CX-2632	C	Medytox-ITC-00264724	Medytox-ITC-00264724	Strain vial photo		Withdrawn
CX-2633	C	N/A	N/A	Corrected Witness Statement Errata of Ben Marzouk	Ben Marzouk	Admitted
CX-2634	C	N/A	N/A	Evolus Press Release re Phase III Study		Withdrawn
CX-2635	C	N/A	N/A	Efficacy and Safety of PrabotulinumtoxinA		Withdrawn
CX-2636	C	Medytox-ITC-00264725	Medytox-ITC-00264725	Strain vial photo		Withdrawn
CX-2637	C	Medytox-ITC-00264726	Medytox-ITC-00264726	Strain vial photo		Withdrawn
CX-2638	C	Medytox-ITC-00264727	Medytox-ITC-00264727	Strain vial photo		Withdrawn
CX-2639	C	Medytox-ITC-00264728	Medytox-ITC-00264728	Strain vial photo		Withdrawn
CX-2640	C	Medytox-ITC-00264729	Medytox-ITC-00264729	Strain vial photo		Withdrawn
CX-2641	C	ALPHAEN00000001	ALPHAEN000000023	Alphaeon Strategic Plan Presentation, dated August 2, 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2642	C	ALPHAEN000000028	ALPHAEN000000035	Evolus Financial Forecasts	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2643	C	ALPHAEN000000036	ALPHAEN000000058	Presentation re Evolus	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2644	C	ALPHAEN00000101	ALPHAEN0000133	Evolus Company Overview	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2645	C	ALPHAEN0000134	ALPHAEN0000140	Email from M. Simhambhatla, dated June 28, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2646	C	ALPHAEN0000141	ALPHAEN0000165	Alphaeon Presentation, dated June 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2647	C	ALPHAEN0000168	ALPHAEN0000194	DWP-450 Presentation, dated December 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2648	C	ALPHAEN0000195	ALPHAEN0000241	Alphaeon Company Overview, dated June 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2649	C	ALPHAEN0000284	ALPHAEN0000301	Evolus Commercial Analysis	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2650	C	ALPHAEN0000318	ALPHAEN0000371	Presentation, dated January 2017	Joint Stipulation (Dkt. No. 701591)	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
CX-2651	C	ALPHAEN000448	ALPHAEN000489	Alphaeon Company Overview, dated April 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2652	C	ALPHAEN000448	ALPHAEN000542	Presentation slides re Evolus	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2653	C	ALPHAEN000554	ALPHAEN000554	Email from C. Marmo to S. Cannizzaro, R. Avelar et al, dated December 10, 2015	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2654	C	ALPHAEN000602	ALPHAEN000616	Evolus Commercial Strategy and Commercial Analysis	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2655	C	ALPHAEN000617	ALPHAEN000630	Alphaeon presentation, dated June 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2656	C	ALPHAEN000631	ALPHAEN000633	Slides re DWP-450 pricing	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2657	C	ALPHAEN000686	ALPHAEN000704	US Toxin Market Overview, dated September 2016	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2658	C	ALPHAEN000722	ALPHAEN000756	Product Profile Presentation	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2660	C	ALPHAEN000868	ALPHAEN000903	Alphaeon Company Overview, dated June 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2661	C	ALPHAEN000904	ALPHAEN000911	Presentation slides for June 21 Discussion	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2662	C	ALPHAEN000926	ALPHAEN000971	Evolus Company Overview, dated June 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2663	C	ALPHAEN000972	ALPHAEN001013	Advisory Board Master Slide Deck, dated May 20, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2664	C	ALPHAEN001025	ALPHAEN001070	Advisory Board Master Slide Deck, dated May 20, 2017	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2665	C	N/A	N/A	Witness Statement Errata of Dr. Seong Hun Chang	Seong Hun Chang	Admitted
CX-2667	C	AGN-ITC-00133371	AGN-ITC-00133371	Guidepoint Tracker U.S. Neurotoxins spreadsheet	David Moatazedi	Admitted
CX-2668	C	DAEWOONG000285022	DAEWOONG000265036	Deposition Ex. 30 - Chung Sei Kim & Kyoung Yoon Kim: DWP450-REP-009: Intermediate Report on the Development of Manufacturing Process for DWP450	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2669	C	DAEWOONG000547472	DAEWOONG000547594	Deposition Ex. 45 - Han Woo Chun: Email from Yang Kyu Cho to Yoon Seok Jang, dated August 29, 2013 and attachments	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2670		N/A	N/A	Deposition Ex. 52 - Chung Sei Kim: Daewoong's U.S. Application No. 14654819 Patent File Wrapper	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2671		N/A	N/A	Deposition Ex. 74 - Chang Woo Suh: Chang Woo Suh Dissertation	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2672		N/A	N/A	Deposition Ex. 102 - Kyoung Yun Kim: Daewoong's U.S. Application No. 14654819 Patent File Wrapper	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2673	C	DAEWOONG000271727	DAEWOONG000271749	Deposition Ex. 105 - Kyoung Yun Kim: DWP450-REP-076: Optimization of the Purification Process for DWP450	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2674	C	DAEWOONG000618283	DAEWOONG000618301	Deposition Ex. 308 - Chung Sei Kim: Kyung Min Min Laboratory Notebook 2010-40 (Excerpt)	Joint Stipulation (Dkt. No. 701591)	Admitted
CX-2675	C	EVOLUS00325378	EVOLUS00325380	Deposition Ex. 355 - Chung Sei Kim: Email from Calvin Koerner (IQ Auditing) to Jin Ki Kim and Jeff Yuen, dated September 8, 2015.		Withdrawn
CX-2676	C	N/A	N/A	Malackowski Report - Appendix 1 CV	James Malackowski	Admitted
CX-2677	C	N/A	N/A	Medytox R&D Center Equipment		Withdrawn
CX-2678	C	BKL-ITC-00000623	BKL-ITC-00000627	Email from BK Lee to Yong Woo Cho, dated October 29, 2010, attaching curriculum vitae	Byung Kook Lee	Admitted
CX-2679	C	BKL-ITC-00000633	BKL-ITC-00000637	Email from BK Lee to Yeon Hui Yoon, dated December 3, 2010, attaching curriculum vitae	Byung Kook Lee	Admitted
CX-2680		N/A	N/A	Declaration of Byung Kook Lee, dated August 30, 2018		Withdrawn
CX-2681	C	N/A	N/A	Redline of August and October 2010 CV	Byung Kook Lee	Admitted
CX-2682	C	N/A	N/A	Email from BK Lee to GE, dated April 18, 2008	Byung Kook Lee	Admitted
CX-2683	C	N/A	N/A	Deposition Designation for Chang Woo Suh, June 27, 2019		Subject to Dkt. No. 702965
CX-2684	C	N/A	N/A	Deposition Designation for Chang Woo Suh, June 28, 2019		Subject to Dkt. No. 702965
CX-2685	C	N/A	N/A	Deposition Designation for Chung Sei Kim, July 11, 2019		Subject to Dkt. No. 702965
CX-2686	C	N/A	N/A	Deposition Designation for Chung Sei Kim, June 25, 2019		Subject to Dkt. No. 702965
CX-2687	C	N/A	N/A	Deposition Designation for Kyoung-Yoon Kim, June 20, 2019		Subject to Dkt. No. 702965
CX-2688	C	N/A	N/A	Deposition Designation for Kyoung-Yoon Kim, June 29, 2019		Subject to Dkt. No. 702965
JX-0001	C	Medytox-ITC-00000911	Medytox-ITC-00000912	Email from Areta Kupchyk to Ben Griffiths dated April 24, 2019	Joint Stipulation (Dkt. No. 701591); Hyun Ho Jung; David Sherman	Admitted
JX-0002	C	Medytox-ITC-00000915	Medytox-ITC-00000916	Letter from Ben Griffiths to Areta Kupchyk, Re: Clostridium botulinum Hall A-hyper strain dated May 2019	Joint Stipulation (Dkt. No. 701591)	Admitted
JX-0003	C	Medytox-ITC-00013048	Medytox-ITC-00013095	The Conditional Permit Application Form of Medicines Manufactured dated November 2001	Hyun Ho Jung	Admitted
JX-0004	C	Medytox-ITC-00131975	Medytox-ITC-00131976	Kyu-Hwan Yang Transfer of Strain and Research Agreement (2017)	Joint Stipulation (Dkt. No. 701591); Hyun Ho Jung; Kyu Hwan Yang	Admitted
JX-0005	C	Medytox-ITC-00132001	Medytox-ITC-00132003	Kyu-Hwan Yang Stock Option Agreement (2004)	Hyun Ho Jung	Admitted
JX-0006	C	DAEWOONG000005075	DAEWOONG000005104	DWP-450 CTD Section 3.2.S.2.2. Description of Manufacturing Process and Process Controls	Chung Sei Kim; Brenda Wilson	Admitted
JX-0007	C	DAEWOONG000005184	DAEWOONG000005259	DWP-450 CTD Section 3.2.S.2.6. Manufacturing Process Development (77 pages)	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
JX-0008	C	DAEWOONG000153260	DAEWOONG000153316	License & Supply Agreement by and between Daewoong Pharmaceutical Co., Ltd. And Evolus Inc. dated as of September 30, 2013	Joint Stipulation (Dkt. No. 701591); James Malackowski	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
JX-0009	C	DAEWOONG000153326	DAEWOONG000153328	Byung Kook Lee Technical Guidance (Consultation) Agreement dated March 1, 2010	Joint Stipulation (Dkt. No. 701591); Byung Kook Lee	Admitted
JX-0010	C	DAEWOONG000153329	DAEWOONG000153329	Record of Payments to Byung Kook Lee from Daewoong	Joint Stipulation (Dkt. No. 701591); Byung Kook Lee; Chang Woo Suh	Admitted
JX-0011	C	DAEWOONG000157017	DAEWOONG000157082	DWP450-REP-002: Clostridium Botulinum Isolation and Identification	Joint Stipulation (Dkt. No. 701591); Andrew Pickett	Admitted
JX-0012	C	DAEWOONG000259978	DAEWOONG000259992	DWP450-REP-033: DWP450 Production Process Development Final Report	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Brenda Wilson; Chung Sei Kim	Admitted
JX-0013	C	DAEWOONG000259993	DAEWOONG000260011	DWP450-REP-080 : Development and Optimization of the Fermentation Process for DWP450	Andrew Pickett; Chung Sei Kim	Admitted
JX-0014	C	DAEWOONG000265037	DAEWOONG000265051	DWP450-REP-099E: Intermediate Report on the Development of Manufacturing Process for DWP450	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Brenda Wilson; Chung Sei Kim	Admitted
JX-0015	C	DAEWOONG000265798	DAEWOONG000265816	DWP450-REP-080E: Development and Optimization of the Fermentation Process for DWP450	Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted
JX-0016	C	DAEWOONG000294638	DAEWOONG000294646	DWP450-REP-066E: Development of the Purification Process for DWP450	Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted
JX-0017	C	DAEWOONG000524086	DAEWOONG000524103	Culture Records for DWP450 DS-001-006	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim; Bal Ram Singh	Admitted
JX-0018	C	DAEWOONG000524250	DAEWOONG000524265	Culture Records for DWP450 DS-011-015	Andrew Pickett; Chung Sei Kim; B. Singh	Admitted
JX-0019	C	DAEWOONG000524325	DAEWOONG000524372	Manufacturing Instruction and Record dated Dec. 22, 2011		Withdrawn
JX-0020	C	DAEWOONG000617013	DAEWOONG000617017	CV for Chang Woo Suh		Withdrawn
JX-0021	C	DAEWOONG000617113	DAEWOONG000617148	Production Order and Record for 450DS-009	Andrew Pickett	Admitted
JX-0022	C	DAEWOONG000617149	DAEWOONG000617184	Production Order and Record for 450DS-010	Andrew Pickett	Admitted
JX-0023	C	DAEWOONG000617188	DAEWOONG000617202	Culture Record (DWP450) for 450DS-002, 450DS-007, 450DS-008, 450DS-009, and 450DS-010	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim; Bal Ram Singh	Admitted
JX-0024	C	DAEWOONG000617222	DAEWOONG000617277	DWP450-REP-171 (Addendum): Botulinum Identification and Characterization Analysis Report," Report	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chang Woo Suh; Andrew Pickett	Admitted
JX-0025	C	DAEWOONG000617278	DAEWOONG000617284	DWP450-REP-171: General Report: Report of Identification and Characterization of Botulinum	Andrew Pickett	Admitted
JX-0026	C	DAEWOONG000617829	DAEWOONG000617869	Chung Sei Kim Lab Notebook (No. 2010-59)	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim	Admitted
JX-0027	C	DAEWOONG000617870	DAEWOONG000618070	Kwan Young Song Lab Notebook (No. 2010-67)	Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted
JX-0028	C	DAEWOONG000618071	DAEWOONG000618271	Yeon Tae Jung Lab Notebook (No. 2009-84)	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim	Admitted
JX-0029	C	DAEWOONG000618272	DAEWOONG000618472	Kyung Min Min, Lab Notebook (No. 2010-40)	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim; David Sherman; Brenda Wilson; Kyoung Yun Kim	Admitted
JX-0030	C	DAEWOONG000620281	DAEWOONG000620302	DWP450-REP-076: Optimization of the Purification Process for DWP450	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim	Admitted
JX-0031	C	DAEWOONG000623544	DAEWOONG000623557	DWP450-REP-009: Intermediate Report on the Development of Manufacturing Process for DWP450	Joint Stipulation (Dkt. No. 701591); Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
JX-0032	C	DAEWOONG000623880	DAEWOONG000623883	CV for Chung Sei Kim		Withdrawn
JX-0033		AGN-ITC-000000001	AGN-ITC-000000254	Allergan plc 10-K for FYE December 31, 2015	Order No. 37	Admitted
JX-0034		AGN-ITC-000002255	AGN-ITC-000002722	Allergan plc 10-K-A for FYE December 31, 2015		Withdrawn
JX-0035		AGN-ITC-000002273	AGN-ITC-00000516	Allergan plc 10-K for FYE December 31, 2016	James Malackowski	Admitted
JX-0036		AGN-ITC-00000517	AGN-ITC-00000797	Allergan plc 10-K for FYE December 31, 2017	James Malackowski	Admitted
JX-0037		AGN-ITC-00000798	AGN-ITC-00001011	Allergan plc 10-K for FYE December 31, 2018	James Malackowski	Admitted
JX-0038		AGN-ITC-00001012	AGN-ITC-00001339	Allergan plc 10-Q for quarterly period end June 30, 2015		Withdrawn
JX-0039		AGN-ITC-00001340	AGN-ITC-00001462	Allergan plc 10-Q for quarterly period end September 30, 2015		Withdrawn
JX-0040		AGN-ITC-00001463	AGN-ITC-00001564	Allergan plc 10-Q for quarterly period end March 31, 2016		Withdrawn
JX-0041		AGN-ITC-00001565	AGN-ITC-00001755	Allergan plc 10-Q for quarterly period end June 30, 2016		Withdrawn
JX-0042		AGN-ITC-00001756	AGN-ITC-00001925	Allergan plc 10-Q for quarterly period end September 30, 2016		Withdrawn
JX-0043		AGN-ITC-00001926	AGN-ITC-00002032	Allergan plc 10-Q for quarterly period end March 31, 2017		Withdrawn
JX-0044		AGN-ITC-00002033	AGN-ITC-00002173	Allergan plc 10-Q for quarterly period end June 30, 2017		Withdrawn
JX-0045		AGN-ITC-00002174	AGN-ITC-00002305	Allergan plc 10-Q for quarterly period end September 30, 2017		Withdrawn
JX-0046		AGN-ITC-00002306	AGN-ITC-00002406	Allergan plc 10-Q for quarterly period end March 31, 2018		Withdrawn
JX-0047		AGN-ITC-00002407	AGN-ITC-00002417	Allergan plc 10-Q for quarterly period end March 31, 2018 - Amendment No. 1		Withdrawn
JX-0048		AGN-ITC-00002418	AGN-ITC-00002525	Allergan plc 10-Q for quarterly period end June 30, 2018		Withdrawn
JX-0049		AGN-ITC-00002526	AGN-ITC-00002629	Allergan plc 10-Q for quarterly period end September 30, 2018		Withdrawn
JX-0050	C	AGN-ITC-00002639	AGN-ITC-00002740	Allergan-Medytox License Agreement dated September 25, 2013	Joint Stipulation (Dkt. No. 701591); James Malackowski; Sesha Neervannan	Admitted
JX-0051	C	AGN-ITC-00002741	AGN-ITC-00002782	Allergan-Medytox Supply Agreement, dated May 2, 2014	Sesha Neervannan	Admitted
JX-0052		AGN-ITC-00005247	AGN-ITC-00005264	Allergan Inc. 10-K for FYE 12/31/1993		Withdrawn
JX-0053		AGN-ITC-00005265	AGN-ITC-00005279	Allergan 10-K for FYE December 31, 1994		Withdrawn
JX-0054		AGN-ITC-00005280	AGN-ITC-00005295	Allergan 10-K for FYE December 31, 1995		Withdrawn
JX-0055		AGN-ITC-00005296	AGN-ITC-00005313	Allergan 10-K for FYE December 31, 1996		Withdrawn
JX-0056		AGN-ITC-00005314	AGN-ITC-00005331	Allergan 10-K for FYE December 31, 1997		Withdrawn
JX-0057		AGN-ITC-00005332	AGN-ITC-00005351	Allergan 10-K for FYE December 31, 1998		Withdrawn
JX-0058		AGN-ITC-00005372	AGN-ITC-00005390	Allergan 10-K for FYE December 31, 2000		Withdrawn
JX-0059		AGN-ITC-00005391	AGN-ITC-00005477	Allergan 10-K for FYE December 31, 2001		Withdrawn
JX-0060		AGN-ITC-00005478	AGN-ITC-00005578	Allergan Inc. 10-K for FYE December 31, 2002		Withdrawn
JX-0061		AGN-ITC-00005579	AGN-ITC-00005688	Allergan Inc. 10-K for FYE December 31, 2003		Withdrawn
JX-0062		AGN-ITC-00005689	AGN-ITC-00005807	Allergan Inc. 10-K for FYE December 31, 2004		Withdrawn
JX-0063		AGN-ITC-00005808	AGN-ITC-00005937	Allergan Inc. 10-K for FYE December 31, 2005		Withdrawn
JX-0064		AGN-ITC-00005938	AGN-ITC-00006086	Allergan Inc. 10-K for FYE December 31, 2006		Withdrawn
JX-0065		AGN-ITC-00006087	AGN-ITC-00006243	Allergan Inc. 10-K for FYE December 31, 2007		Withdrawn
JX-0066		AGN-ITC-00006244	AGN-ITC-00006406	Allergan Inc. 10-K for FYE December 31, 2008		Withdrawn
JX-0067		AGN-ITC-00006407	AGN-ITC-00006566	Allergan Inc. 10-K for FYE December 31, 2009		Withdrawn
JX-0068		AGN-ITC-00006567	AGN-ITC-00006732	Allergan Inc. 10-K for FYE December 31, 2010		Withdrawn
JX-0069		AGN-ITC-00006733	AGN-ITC-00006867	Allergan Inc. 10-K for FYE December 31, 2011		Withdrawn
JX-0070		AGN-ITC-00006868	AGN-ITC-00006997	Allergan Inc. 10-K for FYE December 31, 2012		Withdrawn
JX-0071		AGN-ITC-00006998	AGN-ITC-00007130	Allergan Inc. 10-K for FYE December 31, 2013		Withdrawn
JX-0072		AGN-ITC-00007131	AGN-ITC-00007311	Allergan Inc. 10-K for FYE December 31, 2014	James Malackowski	Admitted
JX-0073		AGN-ITC-00011314	AGN-ITC-00011585	Allergan Plc 10-Q for quarterly period end March 31, 2019		Withdrawn
JX-0074	C	AGN-ITC-00097185	AGN-ITC-00097206	MT10109 DS CTD Section 3.2.S.2.2		Withdrawn
JX-0075	C	EVOLUS00000001	EVOLUS00000057	License & Supply Agreement between Daewoong and Evolus	Joint Stipulation (Dkt. No. 701591); Christopher Marmo; James Malackowski	Admitted
JX-0076	C	EVOLUS00000058	EVOLUS00000059	First Amendment to License and Supply Agreement between Daewoong and Evolus		Withdrawn
JX-0077	C	EVOLUS00000060	EVOLUS00000062	Second Amendment to License and Supply Agreement between Daewoong and Evolus		Withdrawn
JX-0078	C	EVOLUS00042427	EVOLUS00042498	DWP-450 CTD Section 3.2.S.2.4. Controls of Critical Steps and Intermediates		Withdrawn
JX-0079	C	EVOLUS00042499	EVOLUS00042529	DWP-450 CTD Section 3.2.S.2.5. Process Validation and/or Evaluation		Withdrawn
JX-0080	C	EVOLUS00042622	EVOLUS00042654	DWP-450 CTD Section 3.2.S.2.2. Description of Manufacturing Process and Process Controls		Withdrawn
JX-0081	C	EVOLUS00046357	EVOLUS00046362	Response to December 21, 2018 FDA		Withdrawn
JX-0082	C	EVOLUS00046369	EVOLUS00046369	Response to January 22, 2019 FDA		Withdrawn
JX-0083	C	EVOLUS00046370	EVOLUS00046436	Response to September 12, 2017 FDA		Withdrawn
JX-0084	C	EVOLUS00046439	EVOLUS00046439	Response to October 23, 2018 FDA		Withdrawn
JX-0085	C	EVOLUS00046440	EVOLUS00046440	Response to August 29, 2018 FDA		Withdrawn
JX-0086	C	EVOLUS00046442	EVOLUS00046444	Response to January 4, 2018 FDA		Withdrawn
JX-0087	C	EVOLUS00046445	EVOLUS00046446	Response to January 18, 2019 FDA		Withdrawn
JX-0088	C	EVOLUS00046447	EVOLUS00046449	Response to September 22, 2017 FDA		Withdrawn
JX-0089	C	EVOLUS00046450	EVOLUS00046478	Response to August 29, 2017 FDA		Withdrawn
JX-0090	C	EVOLUS00046479	EVOLUS00046487	Response to November 28, 2017 FDA		Withdrawn
JX-0091	C	EVOLUS00046488	EVOLUS00046491	Response to September 27, 2017 FDA		Withdrawn
JX-0092	C	EVOLUS00046496	EVOLUS00046500	Response to October 16, 2018 FDA		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
JX-0093	C	EVOLUS00046501	EVOLUS00046520	List of BLA Information Updates		Withdrawn
JX-0094	C	EVOLUS00046636	EVOLUS00046639	Changes Being Effected Submission		Withdrawn
JX-0095	C	EVOLUS00046640	EVOLUS00046642	Response to January 9, 2019 FDA		Withdrawn
JX-0096	C	EVOLUS00046643	EVOLUS00046661	Response to November 2, 2017, December 7, 2017, December 20, 2017, January 4, 2018, February 9, 2018, and February 21, 2018 FDA		Withdrawn
JX-0097	C	EVOLUS00046662	EVOLUS00046733	Response to December 7, 2017 FDA		Withdrawn
JX-0098	C	EVOLUS00046734	EVOLUS00046739	Response to August 29, 2018 FDA		Withdrawn
JX-0099	C	EVOLUS00046741	EVOLUS00046753	Response to November 2, 2017 and December 7, 2017 FDA		Withdrawn
JX-0100	C	EVOLUS00046755	EVOLUS00046777	Quality Information Amendment		Withdrawn
JX-0101	C	EVOLUS00046778	EVOLUS00046834	Response to March 2, 2018 FDA		Withdrawn
JX-0102	C	EVOLUS00046835	EVOLUS00046853	Response to October 19, 2017 FDA		Withdrawn
JX-0103	C	EVOLUS00046854	EVOLUS00046884	Response to December 7, 2017, December 20, 2017, February 9, 2018, and February 21, 2018 FDA		Withdrawn
JX-0104	C	EVOLUS00046893	EVOLUS00046896	Response to August 29, 2018, October 16, 2018, December 17, 2018, December 18, 2018, and January 11, 2019 FDA		Withdrawn
JX-0105	C	EVOLUS00046921	EVOLUS00046928	Response to November 28, 2017, December 7, 2017, and December 20, 2017		Withdrawn
JX-0106	C	EVOLUS00046929	EVOLUS00046931	Response to August 29, 2018 FDA		Withdrawn
JX-0107	C	EVOLUS00046932	EVOLUS00046951	Response to February 13, 2018 FDA		Withdrawn
JX-0108	C	EVOLUS00046952	EVOLUS00046955	Response to August 29, 2018, October 16, 2018, and October 23, 2018 FDA		Withdrawn
JX-0109	C	EVOLUS00046956	EVOLUS00046969	Response to December 17, 2018 FDA		Withdrawn
JX-0110	C	EVOLUS00046970	EVOLUS00046989	Response to November 2, 2017 FDA	Christopher Marmo	Admitted
JX-0111	C	EVOLUS00046990	EVOLUS00047089	Response to February 21, 2018 FDA		Withdrawn
JX-0112	C	EVOLUS00047161	EVOLUS00047167	Response to November 13, 2017 FDA		Withdrawn
JX-0113	C	EVOLUS00095622	EVOLUS00095625	November 2, 2017 FDA	Christopher Marmo	Admitted
JX-0114	C	EVOLUS00100601	EVOLUS00100603	December 20, 2017 FDA	Christopher Marmo	Admitted
JX-0115		N/A	N/A	A. F. Fourcroy, Sur l'existence de la matière albumineuse dans les végétaux, 3 Annales de chimie 252 (1789)		Withdrawn
JX-0116		N/A	N/A	Adolph Abrams et al., The Purification of Toxin from Clostridium Botulinum Type A, Labs. of the Tech Dep't, Camp Detrick, Frederick, Md. 63-79 (1946)	Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted
JX-0117		N/A	N/A	Allergan Patent US 7,354,740	Joint Stipulation (Dkt. No. 701591); Brenda Wilson	Admitted
JX-0118		N/A	N/A	Bibhuti R. DasGupta & Venugopal Sathyamoorthy, Purification and Amino Acid Composition of Type A Botulinum Neurotoxin, 22 Toxicon 415-24 (1984)	Brenda Wilson	Admitted
JX-0119		N/A	N/A	Carl J. Malizio et al., Purification of Clostridium botulinum Type A Neurotoxin, Bacterial Toxins Methods and Protocols 27-39 (Otto Holst ed., 2000)	Chung Sei Kim; Brenda Wilson	Admitted
JX-0120		N/A	N/A	Chun K. Tse et al., Preparation and Characterisation of Homogenous Neurotoxin Type A from Clostridium botulinum, Its inhibitory action on neuronal release of acetylcholine in the absence and presence of B-bungarotoxin, 122 European J. of Biochemistry, 493-500 (1982).	Chung Sei Kim; Brenda Wilson	Admitted
JX-0121		N/A	N/A	Dario De Medici et al., Multiplex PCR for Detection of Botulinum Neurotoxin-Producing Clostridia in Clinical, Food, and Environmental Samples, 75 Applied and Env'tl. Microbiology 6457 (2009)		Withdrawn
JX-0123		N/A	N/A	E.A. Szabo et al., Polymerase chain reaction for detection of Clostridium botulinum types A, B and E in food, soil and infant feces, 76 J. of Applied Bacteriology 539 (1994)		Withdrawn
JX-0124		N/A	N/A	Edward Schantz & Eric Johnson, Properties and use of botulinum toxin and other microbial neurotoxins in medicine, 56 Microbiological Reviews, 80-99 (1992)	Andrew Pickett; Paul Keim	Admitted
JX-0125		N/A	N/A	Flora Chen et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species, 66 Infection & Immunity 2420-2425 (1998)	Andrew Pickett	Admitted
JX-0126		N/A	N/A	James T. Duff et al., Studies On Immunity to Toxins of Clostridium Botulinum I. A Simplified Procedure for isolation of Type A Toxin, 73 J. Bacteriology 42-47 (1957)	Andrew Pickett; Chung Sei Kim; Brenda Wilson	Admitted
JX-0127		N/A	N/A	James T. Duff et al., Studies On Immunity to Toxins of Clostridium Botulinum II. Production and Purification of Type B Toxin for Toxoid, 73 J. Bacteriology 597-601 (1957)	Andrew Pickett	Admitted
JX-0128		N/A	N/A	Lynn Siegel & Joseph Metzger, Effect of Fermentation Clostridium on Toxin Production by Clostridium botulinum Type B, 40 Applied and Env'tl Microbiology, 1023-1026 (1980)	Chung Sei Kim; Brenda Wilson	Admitted
JX-0129		N/A	N/A	Lynn Siegel & Joseph Metzger, Toxin production by Clostridium botulinum type A under various fermentation conditions, 38 Applied and Env'tl Microbiology, 606-611 (1979)	Chung Sei Kim; Brenda Wilson	Admitted
JX-0130		N/A	N/A	Marite Bradshaw et al., Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916, 10 Anaerobe 321-33 (2004)		Withdrawn
JX-0131		N/A	N/A	Mark A. Schoenbaum et al., An outbreak of type C botulism in 12 horses and a mule, 217 [J]AMA 365 (2000)		Withdrawn
JX-0132		N/A	N/A	Mengfei Ho et al., Recombinant botulinum neurotoxin A heavy chainbased delivery vehicles for neuron cell targeting, 24 Protein Engineering, Design & Selection 247 (2010)		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
JX-0133		N/A	N/A	Na-Ri Shin et al., Development of Enrichment Semi-nested PCR for Clostridium botulinum types A, B, E, and F and Its Application to Korean Environmental Samples, 24 Molecules and Cells 329 (2007)		Withdrawn
JX-0134		N/A	N/A	P. F. Bonventre & L. L. Kempe, Physiology of Toxin Production by Clostridium botulinum Types A and B, 7 Physiology of Toxin of C. Botulinum III, 374-77 (1959)	Andrew Pickett	Admitted
JX-0135		N/A	N/A	P. F. Bonventre & L. L. Kempe, Physiology of Toxin Production by Clostridium botulinum Types A and B, 7 Physiology of Toxin of C. Botulinum II, 372-74 (1959)	Andrew Pickett	Admitted
JX-0136		N/A	N/A	P.F. Bonventre et al., Physiology of toxin production by Clostridium botulinum types A and B. I. Growth, autolysis, and toxin production, J. Bacteriol 18-23 (1960).		Withdrawn
JX-0137		N/A	N/A	Sang On Lee et al., Lysis Induction for Botulinum Neurotoxin of Clostridium botulinum, The Korean Society for Biotechnology and Bioengineering 380-383 (Oct. 2004), http://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE02286466		Withdrawn
JX-0138		N/A	N/A	Sang-On Lee et al., Effects of various culture conditions on cell mass in liquid culture of Clostridium botulinum, The Korean Society for Biotechnology and Bioengineering, 186-189 (2004), http://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE02313793		Withdrawn
JX-0139	C	N/A	N/A	Stipulation of Material Facts Relating to Importation and Inventory		Withdrawn
SX-0001	C	N/A	N/A	Sherman deposition exhibit 9: Dr. Sherman's lab notebook for work on Medytox strains	David Sherman	Admitted
SX-0002		N/A	N/A	Sherman deposition exhibit 10: press release from Pacific Biosciences of California, Inc.		Withdrawn
SX-0003		N/A	N/A	Sherman deposition exhibit 12: list of files produced by Medytox in May 2019, including sequencing data		Withdrawn
SX-0004		N/A	N/A	Sherman deposition exhibit 14: Dr. Sherman's lab notebook for work on Daewoong strains		Withdrawn
SX-0005		N/A	N/A	Sherman deposition exhibit 16: Eyre DW, Golubchik T, et al, "A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance." BMJ Open. 2012 Jun 6;2(3). pii: e001124.		Withdrawn
SX-0006		N/A	N/A	Sherman deposition exhibit 17: Dan Q, Newmister SA, et al, "Fungal indole alkaloid biogenesis through evolution of a bifunctional reductase/Diels-Alderase." Nat Chem. 2019 Nov;11(11):972-980.		Withdrawn
SX-0007		N/A	N/A	Sherman deposition exhibit 18: Schofield MM, Jain S, et al, "Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743." Environ Microbiol. 2015 Oct;17(10):3964-75.		Withdrawn
SX-0008		N/A	N/A	Sherman deposition exhibit 19: Vargas-Asensio G, Pinto-Tomas A, et al, "Uncovering the cultivable microbial diversity of costa rican beetles and its ability to break down plant cell wall components." PLoS One. 2014 Nov 20;9(11):e113303.		Withdrawn
SX-0009		N/A	N/A	Sherman deposition exhibit 20: Coates RC, Podell S, et al, "Characterization of cyanobacterial hydrocarbon composition and distribution of biosynthetic pathways." PLoS One. 2014 Jan 27;9(1):e85140.		Withdrawn
SX-0010		N/A	N/A	Sherman deposition exhibit 21: Sharp K, Arthur KE, et al, "Phylogenetic and chemical diversity of three chemotypes of bloom-forming lyngbya species (Cyanobacteria: Oscillatoriales) from reefs of southeastern Florida." Appl Environ Microbiol. 2009 May;75(9):2879-88.		Withdrawn
SX-0011		N/A	N/A	Sherman deposition exhibit 22: Magarvey NA, Keller JM, et al, "Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites." Appl Environ Microbiol. 2004 Dec;70(12):7520-9.		Withdrawn
SX-0012		N/A	N/A	Keim deposition exhibit 7: Figure 6 to Keim report (enlarged)		Withdrawn
SX-0013		N/A	N/A	Keim deposition exhibit 10: NCBI BioSample links (31 items) print out		Withdrawn
SX-0014		N/A	N/A	Keim deposition exhibit 19: Exhibit C to Dr. Keim's Review of Dr. Sherman's Alternative Analysis		Withdrawn
SX-0015		N/A	N/A	Keim deposition exhibit 31: Pearson T, Okinaka RT, et al, "Phylogenetic understanding of clonal populations in an era of whole genome sequencing." Infect Genet Evol. 2009 Sep;9(5):1010-9. Epub 2009 May 27.		Withdrawn
SX-0016		N/A	N/A	Macdonald TE, Helma CH, et al, "Analysis of Clostridium botulinum Serotype E Strains by Using Multilocus Sequence Typing, Amplified Fragment Length Polymorphism, Variable-Number Tandem-Repeat Analysis, and Botulinum Neurotoxin Gene Sequencing." Appl Environ Microbiol. 2011 Dec;77(24):8625-34.		Withdrawn
SX-0017		N/A	N/A	Current Topics in Microbiology and Immunology, Vol. 364. Botulinum Neurotoxins. 2013 (Rummel A, Binz T (eds.))		Withdrawn
SX-0018		N/A	N/A	Carter AT, Peck MW. "Genomes, neurotoxins and biology of Clostridium botulinum Group I and Group II." Res Microbiol. 2015 May;166(4):303-17.		Withdrawn
SX-0019		N/A	N/A	Weedmark KA, Mabon P, et al, "Clostridium botulinum Group II Isolate Phylogenomic Profiling Using Whole-Genome Sequence Data." Appl Environ Microbiol. 2015 Sep 1;81(17):5938-48.		Withdrawn
SX-0020		N/A	N/A	Bhardwaj T, Sombanshi P. "Pan-genome analysis of Clostridium botulinum reveals unique targets for drug development." Gene. 2017 Aug 5;623:48-62.		Withdrawn
SX-0021		N/A	N/A	Wentz TG, Yao K, et al, "Closed Genome Sequence of Clostridium botulinum Strain CFSAN064329 (62A)." Genome Announc. 2018 Jun 28;6(26).		Withdrawn
SX-0022		N/A	N/A	Giordani F, Fillo S, et al, "Genomic characterization of Italian Clostridium botulinum group I strains." Infect Genet Evol. 2015 Dec;36:62-71.		Withdrawn
SX-0023		N/A	N/A	Raphael BH, Shirey TB, et al, "Distinguishing highly-related outbreak-associated Clostridium botulinum type A(B) strains." BMC Microbiol. 2014 Jul 16;14:192.		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
SX-0024		N/A	N/A	Olsen JS, Scholz H, et al, "Analysis of the genetic distribution among members of Clostridium botulinum group I using a novel multilocus sequence typing (MLST) assay." J Microbiol Methods. 2014 Jan;96:84-91.		Withdrawn
SX-0025		N/A	N/A	Williamson C, Vazquez AJ, et al, "Differentiating Botulinum Neurotoxin-Producing Clostridia with a Simple, Multiplex PCR Assay." Appl Environ Microbiol. 2017 Aug 31;83(18).		Withdrawn
SX-0026		N/A	N/A	Ng V, Lin WJ. "Comparison of assembled Clostridium botulinum A1 genomes revealed their evolutionary relationship." Genomics. 2014 Jan;103(1):94-106.		Withdrawn
SX-0027		N/A	N/A	Peck MW, Stringer SC, et al, "Clostridium botulinum in the post-genomic era." Food Microbiol. 2011 Apr;28(2):183-91.		Withdrawn
SX-0028		N/A	N/A	Janganan TK, Mullin N, et al, "Characterization of the spore surface and exosporium proteins of Clostridium sporogenes; implications for Clostridium botulinum group I strains." Food Microbiol. 2016 Oct;59:205-12.		Withdrawn
SX-0029		N/A	N/A	Kenri T, Sekizuka T, et al, "Genetic Characterization and Comparison of Clostridium botulinum Isolates from Botulism Cases in Japan between 2006 and 2011." Appl Environ Microbiol. 2014 Nov;80(22):6954-64.		Withdrawn
SX-0030		N/A	N/A	Ihekwa A, Mura I, et al, "An Integrative Approach to Computational Modelling of the Gene Regulatory Network Controlling Clostridium botulinum Type A1 Toxin Production." PLoS Comput Biol. 2016 Nov 17;12(11):e1005205.		Withdrawn
SX-0031		N/A	N/A	Fillo S, Giordani, F, et al, "Clostridium botulinum group I strain genotyping by 15-locus multilocus variable-number tandem-repeat analysis." J Clin Microbiol. 2011 Dec;49(12):4252-63.		Withdrawn
SX-0032		N/A	N/A	Gonzalez-Escalona N, Haendiges J, et al, "Closed Genome Sequences of Two Clostridium botulinum Strains Obtained by Nanopore Sequencing." Microbiol Resour Announc. 2018 Sep 6;7(9).		Withdrawn
SX-0033		N/A	N/A	Artin I, Mason DR, et al, "Effects of carbon dioxide on growth of proteolytic Clostridium botulinum, its ability to produce neurotoxin, and its transcriptome." Appl Environ Microbiol. 2010 Feb;76(4):1168-72.		Withdrawn
SX-0034		N/A	N/A	Sakuma T, Kurosaki Y, et al, "Rapid and simple detection of Clostridium botulinum types A and B by loop-mediated isothermal amplification." J Appl Microbiol. 2009 Apr;106(4):1252-9.		Withdrawn
SX-0035		N/A	N/A	Zhang L, Lin WJ, et al, "Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain." Gene. 2003 Oct 2;315:21-32.		Withdrawn
SX-0036		N/A	N/A	Peck MW. "Biology and genomic analysis of Clostridium botulinum." Adv Microb Physiol. 2009;55:183-265, 320.		Withdrawn
SX-0037		N/A	N/A	Christensen KA, Brunelli JP, et al, "Identification of single nucleotide polymorphisms from the transcriptome of an organism with a whole genome duplication." BMC Bioinformatics. 2013 Nov 16;14:325.		Withdrawn
SX-0038		N/A	N/A	Addo-Quaye C, Tuinstra M, et al, "Whole-Genome Sequence Accuracy Is Improved by Replication in a Population of Mutagenized Sorghum." G3 (Bethesda). 2018 Mar 2;8(3):1079-1094.		Withdrawn
SX-0039		N/A	N/A	Schurch AC, Arrendondo-Alonso S, et al, "Whole genome sequencing options for bacterial strain typing and epidemiologic analysis based on single nucleotide polymorphism versus gene-by-gene-based approaches." Clin Microbiol Infect. 2018 Apr;24(4):350-354.		Withdrawn
SX-0040		N/A	N/A	Shin NR, Yoon SY, et al, "Development of enrichment semi-nested PCR for Clostridium botulinum types A, B, E, and F and its application to Korean environmental samples." Mol Cells. 2007 Dec 31;24(3):329-37.		Withdrawn
SX-0041		N/A	N/A	Hill KK, Smith TJ, et al, "Genetic diversity among Botulinum Neurotoxin-producing clostridial strains." J Bacteriol. 2007 Feb;189(3):818-32.		Withdrawn
SX-0042		N/A	N/A	Botulinum Toxin for Asians, Seo KK (ed.) 2017.		Withdrawn
SX-0043		N/A	N/A	Stringer SC, Webb MD, et al, "Lag time variability in individual spores of Clostridium botulinum." Food Microbiol 28 (2), 228-35. Apr 2011.		Withdrawn
SX-0044		N/A	N/A	Methods in Molecular Biology, Vol. 1712. Next Generation Sequencing, Methods and Protocols. 2018 (Head SR, Ordoukhanian P, Salomon DR (eds.)).		Withdrawn
SX-0045		N/A	N/A	Methods in Molecular Biology, Vol. 145. Bacterial Toxins, Methods and Protocols. 2000 (Holst O (ed.)).		Withdrawn
SX-0046		N/A	N/A	Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Centers for Disease Control and Prevention (1998).		Withdrawn
SX-0047		N/A	N/A	Hagemann IS. "Overview of technical aspects and chemistries of next-generation sequencing." Clinical Genomics, 3-19 (2015).		Withdrawn
SX-0048		N/A	N/A	Hutchison CA. "DNA sequencing: bench to bedside and beyond." Nucleic Acids Res. 2007;35(18):6227-37.		Withdrawn
SX-0049		N/A	N/A	Espejo RT, Plaza N. "Multiple Ribosomal RNA Operons in Bacteria; Their Concerted Evolution and Potential Consequences on the Rate of Evolution of Their 16S rRNA." Front Microbiol. 2018 Jun 8;9:1232.		Withdrawn
SX-0050		N/A	N/A	Hashimoto JG, Stevenson BS, Schmidt TM. "Rates and consequences of recombination between rRNA operons." J Bacteriol. 2003 Feb;185(3):966-72.	Paul Keim	Admitted
SX-0051		N/A	N/A	Hill KK, Xie G, et al, "Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains." BMC Biol. 2009 Oct 5;7:66.		Withdrawn

EXHIBIT A - Final Exhibit List of Joint, Complainants, and Staff Exhibits

EXH. NO.	Confidential	Beginning Bates	Ending Bates	Description	Sponsoring Witness	Admitted
SX-0052		N/A	N/A	Baudhuin LM, Lagerstedt SA, et al, "Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger Sequencing." <i>J Mol Diagn.</i> 2015 Jul;17(4):456-61.		Withdrawn
SX-0053		N/A	N/A	Acinas SG, Marcelino LA, et al. "Divergence and Redundancy of 16S rRNA Sequences in Genomes with Multiple <i>rrn</i> Operons." <i>J Bacteriol.</i> 2004 May;186(9):2629-35.		Withdrawn
SX-0054		N/A	N/A	Zheng J, Zhang H, et al, "A comprehensive assessment of NextGeneration Sequencing variants validation using a secondary technology." <i>Mol Genet Genomic Med.</i> 2019 Jul;7(7):e00748.		Withdrawn
SX-0055		N/A	N/A	Zhong Q, Wagner U, et al, "Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing." <i>Pathol Res Pract.</i> 2018 Jul;214(7):957-963.		Withdrawn
SX-0056		N/A	N/A	Tahseen Abdul-Aziz, <i>Botulism in Poultry</i> , in Merck Veterinary Manual, available at https://www.merckvetmanual.com/poultry/botulism/botulism-in-poultry		Withdrawn
SX-0057		N/A	N/A	John Dunn, <i>Market Disease in Poultry</i> , in Merck Veterinary Manual, available at https://www.merckvetmanual.com/poultry/neoplasms/marek-disease-in-poultry#		Withdrawn